AU2016321342A1 - Cartilage-homing peptides - Google Patents

Cartilage-homing peptides Download PDF

Info

Publication number
AU2016321342A1
AU2016321342A1 AU2016321342A AU2016321342A AU2016321342A1 AU 2016321342 A1 AU2016321342 A1 AU 2016321342A1 AU 2016321342 A AU2016321342 A AU 2016321342A AU 2016321342 A AU2016321342 A AU 2016321342A AU 2016321342 A1 AU2016321342 A1 AU 2016321342A1
Authority
AU
Australia
Prior art keywords
seq
peptide
composition
pct
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016321342A
Inventor
Colin CORRENTI
Emily June Girard
Christopher Mehlin
Natalie NAIRN
James Olson
Andrew David Strand
Roland STRONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blaze Bioscience Inc
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Research Center
Blaze Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Research Center, Blaze Bioscience Inc filed Critical Fred Hutchinson Cancer Research Center
Publication of AU2016321342A1 publication Critical patent/AU2016321342A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in amd/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide- active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide- active agent complexes to target regions, tissues, structures or cells targeted by the peptide.

Description

BACKGROUND [0002] Cartilage comprises chondrocytes, a specialized cell-type which produces components of the extracellular matrix, mainly including collagen, proteoglycans (e.g., aggrecan), and elastic fibers. The extracellular matrix proteins provide support, cushion, and durability to cartilage-rich portions of the body such as joints, ears, nose and windpipe. Cartilage is one of few tissues in the body which does not contain blood vessels and is considered an avascular tissue. Unlike many cells in the body which rely on a combination of blood flow and diffusion, chondrocytes rely on diffusion. Because it does not have a direct blood supply, compared to other connective tissues, cartilage grows and repairs much more slowly. As a result, cartilage disorders are particularly difficult to treat.
SUMMARY [0003] The present disclosure relates to compositions and methods for treatment of cartilage disorders. Described herein are peptides that home to, migrate to, accumulate in, bind to, are retained by, or are directed to, and/or bind in cartilage following administration in a subject. In some embodiments, the homing peptides of the present disclosure are used to deliver a detection agent to image and/or diagnose cartilage. In other embodiments, the homing peptides of the present disclosure are used to deliver an active agent to a region, tissue, structure, or cell thereof.
[0004] In various aspects, the present disclosure provides a knotted peptide, wherein upon administration to a subject the knotted peptide homes, targets, migrates to, accumulates in, binds to, is retained by, or is directed to a cartilage of the subject.
[0005] In some aspects, the knotted peptide comprises a sequence of any one of SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216 or a fragment thereof. In other aspects, the knotted peptide comprises a sequence that has at least 80% sequence identity with any one of SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196,
- 1 WO 2017/044894
PCT/US2016/051166
SEQ ID NO: 198 - SEQ ID NO: 216 or a fragment thereof. In still other aspects, the knotted peptide comprises a sequence that has at least 85%, at least 90%, or at least 95% sequence identity with any one of SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO:
198 - SEQ ID NO: 216 or a fragment thereof.
[0006] In some aspects, the knotted peptide comprises a sequence of any one of SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432 or a fragment thereof. In other aspects, the knotted peptide comprises a sequence that has at least 80% sequence identity with any one of SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432 or a fragment thereof. In still other aspects, the knotted peptide comprises a sequence that has at least 85%, at least 90%, or at least 95% sequence identity with any one of SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432 or a fragment thereof.
[0007] In some aspects, the knotted peptide comprises a sequence of any one of SEQ ID NO: 1 - SEQ ID NO: 20 or a fragment thereof. In other aspects, the knotted peptide comprises a sequence of any one of SEQ ID NO: 217 - SEQ ID NO: 236 or a fragment thereof.
[0008] In other aspects, the knotted peptide is at least 30%, 40%, 50%, 60%, 70%, 80%,
90%, or 95% identical to any one of SEQ ID NO: 436 - SEQ ID NO: 482. In further aspects, the knotted peptide of claim 10, wherein the knotted peptide is SEQ ID NO: 24. In other aspects, the knotted peptide is SEQ ID NO: 111.
[0009] In some aspects, the knotted peptide comprises 4 or more cysteine residues. In further aspects, the knotted peptide comprises three or more disulfide bridges formed between cysteine residues, wherein one of the disulfide bridges passes through a loop formed by two other disulfide bridges. In still further aspects, the knotted peptide comprises a plurality of disulfide bridges formed between cysteine residues. In other aspects, the knotted peptide comprises a disulfide through a disulfide knot.
[0010] In some aspects, at least one amino acid residue of the knotted peptide is in an L configuration or, wherein at least one amino acid residue of the knotted peptide is in a D configuration.
[0011] In some aspects, the sequence comprises at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at
-2WO 2017/044894
PCT/US2016/051166 least 55, at least 56, at least 57, at least 58 residues, at least 59, at least 60, at least 61, at least
62, at least 63, at least 64, at least 65, at least 66, at least 67, at least 68, at least 69, at least
70, at least 71, at least 72, at least 73, at least 74, at least 75, at least 76, at least 77, at least
78, at least 79, at least 80, or at least 81 residues.
[0012] In some aspects, any one or more K residues are replaced by an R residue or wherein any one or more R residues are replaced by for a K residue. In other aspects, any one or more M residues are replaced by any one of the I, L, or V residues. In still other aspects, any one or more L residues are replaced by any one of the V, I, or M residues.
[0013] In other aspects, any one or more I residues are replaced by any of the M, L, or V residues. In still other aspects, any one or more V residues are replaced by any of the Μ, I, or L residues. In some aspects, any one or more G residues are replaced by an A residue or wherein any one or more A residues are replaced by a G residue. In other aspects, any one or more S residues are replaced by a T residue or wherein any one or more T residues are replaced by for an S residue.
[0014] In still other aspects, any one or more Q residues are replaced by an N residue or wherein any one or more N residues are replaced by a Q residue. In some aspects, any one or more D residues are replaced by an E residue or wherein any one or more E residues are replaced by a D residue.
[0015] In some aspects, the knotted peptide has a charge distribution comprising an acidic region and a basic region. In further aspects, the acidic region is a nub. In other aspects, the basic region is a patch. In some aspects, the knotted peptide comprises 6 or more basic residues and 2 or fewer acidic residues. In some aspects, the knotted peptide comprises a 4-19 amino acid residue fragment containing at least 2 cysteine residues, and at least 2 positively charged amino acid residues.
[0016] In other aspects, the knotted peptide comprises a 20-70 amino acid residue fragment containing at least 2 cysteine residues, no more than 2 basic residues and at least 2 positively charged amino acid residues. In still other aspects, the knotted peptide comprises at least 3 positively charged amino acid residues. In some aspects, the positively charged amino acid residues are selected from K, R, or a combination thereof.
[0017] In some aspects, the knotted peptide has a charge greater than 2 at physiological pH.
In other aspects, the knotted peptide has a charge greater than 3.5 at physiological pH. In still other aspects, the knotted peptide has a charge greater than 4.5 at physiological pH. In some aspects, the knotted peptide has a charge greater than 5.5 at physiological pH. In other
- 3 WO 2017/044894
PCT/US2016/051166 aspects, the knotted peptide has a charge greater than 6.5 at physiological pH. In other aspects, the knotted peptide has a charge greater than 7.5 at physiological pH.
[0018] In some aspects, the knotted peptide is selected from a potassium channel agonist, a potassium channel antagonist, a portion of a potassium channel, a sodium channel agonist, a sodium channel antagonist, a calcium channel agonist, a calcium channel antagonist, a hadrucalcin, a theraphotoxin, a huwentoxin, a kaliotoxin, a cobatoxin or a lectin.
[0019] In further aspects, the lectin is SHL-Ib2. In some aspects, the knotted peptide is arranged in a multimeric structure with at least one other knotted peptide.
[0020] In some aspects, at least one residue of the knotted peptide comprises a chemical modification. In further aspects, the chemical modification is blocking the N-terminus of the knotted peptide. In still further aspects, the chemical modification is methylation, acetylation, or acylation. In other aspects, the chemical modification is: methylation of one or more lysine residues or analogue thereof; methylation of the N-terminus; or methylation of one or more lysine residue or analogue thereof and methylation of the N-terminus. In some aspects, the knotted peptide is linked to an acyl adduct.
[0021] In some aspects, the knotted peptide is linked to an active agent. In further aspects, the active agent is fused with the knotted peptide at an N-terminus or a C-terminus of the knotted peptide. In some aspects, the active agent is an antibody. In other aspects, the active agent is an Fc domain. In still other aspects, the knotted peptide fused with an Fc domain comprises a contiguous sequence.
[0022] In further aspects, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 active agents are linked to the knotted peptide. In still further aspects, the knotted peptide is linked to the active agent via a cleavable linker. In some aspects, the knotted peptide is linked to the active agent at an Nterminus, at the epsilon amine of an internal lysine residue, at the carboxylic acid of an aspartic acid or glutamic acid residue, or a C-terminus of the knotted peptide by a linker. In some aspects, the knotted peptide further comprises a non-natural amino acid, wherein the non-natural amino acid is an insertion, appendage, or substitution for another amino acid. [0023] In some aspects, the knotted peptide is linked to the active agent at the non-natural amino acid by a linker. In some aspects, the linker comprises an amide bond, an ester bond, a carbamate bond, a carbonate bond, a hydrazone bond, an oxime bond, a disulfide bond, a thioester bond, or a carbon-nitrogen bond. In further aspects, the cleavable linker comprises a cleavage site for matrix metalloproteinases, thrombin, cathepsins, or beta-glucuronidase. In other aspects, the linker is a hydrolytically labile linker. In still other aspects, the knotted peptide is linked to the active agent via a noncleavable linker.
-4WO 2017/044894
PCT/US2016/051166 [0024] In some aspects, the active agent is: a peptide, an oligopeptide, a polypeptide, a polynucleotide, a polyribonucleotide, a DNA, a cDNA, a ssDNA, a RNA, a dsRNA, a micro RNA, an oligonucleotide, an antibody, an antibody fragment, an aptamer, a cytokine, an enzyme, a growth factor, a chemokine, a neurotransmitter, a chemical agent, a fluorophore, a metal, a metal chelate, an X-ray contrast agent, a PET agent, a radioisotope, a photo sensitizer, a radio sensitizer, a radionuclide chelator, a therapeutic small molecule, a steroid, a corticosteroid, an anti-inflammatory agent, an immune modulator, a protease inhibitor, an amino sugar, a chemotherapeutic agent, a cytotoxic chemical, a toxin, a tyrosine kinase inhibitor, an anti-infective agent, an antibiotic, an anti-viral agent, an anti-fungal agent, an aminoglycoside, a nonsteroidal anti-inflammatory drug (NSAID), a statin, a nanoparticle, a liposome, a polymer, a biopolymer, a polysaccharide, a proteoglycan, a glycosaminoglycan, a glucocorticoid, an anti-cytokine agent, a pain-reducing agent, a dendrimer, a fatty acid, an Fc region, or a combination thereof.
[0025] In some aspects, the NSAID is ketorolac. In other aspects, the NSAID is ibuprofen. In some aspects, the steroid is dexamethasone. In other aspects, the steroid is budesonide. In some aspects, the active agent induces programmed cell death. In further aspects, the programmed cell death is apoptosis. In some aspects, the active agent is a tumor necrosis factor alpha inhibitor. In further aspects, the active agent is a TNF receptor family activator.
In still further aspects, the active agent is a TNF alpha antibody. In some aspects, the protease inhibitor is a collagenase inhibitor, elastase inhibitor, or a matrix metalloprotease inhibitor. In further aspects, the matrix metalloprotease is MMP13.
[0026] In some aspects, the knotted peptide is linked to a detectable agent. In further aspects, the detectable agent is fused with the knotted peptide at an N-terminus or a C-terminus of the knotted peptide. In still further aspects, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 detectable agents are linked to the knotted peptide. In some aspects, the knotted peptide is linked to the detectable agent via a cleavable linker.
[0027] In some aspects, the knotted peptide is linked to the detectable agent at an N-terminus, at the epsilon amine of an internal lysine residue, or a C-terminus of the knotted peptide by a linker. In further aspects, the peptide further comprises a non-natural amino acid, wherein the non-natural amino acid is an insertion, appendage, or substitution for another amino acid. In still further aspects, the knotted peptide is linked to the active agent at the non-natural amino acid by a linker.
[0028] In still further aspects, the linker comprises an amide bond, an ester bond, a carbamate bond, a hydrazone bond, an oxime bond, or a carbon-nitrogen bond. In some aspects, the
-5WO 2017/044894
PCT/US2016/051166 cleavable linker comprises a cleavage site for matrix metalloproteinases, thrombin, cathepsins, or beta-glucuronidase. In other aspects, the knotted peptide is linked to the detectable agent via a noncleavable linker.
[0029] In some aspects, the detectable agent is a fluorophore, a near-infrared dye, a contrast agent, a nanoparticle, a metal-containing nanoparticle, a metal chelate, an X-ray contrast agent, a PET agent, a radioisotope, or a radionuclide chelator. In further aspects, the detectable agent is a fluorescent dye. In some aspects, the knotted peptide has an isoelectric point of about 9.
[0030] In some aspects, the knotted peptide is SEQ ID NO: 24. In other aspects, the knotted peptide is SEQ ID NO: 111.
[0031] In various aspects, the present disclosure provides a pharmaceutical composition comprising any of the above compositions or a salt thereof, and a pharmaceutically acceptable carrier.
[0032] In further aspects, the pharmaceutical composition is formulated for administration to a subject. In still further aspects, the pharmaceutical composition is formulated for inhalation, intranasal administration, oral administration, topical administration, intravenous administration, subcutaneous administration, intra-articular administration, intramuscular administration, intraperitoneal administration, or a combination thereof.
[0033] In various aspects, the present disclosure provides a method of treating a condition in a subject in need thereof, the method comprising: administering to the subject a knotted peptide comprising any of the above compositions or any of the above pharmaceutical compositions.
[0034] In some aspects, the composition is administered by inhalation, intranasally, orally, topically, intravenously, subcutaneously, intra-articularly, intramuscularly administration, intraperitoneally, or a combination thereof. In further aspects, the composition homes, targets, or migrates to cartilage of the subject following administration.
[0035] In some aspects, the condition is associated with a function of cartilage. In some aspects, the condition is an inflammation, a cancer, a degradation, a growth disturbance, genetic, a tear, an infection, or an injury. In other aspects, the condition is a chondrodystrophy. In still other aspects, the condition is a traumatic rupture or detachment. In some aspects, the condition is a costochondritis. In other aspects, the condition is a herniation. In still other aspects, the condition is a polychondritis.
[0036] In other aspects, the condition is a chordoma. In some aspects, the condition is a type of arthritis. In further aspects, the type of arthritis is rheumatoid arthritis. In other aspects, the
-6WO 2017/044894
PCT/US2016/051166 type of arthritis is osteoarthritis. In some aspects, the condition is achondroplasia. In some aspects, the cancer is benign chondroma or malignant chondrosarcoma. In other aspects, the condition is bursitis, tendinitis, gout, pseudogout, an arthropathy, or an infection.
[0037] In some aspects, the composition is administered to treat the injury, to repair a tissue damaged by the injury, or to treat a pain caused by the injury. In further aspects, the composition is administered to treat the tear or to repair a tissue damaged by the tear.
[0038] In various aspects, the present disclosure provides a method of imaging an organ or body region of a subject, the method comprising: administering to the subject composition of any one of knotted peptide previously described or a pharmaceutical composition as previously described; and imaging the subject.
[0039] In some aspects, the method further comprises detecting a cancer or diseased region, tissue, structure or cell. In further aspects, the method further comprises performing surgery on the subject. In some aspects, the method further comprises treating the cancer.
[0040] In other aspects, the surgery comprises removing the cancer or the diseased region, tissue, structure or cell of the subject. In still other aspects, the method further comprises imaging the cancer or diseased region, tissue, structure, or cell of the subject after surgical removal.
INCORPORATION BY REFERENCE [0041] All publications, patents, and patent applications mentioned, disclosed or referenced in this specification are herein incorporated by reference in their entirety and to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
BRIEF DESCRIPTION OF THE FIGURES [0042] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:
[0043] FIG. 1 illustrates the 14C signal in the cartilage of animals treated with various peptides of this disclosure. FIG. 1A illustrates the 14C signal in the cartilage of an animal treated with a peptide of SEQ ID NO: 26. FIG. IB illustrates the 14C signal in the cartilage of an animal treated with a peptide of SEQ ID NO: 28. FIG. 1C illustrates the 14C signal in the cartilage of an animal treated with a peptide of SEQ ID NO: 24. FIG. ID illustrates the 14C
- 7 WO 2017/044894
PCT/US2016/051166 signal in the cartilage of an animal treated with a peptide of SEQ ID NO: 23. FIG. IE illustrates the 14C signal in the cartilage of an animal treated with a peptide of SEQ ID NO:
27. FIG. IF illustrates the 14C signal in the cartilage of an animal treated with a peptide of SEQ ID NO: 25. FIG. 1G illustrates the 14C signal in the cartilage of an animal treated with a peptide of SEQ ID NO: 22. FIG. 1H illustrates the 14C signal in the cartilage of an animal treated with a peptide of SEQ ID NO: 31. FIG. II illustrates the 14C signal in the cartilage of an animal treated with a peptide of SEQ ID NO: 21. FIG. 1J illustrates the 14C signal in the cartilage of an animal treated with a peptide of SEQ ID NO: 29. FIG. IK illustrates the 14C signal in the cartilage of an animal treated with a peptide of SEQ ID NO: 30. FIG. IL illustrates the 14C signal in the cartilage of an animal treated with a peptide of SEQ ID NO: 32. FIG. 1M illustrates the 14C signal in the cartilage of an animal treated with a peptide of SEQ ID NO: 27.
[0044] FIG. 2 illustrates the identification of the 14C signal in the joint and other cartilage of an animal treated with the peptide of SEQ ID NO: 24.
[0045] FIG. 3 illustrates the identification of the 14C signal in rib, spinal, and other cartilage of an animal treated with the peptide of SEQ ID NO: 24.
[0046] FIG. 4 illustrates the identification of locations the 14C signal in the nasal, spinal, tracheal, and other cartilage of an animal treated with the peptide of SEQ ID NO: 24.
[0047] FIG. 5 illustrates the 14C signal in the cartilage of an animal with intact kidneys 24 hours after treatment with a peptide of SEQ ID NO: 24.
[0048] FIG. 6 illustrates the High Performance Liquid Chromatography (HPLC) profiles of peptides of this disclosure. FIG. 6A illustrates the HPLC profile of a peptide of FIG.
ID and SEQ ID NO: 23. FIG. 6B illustrates the HPLC profile of a peptide of FIG. 1C and SEQ ID NO: 24.
[0049] FIG. 7 illustrates the immunogenicity profiles of the peptides of SEQ ID NO: 21 SEQ ID NO: 33.
[0050] FIG. 8 illustrates a three-dimensional structure and a line structure of a peptide of FIG. IB and SEQ ID NO: 28.
[0051] FIG. 9 illustrates an exemplary architecture of constructs expressing sequences of FIGS. 1A-1M and SEQ ID NO: X, where X can be any one of peptides of SEQ ID NO: 21 SEQ ID NO: 33.
[0052] FIG. 10 illustrates a schematic of a method of manufacturing of a peptide of the disclosure.
-8WO 2017/044894
PCT/US2016/051166 [0053] FIG. 11 shows a white light image and corresponding autoradiographic image from a section of a mouse 24 hours after administration of 100 nmol of radiolabeled GSHainantoxin (GSKCLPPGKPCYGATQKIPCCGVCSHNNCT) (SEQ ID NO: 433) peptide, which does not home to cartilage. FIG. 11A illustrates a white light image of a frozen section of a mouse 24 hours after administration of 100 nmol of SEQ ID NO: 433. FIG.
11B shows an autoradiographic image corresponding to FIG. 11A in which the 14C signal identifies the radiolabeled SEQ ID NO: 433 peptide.
[0054] FIG. 12 illustrates alignment of cartilage homers as depicted by the examples and of SEQ ID NO: 9, SEQ ID NO: 24, SEQ ID NO: 23, SEQ ID NO: 27, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 25, SEQ ID NO: 21, SEQ ID NO: 30, SEQ ID NO: 10, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 22 and SEQ ID NO: 33.
[0055] FIG. 13 shows a white light image and corresponding autoradiographic image of a frozen section of a mouse 4 hours after administration of 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 13A illustrates a white light image of a frozen section of the mouse 4 hours after administration 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 13B illustrates an autoradiographic image corresponding to FIG. 13A in which the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the cartilage of the mouse 4 hours after administration of 100 nmol.
[0056] FIG. 14 shows a white light image and corresponding autoradiographic image of a frozen section of a mouse 24 hours after administration of 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 14A illustrates a white light image of a frozen section of the mouse 24 hours after administration 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 14B illustrates an autoradiographic image corresponding to FIG. 14A in which the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the cartilage of the mouse 24 hours after administration of 100 nmol.
[0057] FIG. 15 shows white light images and corresponding autoradiographic images of frozen hind limb sections of a mouse 4 hours after administration of 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 15A illustrates a white light image of a frozen section of a hind limb of a mouse 4 hours after administration 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 15B illustrates an autoradiographic image corresponding to FIG. 15A in which the the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the ankle and digit cartilage of a mouse 4 hours after administration of 100 nmol. FIG. 15C illustrates an autoradiographic image in which the the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the ankle and digit cartilage of a mouse 4 hours after
-9WO 2017/044894
PCT/US2016/051166 administration of 100 nmol. FIG. 15D illustrates a white light image of a frozen section of a hind limb of a mouse 4 hours after administration 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 15E illustrates an autoradiographic image corresponding to FIG. 15D in which the the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the ankle and digit cartilage of a mouse 4 hours after administration of 100 nmol. FIG. 15F illustrates a white light image of a frozen section of a hind limb of a mouse 4 hours after administration 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 15G illustrates an autoradiographic image corresponding to FIG. 15F in which the the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the ankle and digit cartilage of a mouse 4 hours after administration of 100 nmol.
[0058] FIG. 16 shows white light images and corresponding autoradiographic images of frozen hind limb sections of a mouse 24 hours after administration of 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 16A illustrates a white light image of a frozen section of a hind limb of a mouse 24 hours after administration 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 16B illustrates an autoradiographic image corresponding to FIG. 16A in which the the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the ankle and digit cartilage of a mouse 24 hours after administration of 100 nmol. FIG. 16C illustrates a white light image of a frozen section of a hind limb of a mouse 24 hours after administration 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 16D illustrates an autoradiographic image corresponding to FIG. 16C in which the the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the ankle and digit cartilage of a mouse 24 hours after administration of 100 nmol. FIG. 16E illustrates a white light image of a frozen section of a hind limb of a mouse 24 hours after administration 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 16F illustrates an autoradiographic image corresponding to FIG. 16E in which the the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the ankle and digit cartilage of a mouse 24 hours after administration of 100 nmol. FIG. 16G illustrates an autoradiographic image in which the the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the ankle and digit cartilage of a mouse 24 hours after administration of 100 nmol.
[0059] FIG. 17 shows white light images and corresponding whole body fluorescence images of a mouse 3 hours after administration of 10 nmol SEQ ID NO: 111 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). FIG. 17A illustrates a white light image of a frozen section of a mouse 3 hours after administration of 10 nmol SEQ ID NO:
111 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). FIG. 17B illustrates a
- 10WO 2017/044894
PCT/US2016/051166 whole body fluorescence image corresponding to the section shown in FIG. 17A showing the fluorescence signal in the mouse 3 hours after administration of 10 nmol SEQ ID NO:
lllpeptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). FIG. 17C illustrates a white light image of a different frozen section of the mouse, 3 hours after administration of nmol SEQ ID NO: 11 lpeptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111A). FIG. 17D illustrates a whole body fluorescence image corresponding to the section shown in FIG. 17C showing the fluorescence signal in the mouse 3 hours after administration of 10 nmol SEQ ID NO: 11 lpeptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111A). FIG. 17E illustrates a white light image of a different frozen section of the mouse, 3 hours after administration of 10 nmol SEQ ID NO: 11 lpeptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111A). FIG. 17F illustrates a whole body fluorescence image corresponding to the section shown in FIG. 17E showing the fluorescence signal in the mouse 3 hours after administration of 10 nmol SEQ ID NO: 11 lpeptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111A).
[0060] FIG. 18 shows white light images and corresponding whole body fluorescence images of a mouse administered 10 nmol of a peptide of SEQ ID NO: 11 lconjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A) at 24 hours post-administration. FIG. 18A illustrates an image of a frozen section of a mouse, 24 hours after administration of 10 nmol of a peptide of SEQ ID NO: 11 lconjugated to a Cy5.5 fluorophore (SEQ ID NO: 111A). FIG. 18B illustrates the fluorescence signal in the mouse, corresponding to the section shown in FIG. 18A, 24 hours after administration of 10 nmol of a peptide of SEQ ID NO:
lconjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). FIG. 18C illustrates an image of a different frozen section of the mouse, 24 hours after administration of 10 nmol of a peptide of SEQ ID NO: 11 lconjugated to a Cy5.5 fluorophore (SEQ ID NO: 111A). FIG. 18D illustrates the fluorescence signal in the mouse, corresponding to the section shown in FIG. 18C, 24 hours after administration of 10 nmol of a peptide of SEQ ID NO: 11 lconjugated to a Cy5.5 fluorophore (SEQ ID NO: 111A). FIG. 18E illustrates an image of a different frozen section of the mouse, 24 hours after administration of 10 nmol of a peptide of SEQ ID NO:
lconjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). FIG. 18F illustrates a fluorescence signal in the mouse, corresponding to the section shown in FIG. 18E, 24 hours after administration of 10 nmol of a peptide of SEQ ID NO: lll conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111A).
[0061] FIG. 19 shows white light images and corresponding whole body fluorescence images of a mouse administered 10 nmol of a peptide of SEQ ID NO: lll conjugated to a
- 11 WO 2017/044894
PCT/US2016/051166
Cy5.5 fluorophore (SEQ ID NO: 111A) at 48 hours post-administration. FIG. 19A illustrates an image of a frozen section of a mouse, 48 hours after administration of 10 nmol of a peptide of SEQ ID NO: 111 conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111A). FIG. 19B illustrates the fluorescence signal in the mouse, corresponding to the section shown in FIG. 19A, 48 hours after administration of 10 nmol of a peptide of SEQ ID NO: 111 conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). FIG. 19C illustrates an image of a different frozen section of the mouse, 48 hours after administration of 10 nmol of a peptide of SEQ ID NO: 111 conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). FIG. 19D illustrates the fluorescence signal in the mouse, corresponding to the section shown in FIG. 19C, 48 hours after administration of 10 nmol of a peptide of SEQ ID NO: 111 conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111A).
[0062] FIG. 20 shows white light images and corresponding whole body fluorescence images of a mouse administered 10 nmol of a peptide of a peptide of SEQ ID NO: 111 conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A) at 72 hours post-administration. FIG. 20A illustrates an image of a frozen section of a mouse, 72 hours after administration of 10 nmol of a peptide of SEQ ID NO: 111 conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111A). FIG. 20B illustrates the fluorescence signal in the mouse, corresponding to the section shown in FIG. 20A, 72 hours after administration of 10 nmol of a peptide of SEQ ID NO: 111 conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). FIG. 20C illustrates an image of a different frozen section of the mouse, 72 hours after administration of 10 nmol of a peptide of SEQ ID NO: 111 conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111A). FIG. 20D illustrates the fluorescence signal in the mouse, corresponding to the section shown in FIG. 20C, 72 hours after administration of 10 nmol of a peptide of SEQ ID NO: 111 conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A).
[0063] FIG. 21 shows IVIS fluorescence imaging of an isolated hind limb from a first mouse and an isolated hind limb from a second mouse after administration of 10 nmol SEQ ID NO: 111 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). Areas of low signal intensity are shown in a thin solid line, areas of medium signal intensity are shown in a thick sold line, and areas of high signal intensity are shown in a thin dotted line. FIG. 21A shows the right hind limb with skin removed from a first mouse and from a second mouse 3 hours after peptide administration. FIG. 21B shows the right hind limb with muscle removed from a first mouse and from a second mouse 3 hours after peptide administration of 10 nmol SEQ ID NO: 111 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). FIG. 21C shows the right hind limb with skin removed from a first mouse and from a second mouse 24
- 12WO 2017/044894
PCT/US2016/051166 hours after peptide administration of 10 nmol SEQ ID NO: 111 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111A). FIG. 21D shows the right hind limb with muscle removed from a first mouse and from a second mouse 24 hours after peptide administration of 10 nmol SEQ ID NO: 111 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). FIG. 21E shows the right hind limb with skin removed from a first mouse and from a second mouse 48 hours after peptide administration of 10 nmol SEQ ID NO: 111 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111A). FIG. 21F shows the right hind limb with muscle removed from a first mouse and from a second mouse 48 hours after peptide administration of 10 nmol SEQ ID NO: 111 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). FIG. 21G shows the right hind limb with skin removed from a first mouse and from a second mouse 72 hours after peptide administration of 10 nmol SEQ ID NO: 111 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). FIG. 21H shows the right hind limb with muscle removed from a first mouse and from a second mouse 72 hours after administration of 10 nmol SEQ ID NO: 111 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111A).
[0064] FIG. 22 illustrates white light images and corresponding autoradiography images of frozen sections of a mouse, 5 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 22A illustrates a white light image of a frozen section of a mouse, 5 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
111. FIG. 22B illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 22A, 5 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 22C illustrates a white light image of a different frozen section of a mouse, 5 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 22D illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 22C, 5 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 22E illustrates a white light image of a different frozen section of a mouse, 5 minutes after administration of 100 nmol of a radiolabeled SEQ ID NO: 111. FIG. 22F illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 22E, 5 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 22G illustrates a white light image of a different frozen section of a mouse, 5 minutes after administration of 100 nmol of a radiolabeled peptide of a SEQ ID NO: 111. FIG. 22H illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 22G, 5 minutes after administration of 100 nmol of a radiolabeled peptide of a SEQ ID NO: 111.
- 13 WO 2017/044894
PCT/US2016/051166 [0065] FIG. 23 illustrates white light images and corresponding autoradiography images of frozen sections of a mouse, 30 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 23A illustrates a white light image of a frozen section of a mouse, 30 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
111. FIG. 23B illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 23A, 30 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 23C illustrates a white light image of a different frozen section of a mouse, 30 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 23D illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 23C, 30 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 23E illustrates a white light image of a different frozen section of the mouse, 30 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 23F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 23E, 30 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111.
[0066] FIG. 24 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 24A illustrates a white light image of a frozen section of a mouse, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 24B illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 24A, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 24C illustrates a white light image of a different frozen section of a mouse, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
111. FIG. 24D illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 24C, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 24E illustrates a white light image of a different frozen section of the mouse, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
111. FIG. 24F illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 24E, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 24G illustrates a white light image of a different frozen section of the mouse, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
111. FIG. 24H illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 24G, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111.
- 14WO 2017/044894
PCT/US2016/051166 [0067] FIG. 25 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 25A illustrates a white light image of a frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
111. FIG. 25B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 25A, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 25C illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 25D illustrates the 14C signal in a different frozen section of the mouse, corresponding to the section shown in FIG. 25C, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 25E illustrates the 14C signal in a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111.
[0068] FIG. 26 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse with ligated kidneys, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 26A illustrates a white light image of a frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 26B illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 26A, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 26C illustrates a white light image of a different frozen section of the mouse with ligated kidneys, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
111. FIG. 26D illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 26C, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 26E illustrates a white light image of a different frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 26F illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to section shown in FIG. 26E, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. [0069] FIG. 27 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 27A illustrates a white light image of a frozen section of a mouse, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
111. FIG. 27B illustrates the 14C signal in a frozen section of the mouse, corresponding to the
- 15WO 2017/044894
PCT/US2016/051166 section shown in FIG. 27A, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 27C illustrates an image of a different frozen section of a mouse, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
111. FIG. 27D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 27C, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 27E illustrates an image of a different frozen section of a mouse, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
111. FIG. 27F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 27E, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 27G illustrates a white light image of a different frozen section of a mouse, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 27H illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 27G, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111.
[0070] FIG. 28 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 28A illustrates a white light image of a frozen section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 28B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 28A, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 28C illustrates a white light image of a different frozen section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 28D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 28C, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 28E illustrates a white light image of a different frozen section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 28F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 28E, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111.
[0071] FIG. 29 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 29A illustrates a white light image of a frozen section of a mouse, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 29B illustrates the 14C signal in a frozen section of the mouse, corresponding to the
- 16WO 2017/044894
PCT/US2016/051166 section shown in FIG. 29A, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 29C illustrates a white light image of a different frozen section of a mouse, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 29D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 29C, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 29E illustrates a white light image of a different frozen section of the mouse, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 29F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 29E, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 29G illustrates a white light image of a different frozen section of a mouse, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 29H illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 29G, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111.
[0072] FIG. 30 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. FIG. 30A illustrates a white light image of a frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
109. FIG. 30B illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 30A, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. FIG. 30C illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. FIG. 30D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 30C, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. FIG. 30E illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. FIG. 30F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 30E, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109.
[0073] FIG. 31 illustrates white light images and a corresponding autoradiography images of frozen sections from a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. FIG. 31A illustrates a white light image of a frozen section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
- 17WO 2017/044894
PCT/US2016/051166
109. FIG. 31B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 31A, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. FIG. 31C illustrates a white light image of a different frozen section of the mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. FIG. 31D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 31C, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. FIG. 31E illustrates a white light image of a different frozen section of the mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. FIG. 31F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 31E, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109.
[0074] FIG. 32 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 32A illustrates a white light image of a frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
110. FIG. 32B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 32A, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 32C illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 32D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 32C, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 32E illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 32F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 32E, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 32G illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 32H illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 32G, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110.
[0075] FIG. 33 illustrates white light images and a corresponding autoradiography images of frozen sections from a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 33A illustrates a white light image of a frozen section of a
- 18WO 2017/044894
PCT/US2016/051166 mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
110. FIG. 33B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 33A, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 33C illustrates a white light image of a different frozen section of the mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 33D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 33C, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 33E illustrates a white light image of a different frozen section of the mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 33F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 33E, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110.
[0076] FIG. 34 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 34A illustrates a white light image of a frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
114. FIG. 34B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 34A, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 34C illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 34D illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 34C, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 34E illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 34F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 34E, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114.
[0077] FIG. 35 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 35A illustrates a white light image of a frozen section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 35B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 35A, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 35C illustrates a white light image of a different frozen
- 19WO 2017/044894
PCT/US2016/051166 section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 35D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 35C, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 35E illustrates a white light image of a different frozen section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 35F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 35E, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114.
[0078] FIG. 36 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 36A illustrates a white light image of a frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 36B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 36A, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 36C illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 36D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 36C, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 36E illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 36F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 36E, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200.
[0079] FIG. 37 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 37A illustrates a white light image of a frozen section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 37B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 37A, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 37C illustrates a white light image of a different frozen section of the mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 37D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 37C, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 37E illustrates a white light image of a
-20WO 2017/044894
PCT/US2016/051166 different frozen section of the mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 37F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 37E, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 37G illustrates a white light image of a different frozen section of the mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 37H illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 37G, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200.
[0080] FIG. 38 illustrates white light images and corresponding autoradiography images of frozen sections a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 195 (GSNFKVEGACSKPCRKYCIDKGARNGKCINGRCHCYY). FIG. 38A illustrates a white light image of a frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 195. FIG. 38B illustrates the 14C signal in a frozen section of a mouse with ligated kidneys, corresponding to the section shown in FIG. 38A, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 195. FIG. 38C illustrates a white light image of a different frozen section of the mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 195. FIG. 38D illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 38C, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 195.
[0081] FIG. 39 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 196. FIG. 39A illustrates a white light image of a frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 196. FIG. 39B illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 39A, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 196. FIG. 39C illustrates a white light image of a different frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 196. FIG. 39D illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 39C, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 196.
-21 WO 2017/044894
PCT/US2016/051166 [0082] FIG. 40 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 197 (GSDRDSCIDKSRCSKYGYYQECQDCCKKAGHNGGTCMFFKCKCA). FIG. 40A illustrates a white light image of a frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 197. FIG. 40B illustrates the 14C signal in a frozen section of a mouse with ligated kidneys, corresponding to the section shown in FIG. 40A, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 197. FIG. 40C illustrates a white light image of a different frozen section of the mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 197. FIG. 40D illustrates the 14C signal in a frozen section of a mouse with ligated kidneys, corresponding to the section shown in FIG. 40C, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 197.
[0083] FIG. 41 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 198. FIG. 41A illustrates a white light image of a frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 198. FIG. 41B illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 41A, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 198. FIG. 41C illustrates a white light image of a different frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 198. FIG. 41D illustrates the 14C signal in a frozen section of a mouse with ligated kidneys, corresponding to the section shown in FIG. 41C, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 198.
[0084] FIG. 42 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434 (GSGVPINVRSRGSRDSLDPSRRAGMRFGRSINSRSHSTP). FIG. 42A illustrates a white light image of a frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 42B illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 42A, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 42C illustrates a white light image of a different frozen
-22WO 2017/044894
PCT/US2016/051166 section of the mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 42D illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 42C, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 42E illustrates a white light image of a different frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 42F illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 42E, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 42G illustrates a white light image of a different frozen section of the mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 42H illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 42G, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434.
[0085] FIG. 43 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 43A illustrates a white light image of a frozen section of a mouse, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 43B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 43A, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 43C illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 43D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 43C, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 43E illustrates a white light image of a different frozen section of the mouse, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 43F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 43E, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 43G illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 43H illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 43G, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434.
-23WO 2017/044894
PCT/US2016/051166 [0086] FIG. 44 illustrates white light images and corresponding autoradiography images of frozen sections from a mouse, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 44A illustrates a white light image of a frozen section of a mouse, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 44B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 44A, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 44C illustrates a white light image of a different frozen section of a mouse, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 44D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 44C, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 44E illustrates an image of a different frozen section of the mouse, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 44F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 44E, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 44G illustrates a white light image of a different frozen section of a mouse, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 44H illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 44G, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434.
[0087] FIG. 45 illustrates the cartilage homing of various peptides of this disclosure plotted against the calculated Expasy pi.
[0088] FIG. 46 shows cartilage homing of various peptides of this disclosure plotted against the calculated Sillero pi using R implementation.
[0089] FIG. 47 depicts the topology of the “hitchins” class of cartilage homing peptides, with disulfide connectivity labeled as C1-C4, C2-C5, and C3-C6.
[0090] FIG. 48 illustrates structural analysis of peptides of SEQ ID NO: 28, SEQ ID NO: 23, and SEQ ID NO: 27. FIG. 48A illustrates the structural analysis of a peptide of SEQ ID NO: 28 and displays the contiguous surface of positive charge and the position of positively charged residues. FIG. 48B illustrates the structural analysis of a peptide of SEQ ID NO: 23 and displays the contiguous surface of positive charge and the position of positively charged residues. FIG. 48C illustrates the structural analysis of a peptide of SEQ ID NO: 27 and displays the contiguous surface of positive charge and the position of positively charged residues. FIG. 48D illustrates the structural analysis of a peptide of SEQ ID NO: 111 and
-24WO 2017/044894
PCT/US2016/051166 displays the contiguous surface of positive charge and the position of positively charged residues.
[0091] FIG. 49 illustrates HPLC chromatograms of peptides of SEQ ID NO: 24 and SEQ ID NO: 111 in different buffer conditions. FIG. 49A illustrates the HPLC trace of a peptide of SEQ ID NO: 24 in PBS. FIG. 49B illustrates the HPLC trace of a peptide of SEQ ID NO: 24 in DTT in PBS. FIG. 49C illustrates the HPLC trace of a peptide of SEQ ID NO: 24in 50 U trypsin and 1 mg/ml inhibitor in PBS. FIG. 49D illustrates the HPLC trace of a peptide of SEQ ID NO: 24in 50 U trypsin, 1 mg/ml inhibitor, and DTT in PBS. FIG. 49E illustrates the HPLC trace of a peptide of SEQ ID NO: 111 in PBS. FIG. 49F illustrates the HPLC trace of a peptide of SEQ ID NO: 11 lin DTT in PBS. FIG. 49G illustrates the HPLC trace of a peptide of SEQ ID NO: 111 in 50 U trypsin and 1 mg/ml inhibitor in PBS. FIG. 49H illustrates the HPLC trace of a peptide of SEQ ID NO: 111 in 50 U trypsin, 1 mg/ml inhibitor, and DTT in PBS.
[0092] FIG. 50 illustrates alignment of SEQ ID NO: 24 with SEQ ID NO: 23, SEQ ID NO: 24 with SEQ ID NO: 27, and SEQ ID NO: 24 with SEQ ID NO: 206. FIG. 50A illustrates the alignment of the peptide of SEQ ID NO: 24 with the peptide of SEQ ID NO: 23. Boxes delineate conserved positively charged residues. FIG. 50B illustrates the alignment of the peptide of SEQ ID NO: 24 with the peptide of SEQ ID NO: 27. Boxes delineate conserved positively charged residues. FIG. 50C illustrates the alignment of the peptide of SEQ ID NO: 24 with the peptide of SEQ ID NO: 206. Boxes delineate conserved positively charged residues.
[0093] FIG. 51 illustrates the alignment of the peptide of SEQ ID NO: 27 with the peptide of SEQ ID NO: 207. Boxes delineate conserved positively charged residues.
[0094] FIG. 52 shows HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 24 suspended in various solutions including SPTD, simulated gastric fluid (SGF) at pH 1.05 and 20 pg pepsin (P), SGF, Dithiothreitol (DTT), and non-reducing (NR) conditions using a Tris buffer.
[0095] FIG. 53 shows HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 111 suspended in various solutions including SPTD, simulated gastric fluid (SGF) at pH 1.05 and 20 pg pepsin (P), SGF, Dithiothreitol (DTT), and non-reducing (NR) conditions using a Tris buffer.
[0096] FIG. 54 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 483 (GSISIGIKCSPSIDLCEGQCRIRKYFTGYCSGDTCHCSG)
-25WO 2017/044894
PCT/US2016/051166 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions.
[0097] FIG. 55 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 22 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions.
[0098] FIG. 56 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 24 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions.
[0099] FIG. 57 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 32 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions.
[0100] FIG. 58 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 485 (GSECLGFGKGCNPSNDQCCKSSNLVCSRKHRWCKYEIGK) suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions.
[0101] FIG. 59 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 27 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions.
[0102] FIG. 60 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 205 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions.
[0103] FIG. 61 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 195 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions.
[0104] FIG. 62 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of
-26WO 2017/044894
PCT/US2016/051166 a peptide of SEQ ID NO: 196 suspended in various solutions including (T, I, DTT), (T,I),
DTT, and non-reducing (NR) conditions.
[0105] FIG. 63 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 197 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions.
[0106] FIG. 64 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 198 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions.
[0107] FIG. 65 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 206 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions.
[0108] FIG. 66 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 111 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions.
[0109] FIG. 67 shows the HPLC chromatograms of various peptides and the mass spectrometry results of various peptides after direct-infusion electrospray mass spectrometry. All peptides tested are shown under reducing and non-reducing conditions. FIG. 67A shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 483.
The peak near 9.5 minutes is the peptide under non-reducing conditions and the peak near 8.4 minutes shows reduced peptide. FIG. 67B shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 22. The peak near 6.4 minutes is the peptide under non-reducing conditions and the peak near 5.4 minutes shows reduced peptide. FIG. 67C shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 24. Peaks showing the peptide under non-reducing conditions and reducing conditions are overlapping. FIG. 67D shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 32. The peak near 9.4 minutes is the peptide under non-reducing conditions and the peak near 9.0 minutes shows reduced peptide. FIG. 67E shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 485. The peak near 9.4 minutes is the peptide under non-reducing conditions and the peak near 8.1 minutes shows reduced peptide. FIG. 67F shows the HPLC chromatogram and mass spectrometry
-27WO 2017/044894
PCT/US2016/051166 results of a peptide of SEQ ID NO: 27. The peak near 8.2 minutes is the peptide under nonreducing conditions and the peak near 5.4 minutes shows reduced peptide. FIG. 67G shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 205.
The peak near 6.6 minutes is the peptide under non-reducing conditions and the peak near 5.6 minutes shows reduced peptide. FIG. 67H shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 195. The peak near 9.5 minutes is the peptide under non-reducing conditions and the peak near 8.4 minutes shows reduced peptide. FIG. 671 shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 196. Peaks showing the peptide under non-reducing conditions and reducing conditions are overlapping. FIG. 67J shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 197. The peak near 8.5 minutes is the peptide under nonreducing conditions and the peak near 7.7 minutes shows reduced peptide. FIG. 67K shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 198.
The peak near 9.7 minutes is the peptide under non-reducing conditions and the peak near 6.7 minutes shows reduced peptide. FIG. 67L shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 206. The peak near 8.2 minutes is the peptide under non-reducing conditions and the peak near 7.2 minutes shows reduced peptide. FIG. 67M shows the HPLC chromatogram of a peptide of SEQ ID NO: lll. Peaks showing the peptide under non-reducing conditions and reducing conditions are fully overlapping. [0110] FIG. 68 shows the concentration of a radiolabeled peptide of SEQ ID NO: 24 in plasma after administration of the peptide to a mouse. FIG. 68A shows the concentration of peptide in plasma after intravenous (IV) administration of 20 nmol of a radiolabeled peptide of SEQ ID NO: 24 and oral (PO) administration of 100 nmol the radiolabeled peptide of SEQ ID NO: 24, as quantified by measuring the 14C signal using liquid scintillation counting. The delivered dose of 14C was 4.8 pCi for intravenous administration and 24 pCi for oral administration. Time points examined included 0.08, 0.5, 1, 3, 8, 24, 48 hours and three mice were examined per time point. FIG. 68B shows the percent of administered peptide dose recovered in plasma after intravenous (IV) administration of 20 nmol of a radiolabeled peptide of SEQ ID NO: 24 and oral (PO) administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 24, as quantified by measuring the 14C signal using liquid scintillation counting. The delivered dose of 14C was 4.8 pCi for intravenous administration and 24 pCi for oral administration. Time points examined included 0.08, 0.5, 1, 3, 8, 24, 48 hours and three mice were examined per time point. FIG. 68C shows the intensity of peptide and peptide fragment peaks in plasma as measured by tandem HPLC and liquid scintillation
-28WO 2017/044894
PCT/US2016/051166 counting after oral administration by gavage of 100 nmol of a radiolabeled peptide of SEQ ID
NO: 24. The delivered dose of 14C was 24 μ Ci for oral administration. Time points examined included 0.5, 1, and 3 hours.
[0111] FIG. 69 shows the concentration of a radiolabeled peptide of SEQ ID NO: 24 in urine after administration of the peptide to a mouse. FIG. 69A shows the concentration of peptide in urine after intravenous (IV) administration of 20 nmol of a radiolabeled peptide of SEQ ID NO: 24 and oral (PO) administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 24, as quantified by measuring the 14C signal using liquid scintillation counting. The delivered dose of 14C was 4.8 pCi for intravenous administration and 24 pCi for oral administration. Time points examined included 0.08, 0.5, 1, 3, 8, 24, 48 hours and three mice were examined per time point. FIG. 69B shows the intensity of peptide and peptide fragment peaks in urine as measured by tandem HPLC and liquid scintillation counting after oral administration by gavage of 100 nmol of a radiolabeled peptide of SEQ ID NO: 24. The delivered dose of 14C was 24 μ Ci for oral administration. Time points examined included 0.5, 1, 3, 8, 24, and 48 hours.
[0112] FIG. 70 shows the concentration of a radiolabeled peptide of SEQ ID NO: 24 in urine after administration of the peptide to a mouse. FIG. 70A shows the concentration of peptide in feces after intravenous (IV) administration of 20 nmol of a radiolabeled peptide of SEQ ID NO: 24 and oral (PO) administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 24, as quantified by measuring the 14C signal using liquid scintillation counting. The delivered dose of 14C was 4.8 pCi for intravenous administration and 24 pCi for oral administration. Time points examined included 0.08, 0.5, 1, 3, 8, 24, 48 hours and three mice were examined per time point. FIG. 70B shows the intensity of peptide and peptide fragment peaks in feces as measured by tandem HPLC and liquid scintillation counting after oral administration by gavage of 100 nmol of a radiolabeled peptide of SEQ ID NO: 24. The delivered dose of 14C was 24 μ Ci for oral administration. Time points examined included 3 and 8 hours.
[0113] FIG. 71 illustrates HPLC chromatograms of two peptides after exposure to reducing agents, proteinases, and/or simulated gastric fluid conditions. FIG. 71A illustrates the HPLC trace of a peptide of SEQ ID NO: 24 incubated in PBS. FIG. 71B illustrates the HPLC trace of a peptide of SEQ ID NO: 24 incubated in DTT in PBS. FIG. 71C illustrates the HPLC trace of a peptide of SEQ ID NO: 24 incubated in simulated gastric fluid (SGF). FIG. 71D illustrates the HPLC trace of a peptide of SEQ ID NO: 24 incubated in 500 U pepsin in SGF. FIG. 71E illustrates the HPLC trace of a peptide of SEQ ID NO: 24 incubated in 500 U
-29WO 2017/044894
PCT/US2016/051166 pepsin, 0.5 M Tris, and DTT in SGF. FIG. 71F illustrates the HPLC trace of a peptide of SEQ ID NO: 111 incubated in PBS. FIG. 71G illustrates the HPLC trace of a peptide of SEQ ID NO: 11 lincubated in DTT in PBS. FIG. 71H illustrates the HPLC trace of a peptide of SEQ ID NO: 11 lincubated in simulated gastric fluid (SGF). FIG. 711 illustrates the HPLC trace of a peptide of SEQ ID NO: 11 lincubated in 500 U pepsin in SGF. FIG. 71J illustrates the HPLC trace of a peptide of SEQ ID NO: 111 incubated in 500 U pepsin, 0.5 M Tris, and DTT in SGF.
[0114] FIG. 72 illustrates HPLC chromatograms of peptides of SEQ ID NO: 111 and SEQ ID NO: 434 after exposure to a range of conditions including oxidative, reductive, and acidic conditions as well as after exposure to proteinases. FIG. 72A illustrates the HPLC trace of a peptide of SEQ ID NO: 111 under reducing and acidic conditions. FIG. 72B illustrates the HPLC trace of a peptide of SEQ ID NO: 111 under various combinations of reducing agents and proteases including 10 mM DTT in 500 U pepsin, 500 U pepsin, 10 mM DTT in 50 U trypsin, and 50 U trypsin. FIG. 72C illustrates the HPLC trace of a peptide of SEQ ID NO: 434 under various protease conditions including in 500 U pepsin, in 50 U trypsin, nonreducing (NR, oxidized conditions) in simulated gastric fluid (SGF) at pH 1.05, and NR. [0115] FIG. 73 illustrates alignment of peptides within the pfam00451:toxin_2 structural class family of SEQ ID NO: 436 - SEQ ID NO: 482. Boxed and bolded residues indicate relative conservation of sequence while non-boxed and non-bolded residues indicate areas of higher sequence variability.
[0116] FIG. 74 illustrates alignment of a peptide of SEQ ID NO: 436 from the pfam0045 l:toxin 2 structural class family with a cartilage homing peptide of this disclosure of SEQ ID NO: 24. Asterisks indicate positions with a single, fully conserved residue, a colon indicates conservation between groups of strongly similar properties (scoring > 0.5 in the Gonnet point accepted mutation (PAM) 250 matrix), and a period indicates conservation between groups of weakly similar properties (scoring < 0.5 in the Gonnet PAM 250 matrix).
DETAILED DESCRIPTION [0117] The present disclosure relates generally to compositions and methods for cartilage therapy. In some embodiments, the compositions and methods herein utilize peptides that home, target, are directed to, are retained by, accumulate in, migrate to, and/or bind to cartilage following administration to a subject. In some embodiments, the cartilage homing peptides of the present disclosure are used to deliver an active agent to cartilage or tissue or cell thereof. The active agent can exert a therapeutic effect on cartilage or tissue or cell
- 30WO 2017/044894
PCT/US2016/051166 thereof. For example, in certain embodiments, the active agent allows for localized delivery of an anti-inflammatory agent to cartilage or tissue or cell thereof. As another example, the active agent is a fluorophore that can be used for imaging of cartilage. In certain embodiments, the peptide itself induces therapeutic responses.
[0118] Cartilage disorders are particularly difficult to treat. A direct route for drug administration can be intravenously, intra-articularly, or orally. However, cartilage can be avascular thus intravenous administration of drugs can fail to reach the cartilage. Drugs for cartilage diseases, such as osteoarthritis, can be injected directly locally into the affected area, for example, directly injected into the joint. Few drugs aimed at treating cartilage disorders have proved therapeutically viable with lack of access to target tissue being a primary reason for failure. The lack of access to the target tissue can also lead to administration of doses that are higher than would be necessary if a drug could home, target, or be directed to, is retained by, and/or binds to a target region, tissue, structure or cell. Thus, treatment of cartilage conditions often requires the use of high concentrations of non-specific drugs. In addition, a number of therapeutics are of interest in treating joint disorders, but are problematic because of the level of side effects caused by systemic administration of the drug (Dancevic and McCulloch, Arthritis Research & Therapy 16:429 (2014)).
[0119] Specific and potent drugs that are capable of contacting the cartilage can counteract the non-specificity of many treatments by selectively targeting and delivering compounds to specific regions, tissues, cells and structures. Such drugs can also be useful to modulate ion channels, protein-protein interactions, extracellular matrix remodeling (i.e., protease inhibition), and the like. Such targeted therapy can allow for lower dosing, reduced side effects, improved patient compliance, and improvement in therapeutic outcomes, which would be advantageous not only in acute disease of the cartilage, but in chronic conditions as well.
[0120] The present disclosure describes a class of peptides derived from knottins that can effectively contact cartilage and be used either directly or as carriers of active drugs, peptides, or molecules to treat a cartilage condition. For instance, osteoarthritis is a cartilage condition that is associated with the thinning of cartilage covering the ends of bones resulting in bone directly contacting bone within the joint. Over time, the ends of the bones are subjected to increased levels of friction which causes erosion of the end of the bone. Individuals suffering from osteoarthritis experience reduced motion and increased pain. A therapeutic peptide that could contact the cartilage at the joint and ends
- 31 WO 2017/044894
PCT/US2016/051166 of the bone to interact with the chondrocytes and induce increased expression of extracellular matrix proteins could be used in the treatment and prevention of osteoarthritis by increasing expression of collagen through, for example, the rate of production, amount of production, inhibition of proteins which degrade collagen, promote expression of other proteins which maintain the integrity of existing collagen proteins, or other mechanism. A peptide could also affect nearby tissues or cells such as the bone, osteoclasts, osteoblasts, ligaments, muscle, tendons, and bursa. The peptides of the disclosure can be used to treat the symptoms of various conditions. The peptides of the disclosure can bind to chondrocytes, to cartilage, to extracellular matrix, to collagen, hyaluranon, aggrecan (also known as cartilage-specific proteoglycan core protein (CSPCP)), or other components of the extracellular matrix, or to other components in joints and cartilaginous tissues.
[0121] Also described herein are peptides that selectively home, target, are directed to, migrate to, are retained by, or accumulate in and/or bind to specific regions, tissues, structures or cells of the cartilage that aid in managing, decreasing, ablating or reducing pain (e.g., joint pain) due to chronic disease or cartilage injury or other therapeutic indications as described herein. A peptide that homes, targets, migrates to, is directed to, is retained by, or accumulates in and/or binds to one or more specific regions, tissues, structures or cells of the cartilage can have fewer off-target and potentially negative effects, for example, side effects that often limit use and efficacy of pain drugs. In addition, such peptides can reduce dosage and increase the efficacy of existing drugs by directly targeting them to a specific region, tissue, structure or cell of the cartilage and helping the contact the cartilage or increasing the local concentration of agent. The peptide itself can modulate pain or it can be conjugated to an agent that modulates pain. Such pain modulation may operate by various mechanisms such as modulating inflammation, autoimmune responses, direct or indirect action on pain receptors, cell killing, or programmed cell death (whether via an apoptotic and/or non-apoptotic pathway of diseased cells or tissues, and the like (Tait et al. J Cell Sci 127(Pt 10):2135-44 (2014)). [0122] Peptides of this disclosure that home, target, are directed to, migrate to, are retained by, accumulate in, or bind to specific regions, tissues, structures or cells of the cartilage can do so with different degrees of efficiency. Peptides can have a higher concentration in cartilage than in other locations, such as blood or muscle. Peptides can be recorded as having a signal in cartilage as a percentage of signal in blood. For example, a cartilage signal of 200% indicates that the signal in cartilage is twice as high as the signal in blood. In some embodiments, peptides that have cartilage homing properties can have a cartilage
- 32WO 2017/044894
PCT/US2016/051166 signal of >170% by radio densitometry measurements. In other embodiments, peptides that are cartilage homers can have a cartilage signal of >200% by radio densitometry measurements. In other embodiments, peptides that are more efficient cartilage homers can have a cartilage signal of >300% by radio densitometry measurements. In other embodiments, peptides that are more efficient cartilage homers can have a cartilage signal of >400% by radio densitometry measurements. In other embodiments, peptides that are strongest cartilage homers of highest interest can have a cartilage signal of >500% by radio densitometry measurements.
[0123] Peptides that selectively home, target, are directed to, migrate to, are retained by, or accumulate in and/or bind to specific regions, tissues, structures or cells of the cartilage can occur after administration of the peptide to a subject. A subject can be a human or a non-human animal.
[0124] The peptides disclosed herein can be used as active agents such a fluorophores for imaging or to carry agents such as anti-inflammatory agents to the joint to treat inflammation.
[0125] The peptides disclosed herein can be used to bind cartilage explants ex vivo. Cartilage explants can be from any subject, such as a human or an animal. Assessment of peptide binding to cartilage explants can be used to screen peptides that may efficiently home to cartilage in vivo.
[0126] Additional aspects and advantages of the present disclosure will become apparent to those skilled in this art from the following detailed description, wherein illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.
[0127] As used herein, the abbreviations for the natural L-enantiomeric amino acids are conventional and are as follows: alanine (A, Ala); arginine (R, Arg); asparagine (N, Asn); aspartic acid (D, Asp); cysteine (C, Cys); glutamic acid (E, Glu); glutamine (Q, Gin); glycine (G, Gly); histidine (H, His); isoleucine (I, He); leucine (L, Leu); lysine (K, Lys); methionine (M, Met); phenylalanine (F, Phe); proline (P, Pro); serine (S, Ser); threonine (T, Thr); tryptophan (W, Trp); tyrosine (Y, Tyr); valine (V, Val). Typically, Xaa can indicate any amino acid. In some embodiments, X can be asparagine (N), glutamine (Q), histidine (H), lysine (K), or arginine (R).
- 33 WO 2017/044894
PCT/US2016/051166 [0128] Some embodiments of the disclosure contemplate D-amino acid residues of any standard or non-standard amino acid or analogue thereof. When an amino acid sequence is represented as a series of three-letter or one-letter amino acid abbreviations, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxy terminal direction, in accordance with standard usage and convention.
Peptides [0129] Knottins are a class of peptides, usually ranging from about 20 to about 80 amino acids in length that are often folded into a compact structure. Knottins are typically assembled into a complex tertiary structure that is characterized by a number of intramolecular disulfide crosslinks and may contain beta strands and other secondary structures. The presence of the disulfide bonds gives knottins remarkable environmental stability, allowing them to withstand extremes of temperature and pH and to resist the proteolytic enzymes of the blood stream.
[0130] A wider examination of the sequence structure and homology of knottins reveals that they have arisen by convergent evolution in all kinds of animals and plants. In animals, they are typically found in venoms, for example, the venoms of spiders and scorpions and have been implicated in the modulation of ion channels. Many of this class of peptide can be protease inhibitors, and as such can both home to cartilage and inhibit collagenase or a matrix metalloprotease that breaks down cartilage (e.g., matrix metalloprotease 13 (MMP13)). The knottin proteins of plants can inhibit the proteolytic enzymes of animals or have antimicrobial activity, suggesting that knottins can function in the native defense of plants. Many of this class of peptides can have antimicrobial activity, and as such one of these can both home to cartilage and treat microbial infections. Therefore, knottin peptides can interact with ion channels, and as such can home to cartilage and interact (bind, block, activate) with ion channels such as those in chondrocytes that are known to effect proliferation, mechanotransduction, and other functions (Potassium Ion Channels in Articular Chondrocytes, Ali Mobasheri, in Mechanosensitive Ion Channels Mechanosensitivity in Cells and Tissues Volume 1, 2008, pp 157-178).
[0131] The knotted peptides of the present disclosure provide certain advantages. For instance, the presence of the disulfide bonds gives knotted peptides remarkable environmental stability, allowing them to withstand extremes of temperature and pH and to resist the proteolytic enzymes of the blood stream, the gastrointestinal tract, and elsewhere in
- 34WO 2017/044894
PCT/US2016/051166 the body. The resistance of knotted peptides to degradation can be beneficial in terms of reducing immunogenicity. The rigidity of knotted peptides also allows them to bind to targets without paying the “entropic penalty” that a floppy peptide accrues upon binding a target.
The knotted peptides can bind targets with antibody-like affinity. The knotted peptides can modulate the activity of a plurality of cartilage regions, tissues, structures or cells. Some of the cartilage regions, tissues, structures include: (a) elastic cartilage; (b) hyaline cartilage, such as articular cartilage and physeal cartilage; (c) fibrocartilage; and (d) any cells or cell types in (a) - (c) above. Some of the areas where the knottin peptide can home to cartilage include joints such as knees, hips, or digits, nasal cartilage, spinal cartilage, tracheal cartilage, and rib cartilage. In various aspects, cartilage components include aggrecan and type II collagen. Additionally, in some embodiments, knotted peptides can penetrate into cells. In other embodiments, knotted peptides exhibit more rapid clearance and cellular uptake compared to other types of molecules.
[0132] The present disclosure provides peptides that comprise or are derived from these knotted peptides (or knottins). As used herein, the term “knotted peptide” is considered to be interchangeable with the terms “knottin” and “optide.” [0133] The peptides of the present disclosure can comprise cysteine amino acid residues. In some cases, the peptide has at least 4 cysteine amino acid residues. In some cases, the peptide has at least 6 cysteine amino acid residues. In other cases, the peptide has at least 8 cysteine amino acid residues, at least 10 cysteine amino acid residues, at least 12 cysteine amino acid residues, at least 14 cysteine amino acid residues or at least 16 cysteine amino acid residues. [0134] A knotted peptide can comprise disulfide bridges. A knotted peptide can be a peptide wherein 5% or more of the residues are cysteines forming intramolecular disulfide bonds. A disulfide-linked peptide can be a drug scaffold. In some embodiments, the disulfide bridges form an inhibitor knot. A disulfide bridge can be formed between cysteine residues, for example, between cysteines 1 and 4, 2 and 5, or, 3 and 6. In some cases, one disulfide bridge passes through a loop formed by the other two disulfide bridges, for example, to form the inhibitor knot. In other cases, the disulfide bridges can be formed between any two cysteine residues.
[0135] The present disclosure further includes peptide scaffolds that, e.g., can be used as a starting point for generating additional peptides that can target and home to cartilage. In some embodiments, these scaffolds can be derived from a variety of knotted peptides (or knottins). In certain embodiments, knotted peptides are assembled into a complex tertiary structure that is characterized by a number of intramolecular disulfide crosslinks, and optionally contain
-35WO 2017/044894
PCT/US2016/051166 beta strands and other secondary structures such as an alpha helix. For example, knotted peptides include, in some embodiments, small disulfide-rich proteins characterized by a disulfide through disulfide knot. This knot can be, e.g., obtained when one disulfide bridge crosses the macrocycle formed by two other disulfides and the interconnecting backbone. In some embodiments, the knotted peptides can include growth factor cysteine knots or inhibitor cysteine knots. Other possible peptide structures can include peptide having two parallel helices linked by two disulfide bridges without β- sheets (e.g., hefutoxin).
[0136] A knotted peptide can comprise at least one amino acid residue in an L configuration. A knotted peptide can comprise at least one amino acid residue in a D configuration. In some embodiments , a knotted peptide is 15-40 amino acid residues long. In other embodiments, a knotted peptide is 11-57 amino acid residues long. In further embodiments, a knotted peptide is at least 20 amino acid residues long.
[0137] These kinds of peptides can be derived from a class of proteins known to be present or associated with toxins or venoms. In some cases, the peptide can be derived from toxins or venoms associated with scorpions or spiders. The peptide can be derived from venoms and toxins of spiders and scorpions of various genus and species. For example, the peptide can be derived from a venom or toxin of the Leiurus quinquestriatus hebraeus, Buthus occitanus tunetanus, Hottentotta judaicus, Mesobuthus eupeus, Buthus occitanus Israelis, Hadrurus gertschi, Androctonus australis, Centruroides noxius, Heterometrus laoticus,
Opistophthalmus carinatus, Haplopelma schmidti, Isometrus maculatus, Grammostola rosea or another suitable genus or species of scorpion. In some cases, a peptide can be derived from a Buthus martensii Karsh (scorpion) toxin.
[0138] In some embodiments, the peptides are members of the pfam00451:toxin_2 family. The pfam00451:toxin_2 structural class family can include a peptide of any one of SEQ ID NO: 436 - SEQ ID NO: 482. A cartilage homoing peptide of this disclosure can be a variant of any peptide members of the pfam00451:toxin_2 family. In some embodiments, an exemplary cartilage homing peptide of this disclosure that is a variant of the pfam00451:toxin_2 structural class family is a peptide of SEQ ID NO: 24. In other embodiments, an exemplary cartilage homing peptide of this disclosure that is a variant of the pfam00451 :toxin_2 structural class family is a peptide of SEQ ID NO: 111. In other embodiments, the variant peptides are at least 30% identical to a peptide of the structural class pfam00451:toxin_2 family. In some embodiments, the variant peptides are 30%, 40%, 50%, 60%, 80%, 90% or 95% identical to a peptide of the structural class pfam00451:toxin_2 family. In some embodiments, the variant peptides are at least 30%, at least 40%, at least
- 36WO 2017/044894
PCT/US2016/051166
50%, at least 60%, at least 80%, at least 90% or at least 95% identical to a peptide of the structural class pfam00451:toxin_2 family. The pfam00451:toxin_2 family comprises peptide family members found as portions of various scorpion toxins, often functioning to block potassium channels. Features of the pfam00451:toxin_2 family include, but are not limited to, a features associated with members of a knottin 1 (CL0054) clan, which has at least 120 family members. For example, the average family member amino acid residue lengths is 31.4 amino acid residues, the average identity of family member sequence homology to the consensus sequence is 46%, and family members are derived from at least the following organisms: Tityus costatus, Centruroides noxius, Tityus serrulatus, Mesobuthus gibbosus, Centruroides elegans, Hottentotta judaicus, Mesobuthus eupeus, Parabuthus transvaalicus, Isometroides vescus, Hottentotta tamulus sindicus, Centruroides margaritatus, Centruroides suffusus suffusus, Buthus occitanus Israelis, Centruroides limpidus limpidus, Leiurus quinquestriatus hebraeus, Odontobuthus doriae, Mesobuthus tamulus, Tityus stigmurus, Lychas mucronatus, Androctonus australis, Orthochirus scrobiculosus, Mesobuthus martensii, Androctonus mauretanicus mauretanicus, Centruroides limbatus, Isometrus maculatus, Tityus discrepans, Androctonus amoreuxi, Buthus occitanus tunetanus, Tityus trivittatus and Tityus obscurus (Amazonian scorpion).
[0139] In some embodiments, cartilage homing peptides are members of family with the sequence GSXVXXXVKCXGSKQCXXPCKRXXGXRXGKCINKKXCKCYXXX (SEQ ID NO: 9), in which this sequence is based on the most common elements found in the following sequences:
GSGVPINVKCRGSRDCLDPCKKA-GMRFGKCINSK-CHCTP— (SEQ ID NO: 24), GS-VRIPVSCKHSGQCLKPCKDA-GMRFGKCMNGK-CDCTPK- (SEQ ID NO: 23), GSQVQTNVKCQGGS-CASVCRREIGVAAGKCINGK-CVCYRN- (SEQ ID NO: 27), GS——ISCTGSKQCYDPCKRKTGCPNAKCMNKS-CKCYGCG (SEQ ID NO: 26), GSEV—IRCSGSKQCYGPCKQQTGCTNSKCMNKV-CKCYGCG (SEQ ID NO: 28),
GSAVCVYRT------CDKDCKRR-GYRSGKCINNA-CKCYPYG (SEQ ID NO: 25),
GS—-GIVC—KVCKIICGMQ-GKKVNICKAPIKCKCKKG- (SEQ ID NO: 21), and GSQIYTSKECNGSSECYSHCEGITGKRSGKCINKK-CYCYR— (SEQ ID NO: 30), where the following residues may be independently interchanged in the sequences: K and R; Μ, I,
L, and V; G and A; S and T; Q and N; and X can independently be any number of any amino acid or no amino acid. The N-terminal GS sequence can be included or excluded between the peptides of the present disclosure.
-37WO 2017/044894
PCT/US2016/051166 [0140] In other embodiments, peptides are members of family with the sequence
GSXXXGCVXXXXKCRPGXKXCCXPXKRCSRRFGXXXXKKCKXXXX (SEQ ID NO:
10), in which the sequence is based on the most common elements found in the following sequences:
GS—ACKGVFDACTPGKNECC-PNRVCSDK-H—-KWCKWKL— (SEQ ID NO: 29), GS—GCLEFWWKCNPNDDKCCRPKLKCSKLF——KLCNFSFG— (SEQ ID NO: 31),
GSSEKDCIKHLQRCR-ENKDCC—SKKCSRR-GTNPEKRCR------(SEQ ID NO: 22), and
GS—GCFGY—KCDYY-KGCCSGYV-CSPTW—-KWCVRPGPGR (SEQ ID NO: 33), where the following residues may be independently interchanged in the sequences: K and R; Μ, I, L, and V; G and A; S and T; Q and N; and X can independently be any number of any amino acid or no amino acid. The N-terminal GS sequence can be included or excluded between the peptides of the present disclosure.
[0141] In some embodiments, a peptide comprises the sequence gsgvx1ix2x3kcx4gskqcx5dpckx6x7x8gx9rx10gkcx11nkkckcx12x13x14x15 (SEQ ID NO: 1), wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14and X15 are each individually any amino acid or amino acid analogue or null. In some cases, the peptide comprises the sequence gsgvx1ix2x3kcx4gskqcx5dpckx6x7x8gx9rx10gkcx11nkkckcx12x13x14x15
2 (SEQ ID NO: 2), where X is selected from P or R, wherein X is selected from P or N, wherein X is selected from V or I, wherein X is selected from S, T, R or K, wherein X is selected from Y or L, wherein X6 is selected from Q, R or K, wherein X7 is selected from A, K or R, wherein X8 is selected from T or A, wherein X9 is selected from C or M, wherein X10 is selected from F or N, wherein X is selected from M or I, wherein X is selected from Y or T, wherein X13 is selected from G or P, wherein X14 is selected from C or null, and wherein X15 is selected from G or null.
[0142] In some embodiments, a peptide comprises the sequence
X1X2X3X4IX5CX6GSKQCYX7PCKX8X9TGCX10X11X12KCX13X14KX15CKCYGCG (SEQ ID NO: 3), wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, and X15are each individually any amino acid or amino acid analogue or null. In some cases, the peptide comprises the sequence
X1X2X3X4IX5CX6GSKQCYX7PCKX8X9TGCX10X11X12KCX13X14KX15CKCYGCG, (SEQ ID NO: 4), where X is selected from G or null, wherein X is selected from S or null, wherein X is selected from E, G or null, wherein X is selected from V, S, or null, wherein X5 is selected from R or S, wherein X6 is selected from S or T, wherein X7 is selected from G
-38WO 2017/044894
PCT/US2016/051166 or D, wherein X8 is selected from Q or R, wherein X9 is selected from Q or K, wherein X10 is selected from T or P, wherein X is selected from N or Q, wherein X is selected from S or
A, wherein X13 is selected from M or L, wherein X14 is selected from N or Q, and wherein
X15 is selected from V or S.
[0143] In some embodiments, a peptide comprises the sequence
X1X2X3VX4IX5VX6CX7X8SX9X10CLX11PCKX12AGMRFGKCX13NX14KCX15CTPX16 (SEQ
ID NO: 5), wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16are each individually any amino acid or amino acid analogue or null. In some cases, the peptide comprises the sequence
X1X2X3VX4IX5VX6CX7X8SX9X10CLX11PCKX12AGMRFGKCX13NX14KCX15CTPX16 (SEQ
2
ID NO: 6), where X is selected from G or null, wherein X is selected from G, S or null, wherein X is selected from G, S or null, wherein X is selected from P or R, wherein X is selected from N or P, wherein X6 is selected from K or S, wherein X7 is selected from R or K, wherein X8 is selected from G or H, wherein X9 is selected from R or G, wherein X10 is selected from D or Q, wherein X is selected from D or K, wherein X is selected from K or D, wherein X13 is selected from I or M, wherein X14 is selected from S or G, wherein X15 is selected from H or D, and wherein X16 is selected from K or null.
[0144] In some embodiments, a peptide comprises the sequence
XVXVKCXGSKQCXPCKRXGXRXGKCINKKXCKCYX (SEQ ID NO: 7) or
XGCVXKCRPGXKXCCXPXKRCSRRFGXKKCKX (SEQ ID NO: 8), wherein each letter is each individually any amino acid or amino acid analogue and where X is no amino acid or a 1-10 amino acid long peptide fragment wherein each amino acid within such peptide fragment can in each case be any amino acid or amino acid analogue.
[0145] In some embodiments, a peptide comprises the sequence
GSGVX1IX2X3RCX4GSRQCX5DPCRX6X7X8GX9RX10GRCX11NRRCRCX12X13X14X15 (SEQ ID NO: 11), wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14and X15 are each individually any amino acid or amino acid analogue or null. In some cases, the peptide comprises the sequence
GSGVX1IX2X3RCX4GSRQCX5DPCRX6X7X8GX9RX10GRCX11NRRCRCX12X13X14X15 (SEQ ID NO: 12), where X is selected from P or R, wherein X is selected from P or N, wherein X is selected from V or I, wherein X is selected from S, T, R or K, wherein X is selected from Y or L, wherein X6 is selected from Q, R or K, wherein X7 is selected from A, K or R, wherein X8 is selected from T or A, wherein X9 is selected from C or M, wherein X10 is selected from F or N, wherein X is selected from M or I, wherein X is selected from Y
- 39WO 2017/044894
PCT/US2016/051166 or T, wherein X13 is selected from G or P, wherein X14 is selected from C or null, and wherein X15 is selected from G or null.
[0146] In some embodiments, a peptide comprises the sequence
X1X2X3X4IX5CX6GSRQCYX7PCRXsX9TGCX 1 °X1 ^^RCX^X^RX^CRCYGCG (SEQ ID NO: 13), wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, and X15are each individually any amino acid or amino acid analogue or null. In some cases, the peptide comprises the sequence
X1X2X3X4IX5CX6GSRQCYX7PCRX8X9TGCX10X11X12RCX13X14RX15CRCYGCG, (SEQ ID NO: 14), where X is selected from G or null, wherein X is selected from S or null, wherein X is selected from E, G or null, wherein X is selected from V, S, or null, wherein X5 is selected from R or S, wherein X6 is selected from S or T, wherein X7 is selected from G or D, wherein X is selected from Q or R, wherein X is selected from Q, R, or K, wherein X10 is selected from T or P, wherein X11 is selected from N or Q, wherein X12 is selected from S or A, wherein X13 is selected from M or L, wherein X14 is selected from N or Q, and wherein X15 is selected from V or S.
In some embodiments, a peptide comprises the sequence
X1X2X3VX4IX5VX6CX7X8SX9X10CLX11PCRX12AGMRFGRCX13NX14RCX15CTPX16 (SEQ
ID NO: 15), wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16are each individually any amino acid or amino acid analogue or null. In some cases, the peptide comprises the sequence
X1X2X3VX4IX5VX6CX7X8SX9X10CLX11PCRX12AGMRFGRCX13NX14RCX15CTPX16 (SEQ
2
ID NO: 16), where X is selected from G or null, wherein X is selected from G, S or null, wherein X is selected from G, S or null, wherein X is selected from P or R, wherein X is selected from N or P, wherein X6 is selected from R, K or S, wherein X7 is selected from R or K, wherein X8 is selected from G or H, wherein X9 is selected from R or G, wherein X10 is selected from D or Q, wherein X is selected from D, R, or K, wherein X is selected from K, R, or D, wherein X13 is selected from I or M, wherein X14 is selected from S or G, wherein X15 is selected from H or D, and wherein X16 is selected from K, R, or null.
[0147] In some embodiments, a peptide comprises the sequence
XVXVRCXGSRQCXPCRRXGXRXGRCINRRXCRCYX (SEQ ID NO: 17) or
XGCVXRCRPGXRXCCXPXRRCSRRFGXRRCRX (SEQ ID NO: 18), wherein each letter is each individually any amino acid or amino acid analogue and where X is no amino acid or a 1-10 amino acid long peptide fragment wherein each amino acid within such peptide fragment can in each case be any amino acid or amino acid analogue.
-40WO 2017/044894
PCT/US2016/051166 [0148] In some embodiments, a peptide comprises one or more of the following peptide fragments: SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID
NO: 104, SEQ ID NO: 105, SEQ ID NO: 186, SEQ ID NO: 187, SEQ ID NO: 188, SEQ ID
NO: 189, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 193, and SEQ ID NO: 194.
[0149] TABLE 1 lists some exemplary peptides according to the present disclosure.
TABLE 1
SEQ ID NO Amino Acid Sequence
SEQ ID NO: 21 GSGIVCKVCKIICGMQGKKVNICKAPIKCKCKKG
SEQ ID NO: 22 GSSEKDCIKHLQRCRENKDCCSKKCSRRGTNPEKRCR
SEQ ID NO: 23 GSVRIPVSCKHSGQCLKPCKDAGMRFGKCMNGKCDCTPK
SEQ ID NO: 24 GSGVPINVKCRGSRDCLDPCKKAGMRFGKCINSKCHCTP
SEQ ID NO: 25 GSAVCVYRTCDKDCKRRGYRSGKCINNACKCYPYG
SEQ ID NO: 26 GSISCTGSKQCYDPCKRKTGCPNAKCMNKSCKCYGCG
SEQ ID NO: 27 GSQVQTNVKCQGGSCASVCRREIGVAAGKCINGKCVCYRN
SEQ ID NO: 28 GSEVIRCSGSKQCYGPCKQQTGCTNSKCMNKVCKCYGCG
SEQ ID NO: 29 GSACKGVFDACTPGKNECCPNRVCSDKHKWCKWKL
SEQ ID NO: 30 GSQIYTSKECNGSSECYSHCEGITGKRSGKCINKKCYCYR
SEQ ID NO: 31 GSGCLEFWWKCNPNDDKCCRPKLKCSKLFKLCNFSFG
SEQ ID NO: 32 GSDCVRFWGKCSQTSDCCPHLACKSKWPRNICVWDGSVG
SEQ ID NO: 33 GSGCFGYKCDYYKGCCSGYVCSPTWKWCVRPGPGR
SEQ ID NO: 34 GSMNAKFILLLVLTTMMLLPDTKGAEVIRCSGSKQCYGPCKQQTGCT NSKCMNKVCKCYGCG
SEQ ID NO: 35 GSMNAKLIYLLLVVTTMTLMFDTAQAVDIMCSGPKQCYGPCKKETG CPNAKCMNRRCKCYGCV
SEQ ID NO: 36 GSMNAKLIYLLLVVTTMMLTFDTTQAGDIKCSGTRQCWGPCKKQTT CTNSKCMNGKCKCYGCVG
SEQ ID NO: 37 GSMNTKFIFLLLVVTNTMMLFDTKPVEGISCTGSKQCYDPCKRKTGC PNAKCMNKSCKCYGCG
SEQ ID NO: 38 GSGVPINVKCSGSRDCLEPCKKAGMRFGKCINRKCHCTPK
SEQ ID NO: 39 GSGVPINVKCTGSPQCLKPCKDAGMRFGKCINGKCHCTPK
SEQ ID NO: 40 GSGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK
SEQ ID NO: 41 GSGVPINVKCRGSPQCIQPCRDAGMRFGKCMNGKCHCTPQ
-41 WO 2017/044894
PCT/US2016/051166
SEQ ID NO Amino Acid Sequence
SEQ ID NO: 42 GSGVEINVKCTGSHQCIKPCKDAGMRFGKCINRKCHCTPK
SEQ ID NO: 43 GSGVEINVKCSGSPQCLKPCKDAGMRFGKCMNRKCHCTPK
SEQ ID NO: 44 GSGVPTDVKCRGSPQCIQPCKDAGMRFGKCMNGKCHCTPK
SEQ ID NO: 45 GSGVPINVSCTGSPQCIKPCKDAGMRFGKCMNRKCHCTPK
SEQ ID NO: 46 GSGVPINVPCTGSPQCIKPCKDAGMRFGKCMNRKCHCTPK
SEQ ID NO: 47 GSVGINVKCKHSGQCLKPCKDAGMRFGKCINGKCDCTPK
SEQ ID NO: 48 GSVGINVKCKHSGQCLKPCKDAGMRFGKCMNGKCDCTPK
SEQ ID NO: 49 GSVGIPVSCKHSGQCIKPCKDAGMRFGKCMNRKCDCTPK
SEQ ID NO: 50 GSRKGCFKEGHSCPKTAPCCRPLVCKGPSPNTKKCTRP
SEQ ID NO: 51 GSSFCIPFKPCKSDENCCKKFKCKTTGIVKLCRW
SEQ ID NO: 52 GSLKGCLPRNRFCNALSGPRCCSGLRCKELSIWASKCL
SEQ ID NO: 53 GSGNYCLRGRCLPGGRKCCNGRPCECFAKICSCKPK
SEQ ID NO: 54 GSTVKCGGCNRKCCPGGCRSGKCINGKCQCY
SEQ ID NO: 55 GSGCMKEYCAGQCRGKVSQDYCLKHCKCIPR
SEQ ID NO: 56 GSACLGFGEKCNPSNDKCCKSSSLVCSQKHKWCKYG
SEQ ID NO: 57 GSRGGCLPHNRFCNALSGPRCCSGLRCKELSIRDSRCLG
SEQ ID NO: 58 GSRGGCLPRNKFCNPSSGPRCCSGLTCKELNIWASKCL
SEQ ID NO: 59 GSQRSCAKPGDMCMGIKCCDGQCGCNRGTGRCFCK
SEQ ID NO: 60 GSARGCADAYKSCNHPRTCCDGYNGYKRACICSGSNCKCKKS
SEQ ID NO: 61 GSRGGCLPHNRFCNALSGPRCCSGLRCKELSIWDSRCLG
SEQ ID NO: 62 GSRGGCLPHNRFCNALSGPRCCSGLKCKELSIYDSRCLG
SEQ ID NO: 63 GSRGGCLPHNRFCNALSGPRCCSRLKCKELSIWDSRCLG
SEQ ID NO: 64 GSRGGCLPHNRFCNALTGPRCCSRLRCKELSIWDSICLG
SEQ ID NO: 65 GSSCADAYKSCDSLKCCNNRTCMCSMIGTNCTCRKK
SEQ ID NO: 66 GSERRCLPAGKTCVRGPMRVPCCGSCSQNKCT
SEQ ID NO: 67 GSLCSREGEFCYKLRKCCAGFYCKAFVLHCYRN
SEQ ID NO: 68 GSACGSCRKKCKGSGKCINGRCKCY
SEQ ID NO: 69 GSACGSCRKKCKGPGKCINGRCKCY
SEQ ID NO: 70 GSACQGYMRKCGRDKPPCCKKLECSKTWRWCVWN
SEQ ID NO: 71 GSGRYCQKWMWTCDSKRACCEGLRCKLWCRKI
SEQ ID NO: 72 GSNAKCRGSPECLPKCKEAIGKAAGKCMNGKCKCYP
-42WO 2017/044894
PCT/US2016/051166
SEQ ID NO Amino Acid Sequence
SEQ ID NO: 73 GSNVKCRGSKECLPACKAAVGKAAGKCMNGKCKCYP
SEQ ID NO: 74 GSNVKCRGSPECLPKCKEAIGKSAGKCMNGKCKCYP
SEQ ID NO: 75 GSNAKCRGSPECLPKCKQAIGKAAGKCMNGKCKCYP
SEQ ID NO: 76 GSRGYCAEKGIKCHNIHCCSGLTCKCKGSSCVCRK
SEQ ID NO: 77 GSERGCKLTFWKCKNKKECCGWNACALGICMPR
SEQ ID NO: 78 GSKKKCIAKDYGRCKWGGTPCCRGRGCICSIMGTNCECKPR
SEQ ID NO: 79 GSGCKLTFWKCKNKKECCGWNACALGICMPR
SEQ ID NO: 80 GSACKGLFVTCTPGKDECCPNHVCSSKHKWCKYK
SEQ ID NO: 81 GSIACAPRGLLCFRDKECCKGLTCKGRFVNTWPTFCLV
SEQ ID NO: 82 GSACAGLYKKCGKGVNTCCENRPCKCDLAMGNCICKKK
SEQ ID NO: 83 GSFTCAISCDIKVNGKPCKGSGEKKCSGGWSCKFNVCVKV
SEQ ID NO: 84 GSGFCAQKGIKCHDIHCCTNLKCVREGSNRVCRKA
SEQ ID NO: 85 GSCAKKRNWCGKNEDCCCPMKCIYAWYNQQGSCQSTITGLFKKC
SEQ ID NO: 86 GSYCQKWMWTCDSARKCCEGLVCRLWCKKI
SEQ ID NO: 87 GSRGGCLPHNKFCNALSGPRCCSGLKCKELTIWNTKCLE
SEQ ID NO: 88 GSNVKCTGSKQCLPACKAAVGKAAGKCMNGKCKCYT
SEQ ID NO: 89 GSQRSCAKPGEMCMRIKCCDGQCGCNRGTGRCFCK
SEQ ID NO: 90 GSGCIPKHKRCTWSGPKCCNNISCHCNISGTLCKCRPG
SEQ ID NO: 91 GSNYCVAKRCRPGGRQCCSGKPCACVGKVCKCPRD
SEQ ID NO: 92 GSERGCSGAYKRCSSSQRCCEGRPCVCSAINSNCKCRKT
SEQ ID NO: 93 GSRYCPRNPEACYNYCLRTGRPGGYCGGRSRITCFCFR
SEQ ID NO: 94 GSQRSCAKPGEMCMGIKCCDGQCGCNRGTGRCFCK
SEQ ID NO: 95 GSRRGCFKEGKWCPKSAPCCAPLKCKGPSIKQQKCVRE
SEQ ID NO: 96 GSTVKCGGCNRKCCAGGCRSGKCINGKCQCYGR
SEQ ID NO: 97 GSERRCEPSGKPCRPLMRIPCCGSCVRGKCA
SEQ ID NO: 98 GSRGGCLPRNKFCNPSSGPRCCSGLTCKELNIWANKCL
SEQ ID NO: 99 GSCAKKRNWCGKNEDCCCPMKCIYAWYNQQGSCQTTITGLFKKC
SEQ ID NO: 100 GSGKCINKKCKC
SEQ ID NO: 101 GSKCIN
SEQ ID NO: 102 GSKKCK
SEQ ID NO: 103 GSPCKR
-43WO 2017/044894
PCT/US2016/051166
SEQ ID NO Amino Acid Sequence
SEQ ID NO: 104 GSKRCSRR
SEQ ID NO: 105 GSKQC
SEQ ID NO: 106 GSVRIPVSCKHSGQCLKPCKDAGMRTGKCMNGKCDCTPK
SEQ ID NO: 107 GSVKCTTSKDCWPPCKKVTGRA
SEQ ID NO: 108 GSGIVCRVCRIICGMQGRRVNICRAPIRCRCRRG
SEQ ID NO: 109 GSSERDCIRHLQRCRENRDCCSRRCSRRGTNPERRCR
SEQ ID NO: 110 GSVRIPVSCRHSGQCLRPCRDAGMRFGRCMNGRCDCTPR
SEQ ID NO: 111 GSGVPINVRCRGSRDCLDPCRRAGMRFGRCINSRCHCTP
SEQ ID NO: 112 GSAVCVYRTCDRDCRRRGYRSGRCINNACRCYPYG
SEQ ID NO: 113 GSISCTGSRQCYDPCRRRTGCPNARCMNRSCRCYGCG
SEQ ID NO: 114 GSQVQTNVRCQGGSCASVCRREIGVAAGRCINGRCVCYRN
SEQ ID NO: 115 GSEVIRCSGSRQCYGPCRQQTGCTNSRCMNRVCRCYGCG
SEQ ID NO: 116 GSACRGVFDACTPGRNECCPNRVCSDRHRWCRWRL
SEQ ID NO: 117 GSQIYTSRECNGSSECYSHCEGITGRRSGRCINRRCYCYR
SEQ ID NO: 118 GSGCLEFWWRCNPNDDRCCRPRLRCSRLFRLCNFSFG
SEQ ID NO: 119 GSDCVRFWGRCSQTSDCCPHLACRSRWPRNICVWDGSVG
SEQ ID NO: 120 GSGCFGYRCDYYRGCCSGYVCSPTWRWCVRPGPGR
SEQ ID NO: 121 GSMNARFILLLVLTTMMLLPDTRGAEVIRCSGSRQCYGPCRQQTGCT NSRCMNRVCRCYGCG
SEQ ID NO: 122 GSMNARLIYLLLVVTTMTLMFDTAQAVDIMCSGPRQCYGPCRRETGC PNARCMNRRCRCYGCV
SEQ ID NO: 123 GSMNARLIYLLLVVTTMMLTFDTTQAGDIRCSGTRQCWGPCRRQTTC TNSRCMNGRCRCYGCVG
SEQ ID NO: 124 GSMNTRFIFLLLVVTNTMMLFDTRPVEGISCTGSRQCYDPCRRRTGCP NARCMNRSCRCYGCG
SEQ ID NO: 125 GSGVPINVRCSGSRDCLEPCRRAGMRFGRCINRRCHCTPR
SEQ ID NO: 126 GSGVPINVRCTGSPQCLRPCRDAGMRFGRCINGRCHCTPR
SEQ ID NO: 127 GSGVIINVRCRISRQCLEPCRRAGMRFGRCMNGRCHCTPR
SEQ ID NO: 128 GSGVPINVRCRGSPQCIQPCRDAGMRFGRCMNGRCHCTPQ
SEQ ID NO: 129 GSGVEINVRCTGSHQCIRPCRDAGMRFGRCINRRCHCTPR
SEQ ID NO: 130 GSGVEINVRCSGSPQCLRPCRDAGMRFGRCMNRRCHCTPR
-44WO 2017/044894
PCT/US2016/051166
SEQ ID NO Amino Acid Sequence
SEQ ID NO: 131 GSGVPTDVRCRGSPQCIQPCRDAGMRFGRCMNGRCHCTPR
SEQ ID NO: 132 GSGVPINVSCTGSPQCIRPCRDAGMRFGRCMNRRCHCTPR
SEQ ID NO: 133 GSGVPINVPCTGSPQCIRPCRDAGMRFGRCMNRRCHCTPR
SEQ ID NO: 134 GSVGINVRCRHSGQCLRPCRDAGMRFGRCINGRCDCTPR
SEQ ID NO: 135 GSVGINVRCRHSGQCLRPCRDAGMRFGRCMNGRCDCTPR
SEQ ID NO: 136 GSVGIPVSCRHSGQCIRPCRDAGMRFGRCMNRRCDCTPR
SEQ ID NO: 137 GSRRGCFREGHSCPRTAPCCRPLVCRGPSPNTRRCTRP
SEQ ID NO: 138 GSSFCIPFRPCRSDENCCRRFRCRTTGIVRLCRW
SEQ ID NO: 139 GSLRGCLPRNRFCNALSGPRCCSGLRCRELSIWASRCL
SEQ ID NO: 140 GSGNYCLRGRCLPGGRRCCNGRPCECFARICSCRPR
SEQ ID NO: 141 GSTVRCGGCNRRCCPGGCRSGRCINGRCQCY
SEQ ID NO: 142 GSGCMREYCAGQCRGRVSQDYCLRHCRCIPR
SEQ ID NO: 143 GSACLGFGERCNPSNDRCCRSSSLVCSQRHRWCRYG
SEQ ID NO: 144 GSRGGCLPHNRFCNALSGPRCCSGLRCRELSIRDSRCLG
SEQ ID NO: 145 GSRGGCLPRNRFCNPSSGPRCCSGLTCRELNIWASRCL
SEQ ID NO: 146 GSQRSCARPGDMCMGIRCCDGQCGCNRGTGRCFCR
SEQ ID NO: 147 GSARGCADAYRSCNHPRTCCDGYNGYRRACICSGSNCRCRRS
SEQ ID NO: 148 GSRGGCLPHNRFCNALSGPRCCSGLRCRELSIWDSRCLG
SEQ ID NO: 149 GSRGGCLPHNRFCNALSGPRCCSGLRCRELSIYDSRCLG
SEQ ID NO: 150 GSRGGCLPHNRFCNALSGPRCCSRLRCRELSIWDSRCLG
SEQ ID NO: 151 GSRGGCLPHNRFCNALTGPRCCSRLRCRELSIWDSICLG
SEQ ID NO: 152 GSSCADAYKSCDSLRCCNNRTCMCSMIGTNCTCRRR
SEQ ID NO: 153 GSERRCLPAGRTCVRGPMRVPCCGSCSQNRCT
SEQ ID NO: 154 GSLCSREGEFCYRLRRCCAGFYCRAFVLHCYRN
SEQ ID NO: 155 GSACGSCRRRCRGSGRCINGRCRCY
SEQ ID NO: 156 GSACGSCRRRCRGPGRCINGRCRCY
SEQ ID NO: 157 GSACQGYMRRCGRDRPPCCRRLECSRTWRWCVWN
SEQ ID NO: 158 GSGRYCQRWMWTCDSRRACCEGLRCRLWCRRI
SEQ ID NO: 159 GSNARCRGSPECLPRCREAIGRAAGRCMNGRCRCYP
SEQ ID NO: 160 GSNVRCRGSRECLPACRAAVGRAAGRCMNGRCRCYP
SEQ ID NO: 161 GSNVRCRGSPECLPRCREAIGRSAGRCMNGRCRCYP
-45WO 2017/044894
PCT/US2016/051166
SEQ ID NO Amino Acid Sequence
SEQ ID NO: 162 GSNARCRGSPECLPRCRQAIGRAAGRCMNGRCRCYP
SEQ ID NO: 163 GSRGYCAERGIRCHNIHCCSGLTCRCRGSSCVCRR
SEQ ID NO: 164 GSERGCRLTFWRCRNRRECCGWNACALGICMPR
SEQ ID NO: 165 GSRRRCIARDYGRCRWGGTPCCRGRGCICSIMGTNCECRPR
SEQ ID NO: 166 GSGCRLTFWRCRNRRECCGWNACALGICMPR
SEQ ID NO: 167 GSACRGLFVTCTPGRDECCPNHVCSSRHRWCRYR
SEQ ID NO: 168 GSIACAPRGLLCFRDRECCRGLTCRGRFVNTWPTFCLV
SEQ ID NO: 169 GSACAGLYRRCGRGVNTCCENRPCRCDLAMGNCICRRR
SEQ ID NO: 170 GSFTCAISCDIRVNGRPCRGSGERRCSGGWSCRFNVCVRV
SEQ ID NO: 171 GSGFCAQRGIRCHDIHCCTNLRCVREGSNRVCRRA
SEQ ID NO: 172 GSCARRRNWCGRNEDCCCPMRCIYAWYNQQGSCQSTITGLFRRC
SEQ ID NO: 173 GSYCQRWMWTCDSARRCCEGLVCRLWCRRI
SEQ ID NO: 174 GSRGGCLPHNRFCNALSGPRCCSGLRCRELTIWNTRCLE
SEQ ID NO: 175 GSNVRCTGSRQCLPACRAAVGRAAGRCMNGRCRCYT
SEQ ID NO: 176 GSQRSCARPGEMCMRIRCCDGQCGCNRGTGRCFCR
SEQ ID NO: 177 GSGCIPRHRRCTWSGPRCCNNISCHCNISGTLCRCRPG
SEQ ID NO: 178 GSNYCVARRCRPGGRQCCSGRPCACVGRVCRCPRD
SEQ ID NO: 179 GSERGCSGAYRRCSSSQRCCEGRPCVCSAINSNCRCRRT
SEQ ID NO: 180 GSQRSCARPGEMCMGIRCCDGQCGCNRGTGRCFCR
SEQ ID NO: 181 GSRRGCFREGRWCPRSAPCCAPLRCRGPSIRQQRCVRE
SEQ ID NO: 182 GSTVRCGGCNRRCCAGGCRSGRCINGRCQCYGR
SEQ ID NO: 183 GSERRCEPSGRPCRPLMRIPCCGSCVRGRCA
SEQ ID NO: 184 GSRGGCLPRNRFCNPSSGPRCCSGLTCRELNIWANRCL
SEQ ID NO: 185 GSCARRRNWCGRNEDCCCPMRCIYAWYNQQGSCQTTITGLFRRC
SEQ ID NO: 186 GSGRCINRRCRC
SEQ ID NO: 187 GSRCIN
SEQ ID NO: 188 GSRRCR
SEQ ID NO: 189 GSPCRR
SEQ ID NO: 190 GSRRCSRR
SEQ ID NO: 191 GSRQC
SEQ ID NO: 192 GSVRIPVSCRHSGQCLRPCRDAGMRTGRCMNGRCDCTPR
-46WO 2017/044894
PCT/US2016/051166
SEQ ID NO Amino Acid Sequence
SEQ ID NO: 193 GSPCKK
SEQ ID NO: 194 GSKKCSKK
SEQ ID NO: 196 GSQKILSNRCNNSSECIPHCIRIFGTRAAKCINRKCYCYP
SEQ ID NO: 198 GSAVCNLKRCQLSCRSLGLLGKCIGDKCECVKHG
SEQ ID NO: 199 GSISIGIRCSPSIDLCEGQCRIRRYFTGYCSGDTCHCSG
SEQ ID NO: 200 GSGDCLPHLRRCRENNDCCSRRCRRRGANPERRCR
SEQ ID NO: 201 GSSCEPGRTFRDRCNTCKCGADGRSAACTLRACPNQ
SEQ ID NO: 202 GSGDCLPHLKRCKADNDCCGKKCKRRGTNAEKRCR
SEQ ID NO: 203 GSGDCLPHLKRCKENNDCCSKKCKRRGTNPEKRCR
SEQ ID NO: 204 GSKDCLKKLKLCKENKDCCSKSCKRRGTNIEKRCR
SEQ ID NO: 205 GSGDCLPHLKRCKENNDCCSKKCKRRGANPEKRCR
SEQ ID NO: 206 GSVFINVKCRGSPECLPKCKEAIGKSAGKCMNGKCKCYP
SEQ ID NO: 207 GSVFINAKCRGSPECLPKCKEAIGKAAGKCMNGKCKCYP
SEQ ID NO: 208 GSVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTP
SEQ ID NO: 209 GSVPTDVKCRGSPQCIQPCKDAGMRFGKCMNGKCHCTP
SEQ ID NO: 210 GSVRIPVSCKHSGQCLKPCKDAGMRFGKCMNGKCDCTP
SEQ ID NO: 211 GSVRIPVSCRHSGQCLRPCRDAGMRFGRCMNGRCDCTP
SEQ ID NO: 212 GSTNVSCTTSKECWSVCQRLHNTSRGKCMNKKCRC
SEQ ID NO: 213 GSNVKCTGSKQCLPACKAAVGKAAGKCMNGKCKC
SEQ ID NO: 214 GSGVPINVRCRGSRDCLDPCRGAGERHGRCGNSRCHCTP
SEQ ID NO: 215 GSVRIPVSCRHSGQCLRPCRDAGERHGRCGGGRCDCTPR
SEQ ID NO: 216 GSQVQTNVRCQGGSCGSVCRREGGGAGGGCGNGRCGCYRN
SEQ ID NO: 237 GIVCKVCKIICGMQGKKVNICKAPIKCKCKKG
SEQ ID NO: 238 SEKDCIKHLQRCRENKDCCSKKCSRRGTNPEKRCR
SEQ ID NO: 239 VRIPVSCKHSGQCLKPCKDAGMRFGKCMNGKCDCTPK
SEQ ID NO: 240 GVPINVKCRGSRDCLDPCKKAGMRFGKCINSKCHCTP
SEQ ID NO: 241 AVCVYRTCDKDCKRRGYRSGKCINNACKCYPYG
SEQ ID NO: 242 ISCTGSKQCYDPCKRKTGCPNAKCMNKSCKCYGCG
SEQ ID NO: 243 QVQTNVKCQGGSCASVCRREIGVAAGKCINGKCVCYRN
SEQ ID NO: 244 EVIRCSGSKQCYGPCKQQTGCTNSKCMNKVCKCYGCG
SEQ ID NO: 245 ACKGVFDACTPGKNECCPNRVCSDKHKWCKWKL
-47WO 2017/044894
PCT/US2016/051166
SEQ ID NO Amino Acid Sequence
SEQ ID NO: 246 QIYTSKECNGSSECYSHCEGITGKRSGKCINKKCYCYR
SEQ ID NO: 247 GCLEFWWKCNPNDDKCCRPKLKCSKLFKLCNFSFG
SEQ ID NO: 248 DCVRFWGKCSQTSDCCPHLACKSKWPRNICVWDGSVG
SEQ ID NO: 249 GCFGYKCDYYKGCCSGYVCSPTWKWCVRPGPGR
SEQ ID NO: 250 MNAKFILLLVLTTMMLLPDTKGAEVIRCSGSKQCYGPCKQQTGCTNS KCMNKVCKCYGCG
SEQ ID NO: 251 MNAKLIYLLLVVTTMTLMFDTAQAVDIMCSGPKQCYGPCKKETGCP NAKCMNRRCKCYGCV
SEQ ID NO: 252 MNAKLIYLLLVVTTMMLTFDTTQAGDIKCSGTRQCWGPCKKQTTCT NSKCMNGKCKCYGCVG
SEQ ID NO: 253 MNTKFIFLLLVVTNTMMLFDTKPVEGISCTGSKQCYDPCKRKTGCPN AKCMNKSCKCYGCG
SEQ ID NO: 254 GVPINVKCSGSRDCLEPCKKAGMRFGKCINRKCHCTPK
SEQ ID NO: 255 GVPINVKCTGSPQCLKPCKDAGMRFGKCINGKCHCTPK
SEQ ID NO: 256 GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK
SEQ ID NO: 257 GVPINVKCRGSPQCIQPCRDAGMRFGKCMNGKCHCTPQ
SEQ ID NO: 258 GVEINVKCTGSHQCIKPCKDAGMRFGKCINRKCHCTPK
SEQ ID NO: 259 GVEINVKCSGSPQCLKPCKDAGMRFGKCMNRKCHCTPK
SEQ ID NO: 260 GVPTDVKCRGSPQCIQPCKDAGMRFGKCMNGKCHCTPK
SEQ ID NO: 261 GVPINVSCTGSPQCIKPCKDAGMRFGKCMNRKCHCTPK
SEQ ID NO: 262 GVPINVPCTGSPQCIKPCKDAGMRFGKCMNRKCHCTPK
SEQ ID NO: 263 VGINVKCKHSGQCLKPCKDAGMRFGKCINGKCDCTPK
SEQ ID NO: 264 VGINVKCKHSGQCLKPCKDAGMRFGKCMNGKCDCTPK
SEQ ID NO: 265 VGIPVSCKHSGQCIKPCKDAGMRFGKCMNRKCDCTPK
SEQ ID NO: 266 RKGCFKEGHSCPKTAPCCRPLVCKGPSPNTKKCTRP
SEQ ID NO: 267 SFCIPFKPCKSDENCCKKFKCKTTGIVKLCRW
SEQ ID NO: 268 LKGCLPRNRFCNALSGPRCCSGLRCKELSIWASKCL
SEQ ID NO: 269 GNYCLRGRCLPGGRKCCNGRPCECFAKICSCKPK
SEQ ID NO: 270 TVKCGGCNRKCCPGGCRSGKCINGKCQCY
SEQ ID NO: 271 GCMKEYCAGQCRGKVSQDYCLKHCKCIPR
SEQ ID NO: 272 ACLGFGEKCNPSNDKCCKSSSLVCSQKHKWCKYG
-48WO 2017/044894
PCT/US2016/051166
SEQ ID NO Amino Acid Sequence
SEQ ID NO: 273 RGGCLPHNRFCNALSGPRCCSGLRCKELSIRDSRCLG
SEQ ID NO: 274 RGGCLPRNKFCNPSSGPRCCSGLTCKELNIWASKCL
SEQ ID NO: 275 QRSCAKPGDMCMGIKCCDGQCGCNRGTGRCFCK
SEQ ID NO: 276 ARGCADAYKSCNHPRTCCDGYNGYKRACICSGSNCKCKKS
SEQ ID NO: 277 RGGCLPHNRFCNALSGPRCCSGLRCKELSIWDSRCLG
SEQ ID NO: 278 RGGCLPHNRFCNALSGPRCCSGLKCKELSIYDSRCLG
SEQ ID NO: 279 RGGCLPHNRFCNALSGPRCCSRLKCKELSIWDSRCLG
SEQ ID NO: 280 RGGCLPHNRFCNALTGPRCCSRLRCKELSIWDSICLG
SEQ ID NO: 281 SCADAYKSCDSLKCCNNRTCMCSMIGTNCTCRKK
SEQ ID NO: 282 ERRCLPAGKTCVRGPMRVPCCGSCSQNKCT
SEQ ID NO: 283 LCSREGEFCYKLRKCCAGFYCKAFVLHCYRN
SEQ ID NO: 284 ACGSCRKKCKGSGKCINGRCKCY
SEQ ID NO: 285 ACGSCRKKCKGPGKCINGRCKCY
SEQ ID NO: 286 ACQGYMRKCGRDKPPCCKKLECSKTWRWCVWN
SEQ ID NO: 287 GRYCQKWMWTCDS KRACCEGLRCKLWCRKI
SEQ ID NO: 288 NAKCRGSPECLPKCKEAIGKAAGKCMNGKCKCYP
SEQ ID NO: 289 NVKCRGSKECLPACKAAVGKAAGKCMNGKCKCYP
SEQ ID NO: 290 NVKCRGSPECLPKCKEAIGKSAGKCMNGKCKCYP
SEQ ID NO: 291 NAKCRGSPECLPKCKQAIGKAAGKCMNGKCKCYP
SEQ ID NO: 292 RGYCAEKGIKCHNIHCCSGLTCKCKGSSCVCRK
SEQ ID NO: 293 ERGCKLTFWKCKNKKECCGWNACALGICMPR
SEQ ID NO: 294 KKKCIAKDYGRCKWGGTPCCRGRGCICSIMGTNCECKPR
SEQ ID NO: 295 GCKLTFWKCKNKKECCGWNACALGICMPR
SEQ ID NO: 296 ACKGLFVTCTPGKDECCPNHVCSSKHKWCKYK
SEQ ID NO: 297 IACAPRGLLCFRDKECCKGLTCKGRFVNTWPTFCLV
SEQ ID NO: 298 ACAGLYKKCGKGVNTCCENRPCKCDLAMGNCICKKK
SEQ ID NO: 299 FTCAISCDIKVNGKPCKGSGEKKCSGGWSCKFNVCVKV
SEQ ID NO: 300 GFCAQKGIKCHDIHCCTNLKCVREGSNRVCRKA
SEQ ID NO: 301 CAKKRNWCGKNEDCCCPMKCIYAWYNQQGSCQSTITGLFKKC
SEQ ID NO: 302 YCQKWMWTCDSARKCCEGLVCRLWCKKI
SEQ ID NO: 303 RGGCLPHNKFCNALSGPRCCSGLKCKELTIWNTKCLE
-49WO 2017/044894
PCT/US2016/051166
SEQ ID NO Amino Acid Sequence
SEQ ID NO: 304 NVKCTGSKQCLPACKAAVGKAAGKCMNGKCKCYT
SEQ ID NO: 305 QRSCAKPGEMCMRIKCCDGQCGCNRGTGRCFCK
SEQ ID NO: 306 GCIPKHKRCTWSGPKCCNNISCHCNISGTLCKCRPG
SEQ ID NO: 307 NYCVAKRCRPGGRQCCSGKPCACVGKVCKCPRD
SEQ ID NO: 308 ERGCSGAYKRCSSSQRCCEGRPCVCSAINSNCKCRKT
SEQ ID NO: 309 RYCPRNPEACYNYCLRTGRPGGYCGGRSRITCFCFR
SEQ ID NO: 310 QRSCAKPGEMCMGIKCCDGQCGCNRGTGRCFCK
SEQ ID NO: 311 RRGCFKEGKWCPKSAPCCAPLKCKGPSIKQQKCVRE
SEQ ID NO: 312 TVKCGGCNRKCCAGGCRSGKCINGKCQCYGR
SEQ ID NO: 313 ERRCEPSGKPCRPLMRIPCCGSCVRGKCA
SEQ ID NO: 314 RGGCLPRNKFCNPSSGPRCCSGLTCKELNIWANKCL
SEQ ID NO: 315 CAKKRNWCGKNEDCCCPMKCIYAWYNQQGSCQTTITGLFKKC
SEQ ID NO: 316 GKCINKKCKC
SEQ ID NO: 317 KCIN
SEQ ID NO: 318 KKCK
SEQ ID NO: 319 PCKR
SEQ ID NO: 320 KRCSRR
SEQ ID NO: 321 KQC
SEQ ID NO: 322 VRIPVSCKHSGQCLKPCKDAGMRTGKCMNGKCDCTPK
SEQ ID NO: 323 VKCTTSKDCWPPCKKVTGRA
SEQ ID NO: 324 GIVCRVCRIICGMQGRRVNICRAPIRCRCRRG
SEQ ID NO: 325 SERDCIRHLQRCRENRDCCSRRCSRRGTNPERRCR
SEQ ID NO: 326 VRIPVSCRHSGQCLRPCRDAGMRFGRCMNGRCDCTPR
SEQ ID NO: 327 GVPINVRCRGSRDCLDPCRRAGMRFGRCINSRCHCTP
SEQ ID NO: 328 AVCVYRTCDRDCRRRGYRSGRCINNACRCYPYG
SEQ ID NO: 329 ISCTGSRQCYDPCRRRTGCPNARCMNRSCRCYGCG
SEQ ID NO: 330 QVQTNVRCQGGSCASVCRREIGVAAGRCINGRCVCYRN
SEQ ID NO: 331 EVIRCSGSRQCYGPCRQQTGCTNSRCMNRVCRCYGCG
SEQ ID NO: 332 ACRGVFDACTPGRNECCPNRVCSDRHRWCRWRL
SEQ ID NO: 333 QIYTSRECNGSSECYSHCEGITGRRSGRCINRRCYCYR
SEQ ID NO: 334 GCLEFWWRCNPNDDRCCRPRLRCSRLFRLCNFSFG
- 50WO 2017/044894
PCT/US2016/051166
SEQ ID NO Amino Acid Sequence
SEQ ID NO: 335 DCVRFWGRCSQTSDCCPHLACRSRWPRNICVWDGSVG
SEQ ID NO: 336 GCFGYRCDYYRGCCSGYVCSPTWRWCVRPGPGR
SEQ ID NO: 337 MNARFILLLVLTTMMLLPDTRGAEVIRCSGSRQCYGPCRQQTGCTNS RCMNRVCRCYGCG
SEQ ID NO: 338 MNARLIYLLLVVTTMTLMFDTAQAVDIMCSGPRQCYGPCRRETGCPN ARCMNRRCRCYGCV
SEQ ID NO: 339 MNARLIYLLLVVTTMMLTFDTTQAGDIRCSGTRQCWGPCRRQTTCTN SRCMNGRCRCYGCVG
SEQ ID NO: 340 MNTRFIFLLLVVTNTMMLFDTRPVEGISCTGSRQCYDPCRRRTGCPNA RCMNRSCRCYGCG
SEQ ID NO: 341 GVPINVRCSGSRDCLEPCRRAGMRFGRCINRRCHCTPR
SEQ ID NO: 342 GVPINVRCTGSPQCLRPCRDAGMRFGRCINGRCHCTPR
SEQ ID NO: 343 GVIINVRCRISRQCLEPCRRAGMRFGRCMNGRCHCTPR
SEQ ID NO: 344 GVPINVRCRGSPQCIQPCRDAGMRFGRCMNGRCHCTPQ
SEQ ID NO: 345 GVEINVRCTGSHQCIRPCRDAGMRFGRCINRRCHCTPR
SEQ ID NO: 346 GVEINVRCSGSPQCLRPCRDAGMRFGRCMNRRCHCTPR
SEQ ID NO: 347 GVPTDVRCRGSPQCIQPCRDAGMRFGRCMNGRCHCTPR
SEQ ID NO: 348 GVPINVSCTGSPQCIRPCRDAGMRFGRCMNRRCHCTPR
SEQ ID NO: 349 GVPINVPCTGSPQCIRPCRDAGMRFGRCMNRRCHCTPR
SEQ ID NO: 350 VGINVRCRHSGQCLRPCRDAGMRFGRCINGRCDCTPR
SEQ ID NO: 351 VGINVRCRHSGQCLRPCRDAGMRFGRCMNGRCDCTPR
SEQ ID NO: 352 VGIPVSCRHSGQCIRPCRDAGMRFGRCMNRRCDCTPR
SEQ ID NO: 353 RRGCFREGHSCPRTAPCCRPLVCRGPSPNTRRCTRP
SEQ ID NO: 354 SFCIPFRPCRSDENCCRRFRCRTTGIVRLCRW
SEQ ID NO: 355 LRGCLPRNRFCNALSGPRCCSGLRCRELSIWASRCL
SEQ ID NO: 356 GNYCLRGRCLPGGRRCCNGRPCECFARICSCRPR
SEQ ID NO: 357 TVRCGGCNRRCCPGGCRSGRCINGRCQCY
SEQ ID NO: 358 GCMREYCAGQCRGRVSQDYCLRHCRCIPR
SEQ ID NO: 359 ACLGFGERCNPSNDRCCRSSSLVCSQRHRWCRYG
SEQ ID NO: 360 RGGCLPHNRFCNALSGPRCCSGLRCRELSIRDSRCLG
SEQ ID NO: 361 RGGCLPRNRFCNPSSGPRCCSGLTCRELNIWASRCL
- 51 WO 2017/044894
PCT/US2016/051166
SEQ ID NO Amino Acid Sequence
SEQ ID NO: 362 QRSCARPGDMCMGIRCCDGQCGCNRGTGRCFCR
SEQ ID NO: 363 ARGCADAYRSCNHPRTCCDGYNGYRRACICSGSNCRCRRS
SEQ ID NO: 364 RGGCLPHNRFCNALSGPRCCSGLRCRELSIWDSRCLG
SEQ ID NO: 365 RGGCLPHNRFCNALSGPRCCSGLRCRELSIYDSRCLG
SEQ ID NO: 366 RGGCLPHNRFCNALSGPRCCSRLRCRELSIWDSRCLG
SEQ ID NO: 367 RGGCLPHNRFCNALTGPRCCSRLRCRELSIWDSICLG
SEQ ID NO: 368 SCADAYKSCDSLRCCNNRTCMCSMIGTNCTCRRR
SEQ ID NO: 369 ERRCLPAGRTCVRGPMRVPCCGSCSQNRCT
SEQ ID NO: 370 LCSREGEFCYRLRRCCAGFYCRAFVLHCYRN
SEQ ID NO: 371 ACGSCRRRCRGSGRCINGRCRCY
SEQ ID NO: 372 ACGSCRRRCRGPGRCINGRCRCY
SEQ ID NO: 373 ACQGYMRRCGRDRPPCCRRLECSRTWRWCVWN
SEQ ID NO: 374 GRYCQRWMWTCDSRRACCEGLRCRLWCRRI
SEQ ID NO: 375 NARCRGSPECLPRCREAIGRAAGRCMNGRCRCYP
SEQ ID NO: 376 NVRCRGSRECLPACRAAVGRAAGRCMNGRCRCYP
SEQ ID NO: 377 NVRCRGSPECLPRCREAIGRSAGRCMNGRCRCYP
SEQ ID NO: 378 NARCRGSPECLPRCRQAIGRAAGRCMNGRCRCYP
SEQ ID NO: 379 RGYCAERGIRCHNIHCCSGLTCRCRGSSCVCRR
SEQ ID NO: 380 ERGCRLTFWRCRNRRECCGWNACALGICMPR
SEQ ID NO: 381 RRRCIARDYGRCRWGGTPCCRGRGCICSIMGTNCECRPR
SEQ ID NO: 382 GCRLTFWRCRNRRECCGWNACALGICMPR
SEQ ID NO: 383 ACRGLFVTCTPGRDECCPNHVCSSRHRWCRYR
SEQ ID NO: 384 IACAPRGLLCFRDRECCRGLTCRGRFVNTWPTFCLV
SEQ ID NO: 385 ACAGLYRRCGRGVNTCCENRPCRCDLAMGNCICRRR
SEQ ID NO: 386 FTCAISCDIRVNGRPCRGSGERRCSGGWSCRFNVCVRV
SEQ ID NO: 387 GFCAQRGIRCHDIHCCTNLRCVREGSNRVCRRA
SEQ ID NO: 388 CARRRNWCGRNEDCCCPMRCIYAWYNQQGSCQSTITGLFRRC
SEQ ID NO: 389 YCQRWMWTCDSARRCCEGLVCRLWCRRI
SEQ ID NO: 390 RGGCLPHNRFCNALSGPRCCSGLRCRELTIWNTRCLE
SEQ ID NO: 391 NVRCTGSRQCLPACRAAVGRAAGRCMNGRCRCYT
SEQ ID NO: 392 QRSCARPGEMCMRIRCCDGQCGCNRGTGRCFCR
- 52WO 2017/044894
PCT/US2016/051166
SEQ ID NO Amino Acid Sequence
SEQ ID NO: 393 GCIPRHRRCTWSGPRCCNNISCHCNISGTLCRCRPG
SEQ ID NO: 394 NYCVARRCRPGGRQCCSGRPCACVGRVCRCPRD
SEQ ID NO: 395 ERGCSGAYRRCSSSQRCCEGRPCVCSAINSNCRCRRT
SEQ ID NO: 396 QRSCARPGEMCMGIRCCDGQCGCNRGTGRCFCR
SEQ ID NO: 397 RRGCFREGRWCPRSAPCCAPLRCRGPSIRQQRCVRE
SEQ ID NO: 398 TVRCGGCNRRCCAGGCRSGRCINGRCQCYGR
SEQ ID NO: 399 ERRCEPSGRPCRPLMRIPCCGSCVRGRCA
SEQ ID NO: 400 RGGCLPRNRFCNPSSGPRCCSGLTCRELNIWANRCL
SEQ ID NO: 401 CARRRNWCGRNEDCCCPMRCIYAWYNQQGSCQTTITGLFRRC
SEQ ID NO: 402 GRCINRRCRC
SEQ ID NO: 403 RCIN
SEQ ID NO: 404 RRCR
SEQ ID NO: 405 PCRR
SEQ ID NO: 406 RRCSRR
SEQ ID NO: 407 RQC
SEQ ID NO: 408 VRIPVSCRHSGQCLRPCRDAGMRTGRCMNGRCDCTPR
SEQ ID NO: 409 PCKK
SEQ ID NO: 410 KKCSKK
SEQ ID NO: 412 QKILSNRCNNSSECIPHCIRIFGTRAAKCINRKCYCYP
SEQ ID NO: 414 AVCNLKRCQLSCRSLGLLGKCIGDKCECVKHG
SEQ ID NO: 415 ISIGIRCSPSIDLCEGQCRIRRYFTGYCSGDTCHCSG
SEQ ID NO: 416 GDCLPHLRRCRENNDCCSRRCRRRGANPERRCR
SEQ ID NO: 417 SCEPGRTFRDRCNTCKCGADGRSAACTLRACPNQ
SEQ ID NO: 418 GDCLPHLKRCKADNDCCGKKCKRRGTNAEKRCR
SEQ ID NO: 419 GDCLPHLKRCKENNDCCSKKCKRRGTNPEKRCR
SEQ ID NO: 420 KDCLKKLKLCKENKDCCSKSCKRRGTNIEKRCR
SEQ ID NO: 421 GDCLPHLKRCKENNDCCSKKCKRRGANPEKRCR
SEQ ID NO: 422 VFINVKCRGSPECLPKCKEAIGKSAGKCMNGKCKCYP
SEQ ID NO: 423 VFINAKCRGSPECLPKCKEAIGKAAGKCMNGKCKCYP
SEQ ID NO: 424 VIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTP
SEQ ID NO: 425 VPTDVKCRGSPQCIQPCKDAGMRFGKCMNGKCHCTP
- 53 WO 2017/044894
PCT/US2016/051166
SEQ ID NO Amino Acid Sequence
SEQ ID NO: 426 VRIPVSCKHSGQCLKPCKDAGMRFGKCMNGKCDCTP
SEQ ID NO: 427 VRIPVSCRHSGQCLRPCRDAGMRFGRCMNGRCDCTP
SEQ ID NO: 428 TNVSCTTSKECWSVCQRLHNTSRGKCMNKKCRC
SEQ ID NO: 429 NVKCTGSKQCLPACKAAVGKAAGKCMNGKCKC
SEQ ID NO: 430 GVPINVRCRGSRDCLDPCRGAGERHGRCGNSRCHCTP
SEQ ID NO: 431 VRIPVSCRHSGQCLRPCRDAGERHGRCGGGRCDCTPR
SEQ ID NO: 432 QVQTNVRCQGGSCGSVCRREGGGAGGGCGNGRCGCYRN
[0150] In any of SEQ ID NO: 1 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432 or fragment thereof, any one or more K residues can be replaced by an R residue or any one or more R residues can be replaced by a K residue. In any of SEQ ID NO: 1 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 SEQ ID NO: 432 or any fragment thereof, any one or more M residues can be replaced by any one of I, L, or V residues, any one or more L residues can be replaced by any one of V, I, or M residues, any one or more I residues can be replaced by any one of M, L, or V residues, or any one or more V residues can be replaced by any one of I, L, or M residues. In any embodiment, at least one of the amino acids alone or in combination can be interchanged in the peptides or peptide fragments as follows: K/R, M/ 1/ L/V, G/A, S/T, Q/N, and D/E wherein each letter is each individually any amino acid or amino acid analogue. In some instances, the peptide can contain only one lysine residue, or no lysine residue. In any of SEQ ID NO: 1 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432 or any fragment thereof, X can independently be any number of any amino acid or no amino acid. In some cases, a peptide can include the first two N-terminal amino acids GS, as with peptides of SEQ ID NO: 1 SEQ ID NO: 194, SEQ ID NO: 196, and SEQ ID NO: 198 - SEQ ID NO: 216, or such Nterminal amino acids (GS) can be substituted by any other one or two amino acids. In other cases, a peptide does not include the first two N-terminal amino acids GS, as with peptides of SEQ ID NO: 217 - SEQ ID NO: 410, SEQ ID NO: 412, and SEQ ID NO: 414 - SEQ ID NO: 432. In some cases, the N-terminus of the peptide is blocked, such as by an acetyl group; in other instances the C-terminus of the peptide is block, such as by an amide group.
[0151] In some instances, the peptide is any one of SEQ ID NO: 1 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - 54WO 2017/044894
PCT/US2016/051166
SEQ ID NO: 432 or a functional fragment thereof. In other embodiments, the peptide of the disclosure further comprises a peptide with 99%, 95%, 90%, 85%, or 80% homology to any one of SEQ ID NO: 1 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432. In further embodiments, the peptide fragment comprises a contiguous fragment of any one of SEQ ID NO: 1 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432 that is at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46 residues long, wherein the peptide fragment is selected from any portion of the peptide. In some embodiments, such peptide fragments contact the cartilage and exhibit properties of those described herein for peptide and peptide-active agent conjugates.
[0152] The peptides of the present disclosure can further comprise negative amino acid residues. In some cases, the peptide has 2 or fewer negative amino acid residues. In other cases, the peptide has 4 or fewer negative amino acid residues, 3 or fewer negative amino acid residues, or 1 or fewer negative amino acid residues. The negative amino acid residues can be selected from any negative charged amino acid residues. The negative amino acid residues can selected from either E or D, or a combination of both E and D.
[0153] The peptides of the present disclosure can further comprise basic amino acid residues. In some embodiments, basic residues are added to the peptide sequence to increase the charge at physiological pH. The added basic residues can be any basic amino acid. The added basic residues can be selected from K or R, or a combination of K or R.
[0154] In some embodiments, the peptide has a charge distribution comprising an acidic region and a basic region. An acidic region can be a nub. A nub is a portion of a peptide extending out of the peptide’s three-dimensional structure. A basic region can be a patch. A patch is a portion of a peptide that does not designate any specific topology characteristic of the peptide’s three-dimensional structure. In further embodiments, a knotted peptide can be 6 or more basic residues and 2 or fewer acidic residues.
[0155] The peptides of the present disclosure can further comprise positively charged amino acid residues. In some cases, the peptide has at least 2 positively charged residues. In other cases, the peptide has at least 3 positively charged residues, at least 4 positively charged residues, at least 5 positively charged residues, at least 6 positively charged residues, at least 7 positively charged residues, at least 8 positively charged residues or at least 9 positively
-55WO 2017/044894
PCT/US2016/051166 charged residues. The positively charged residues can be selected from any positively charged amino acid residues. The positively charged residues can be selected from either K or R, or a combination of K and R.
[0156] In addition, the peptides herein can comprise a 4-19 amino acid residue fragment of any of the above sequences containing at least 2 cysteine residues, and at least 2 or 3 positively charged amino acid residues (for example, arginine, lysine or histidine, or any combination of arginine, lysine or histidine). In other embodiments, the peptides herein is a 20-70 amino acid residue fragment of any of the above sequences containing at least 2 cysteine residues, no more than 2 basic residues, and at least 2 or 3 positively charged amino acid residues (for example, arginine, lysine or histidine, or any combination of arginine, lysine or histidine). In some embodiments, such peptide fragments contact the cartilage and exhibit properties of those described herein for peptide and peptide-active agent conjugates. [0157] In some embodiments, the peptide contains one or more disulfide bonds and has a positive net charge at neutral pH. At physiological pH, peptides can have a net charge, for example, of -5, -4, -3, -2, -1, 0, +1, +2, +3, +4, or +5. When the net charge is zero, the peptide can be uncharged or zwitterionic. In some instances, the peptide can have a positive charge at physiological pH. In some instances, the peptide can have a charge > +2 at physiological pH, > +3.5 at physiological pH, > +4.5 at physiological pH. In some embodiments, the peptide contains one or more disulfide bonds and has a positive net charge at neutral pH where the net charge can be +0.5 or less than +0.5, +1 or less than +1, +1.5 or less than +1.5, +2 or less than +2, +2.5 or less than +2.5, +3 or less than +3, +3.5 or less than +3.5, +4 or less than +4, +4.5 or less than +4.5, +5 or less than +5, +5.5 or less than +5.5, +6 or less than +6, +6.5 or less than +6.5, +7 or less than +7, +7.5 or less than +7.5, +8 or less than +8, +8.5 or less than +8.5, +9 or less than +9.5, +10 or less than +10. In some embodiments, the peptide has a negative net charge at physiological pH where the net charge can be -0.5 or less than -0.5, -1 or less than -1, -1.5 or less than -1.5, -2 or less than -2, -2.5 or less than -2.5, -3 or less than 3, -3.5 or less than -3.5, -4 or less than -4, -4.5 or less than -4.5, -5 or less than -5, -5.5 or less than -5.5, -6 or less than -6, -6.5 or less than -6.5, -7 or less than -7, -7.5 or less than -7.5, -8 or less than -8, -8.5 or less than -8.5, -9 or less than -9.5, -10 or less than -10. In some cases, the engineering of one or more mutations within a peptide yields a peptide with an altered isoelectric point, charge, surface charge, or rheology at physiological pH. Such engineering of a mutation to a peptide derived from a scorpion or spider can change the net charge of the complex, for example, by decreasing the net charge by 1, 2, 3, 4, or 5, or by increasing the net charge by 1, 2, 3, 4, or 5. In such cases, the engineered mutation may facilitate the ability of
- 56WO 2017/044894
PCT/US2016/051166 the peptide to contact the cartilage. Suitable amino acid modifications for improving the rheology and potency of a peptide can include conservative or non-conservative mutations. A peptide can comprises at most 1 amino acid mutation, at most 2 amino acid mutations, at most 3 amino acid mutations, at most 4 amino acid mutations, at most 5 amino acid mutations, at most 6 amino acid mutations, at most 7 amino acid mutations, at most 8 amino acid mutations, at most 9 amino acid mutations, at most 10 amino acid mutations, or another suitable number as compared to the sequence of the venom or toxin that the peptide is derived from. In other cases, a peptide, or a functional fragment thereof, comprises at least 1 amino acid mutation, at least 2 amino acid mutations, at least 3 amino acid mutations, at least 4 amino acid mutations, at least 5 amino acid mutations, at least 6 amino acid mutations, at least 7 amino acid mutations, at least 8 amino acid mutations, at least 9 amino acid mutations, at least 10 amino acid mutations, or another suitable number as compared to the sequence of the venom or toxin that the peptide is derived from. In some embodiments, mutations can be engineered within a peptide to provide a peptide that has a desired charge or stability at physiological pH.
[0158] In some embodiments, charge can play a role in cartilage homing. The interaction of a peptide of this disclosure in solution and in vivo can be influenced by the isoelectric point (pi) of the knottin peptide and/or the pH of the solution or the local environment it is in. The charge of a peptide in solution can impact the solubility of the protein as well as parameters such as biodistribution, bio availability, and overall pharmacokinetics. Additionally, positively charged molecules can interact with negatively charged molecules. Positively charged molecules such as the peptides disclosed herein can interact and bind with negatively charged molecules such as the negatively charged extracellular matrix molecules in the cartilage including hyaluranon and aggrecan. Positively charged residues can also interact with specific regions of other proteins and molecules, such as negatively charged residues of receptors or electronegative regions of an ion channel pore on cell surfaces. As such, the pi of a peptide can influence whether a peptide of this disclosure can efficiently home to cartilage. Identifying a correlation between pi and cartilage homing can be an important strategy in identifying lead peptide candidates of the present disclosure. The pi of a peptide can be calculated using a number of different methods including the Expasy pi calculator and the Sillero method. The Expasy pi can be determined by calculating pKa values of amino acids as described in Bjellqvist et al., which were defined by examining polypeptide migration between pH 4.5 to pH 7.3 in an immobilized pH gradient gel environment with 9.2M and 9.8M urea at 15°C or 25°C (Bjellqvist et al. Electrophoresis. 14(10):1023-31 (1993)). The
-57WO 2017/044894
PCT/US2016/051166
Sillero method of calculating pi can involve the solution of a polynomial equation and the individual pKas of each amino acid. This method does not use denaturing conditions (urea) (Sillero et al. 179(2): 319-35 (1989)) Using these pi calculation methods and quantifying the cartilage to blood ratio of peptide signal after administration to a subject can be a strategy for identifying a trend or correlation in charge and cartilage homing. In some embodiments, a peptide with a pi above biological pH (~pH 7.4) can exhibit efficient homing to cartilage. In some embodiments, a peptide with a pi of at least 8, at least 9, at least 10, or at least 11 can efficiently home to cartilage. In other embodiments, a peptide with a pi of 11 - 12 can home most efficiently to cartilage. In certain embodiments, a peptide can have a pi of about 9. In other embodiments, a peptide can have a pi of 8 - 10. In some embodiments, more basic peptides can home more efficiently to cartilage. In other embodiments, a high pi alone may not be sufficient to cause cartilage homing of a peptides.
[0159] In some embodiments, the tertiary structure and electrostatics of a peptide of the disclosure can impact cartilage homing. Structural analysis or analysis of charge distribution can be a strategy to predict residues important in biological function, such as cartilage homing. For example, several peptides of this disclosure that home to cartilage can be grouped into a structural class defined herein as “hitchins,” and can share the properties of disulfide linkages between C1-C4, C2-C5, and C3-C6. The folding topologies of peptides knotted through three disulfide linkages (C1-C4, C2-C5, and C3-C6), can be broken down into structural families based on the three-dimensional arrangement of the disulfides.
Knottins have the C3-C6 disulfide linkage passing through the macrocycle formed by the ClC4 and C2-C5 disulfide linkages, hitchins have the C2-C5 disulfide linkage passing through the macrocycle formed by the C1-C4 and C3-C6 disulfide linkages, and yet other structural families have the C1-C4 disulfide linkage passing through the macrocycle formed by the C2C5 and C3-C6 disulfide linkages. Variants of “hitchin” class peptides with preserved disulfide linkages at these cysteine residues, primary sequence identity, and/or structural homology can be a method of identifying or predicting other potential knottin peptide candidates that can home to cartilage. Additionally, members and related members of the calcin family of peptides can also home to cartilage, despite having a distinct tertiary structure from the “hitchin” class of peptides. Calcin peptides are structurally a subset of the knottin peptides, with knottin disulfide connectivity and topology, but are further classified on the basis of functioning to bind and activate ryanodine receptors (RyRs). These receptors are calcium channels that act to regulate the influx and efflux of calcium in muscle (Schwartz et al. Br J Pharmacol 157(3):392-403. (2009)). Variants of the calcin family of peptides with
-58WO 2017/044894
PCT/US2016/051166 preserved key residues can be one way to predict promising candidates that can home to cartilage. In some embodiments, structural analysis of a peptide of this disclosure can be determined by evaluating peptides for resistance to degradation in buffers with various proteases or reducing agents. Structural analysis of the distribution of charge density on the surface of a peptide can also be a strategy for predicting promising candidates that can home to cartilage. Peptides with large patches of positive surface charge (when at pH 7.5) can home to cartilage.
[0160] The NMR solution structures, x-ray crystallography, or crystal structures of related structural homo logs can be used to inform mutational strategies that can improve the folding, stability, and manufacturability, while maintaining the ability of a peptide to home to cartilage. They can be used to predict the 3D pharmacophore of a group of structurally homologous scaffolds, as well as to predict possible graft regions of related proteins to create chimeras with improved properties. For example, this strategy can be used to identify critical amino acid positions and loops that can be used to design drugs with improved properties or to correct deleterious mutations that complicate folding and manufacturability for the peptides. These key amino acid positions and loops can be retained while other residues in the peptide sequences can be mutated to improve, change, remove, or otherwise modify function, homing, and activity of the peptide.
[0161] Additionally, the comparison of the primary sequences and the tertiary sequences of two or more peptides can be used to reveal sequence and 3D folding patterns that can be leveraged to improve the peptides and parse out the biological activity of these peptides. For example, comparing two different peptide scaffolds that home to cartilage can lead to the identification of conserved pharmacophores that can guide engineering strategies, such as designing variants with improved folding properties. Important pharmacophore, for example, can comprise aromatic residues or basic residues, which can be important for binding.
[0162] Improved peptides can also be engineered based upon immungenicity information, such as immunogenicity information predicted by TEPITOPE and TEPITOPEpan. TEPITOPE is a computational approach which uses position specific scoring matrix to provide prediction rules for whether a peptide will bind to 51 different HLA-DR alleles, and TEPITOPEpan is method that uses TEPITOPE to extrapolate from HLA-DR molecules with known binding specificities to HLA-DR molecules with unknown binding specificities based on pocket similarity. For example, TEPITOPE and TEPITOPEpan can be used to determine immunogenicity of peptides that home to cartilage. Comparison of peptides with high
- 59WO 2017/044894
PCT/US2016/051166 immunogenecity to peptides with low immunogenicity can guide engineering strategies for designing variants with decreased immunogenicity.
[0163] A peptide of this disclosure can bind to sodium channels. The peptide can bind to calcium channels. The peptide can block potassium channels and/or sodium channels. The peptide can block calcium channels. In some embodiments, the peptide can activate potassium channels and/or sodium channels. In other embodiments, the peptide can activate calcium channels. In still other embodiments, the peptide can be a potassium channel agonist, a potassium channel antagonist, a portion of a potassium channel, a sodium channel agonist, a sodium channel antagonist, a calcium channel agonist, a calcium channel antagonist, a hadrucalcin, a theraphotoxin, a huwentoxin, a kaliotoxin, a cobatoxin or a lectin. In some embodiments, the lectin can be SHL-Ib2. In some embodiments, the peptide can interact with, binds, inhibits, inactivates, or alters expression of ion channels or chloride channels. In some embodiments, the peptide can interact with an Navi.7 ion channel. In some embodiments, the peptide can interact with a Kv 1.3 ion channel. In still other embodiments, the peptide interacts with proteases, matrix metalloproteinase, inhibits cancer cell migration or metastases, has antimicrobial activity, or has antitumor activity. In addition to acting on matrix metalloproteinases, the peptide can interact with other possible proteases (e.g., elastases).
[0164] In some embodiments, the peptide has other therapeutic effects on the cartilage or structures thereof or nearby. Beta defensin expression in articular cartilage can be correlated with immunomodulatory functions as we well as osteoarthritis, autoimmune rheumatic disorders such as systemic lupus erythematosus and rheumatoid arthritis (Vordenbaumen and Schneider 2011, Varoga 2004 and Varoga 2005). In some embodiments, the peptides or their mutants inhibit beta defensins, supplement beta defensins, are competitive inhibitors of beta defensins, active or block activation of beta defensin targets, and are used as immune modulators, or to treat autoimmune, arthritis, infections, and other articular disorders.
[0165] The present disclosure can also encompass multimers of the various peptides described herein. Examples of multimers include dimers, trimers, tetramers, pentamers, hexamers, heptamers, and so on. A multimer can be a homomer formed from a plurality of identical subunits or a heteromer formed from a plurality of different subunits. In some embodiments, a peptide of the present disclosure is arranged in a multimeric structure with at least one other peptide,or two, three, four, five, six, seven, eight, nine, ten, or more other peptides. In certain embodiments, the peptides of a multimeric structure each have the same
- 60WO 2017/044894
PCT/US2016/051166 sequence. In alternative embodiments, some or all of the peptides of a multimeric structure have different sequences.
[0166] The present disclosure further includes peptide scaffolds that, e.g., can be used as a starting point for generating additional peptides. In some embodiments, these scaffolds can be derived from a variety of knotted peptides or knottins. Some suitable peptides for scaffolds can include, but are not limited to, chlorotoxin, brazzein, circulin, stecrisp, hanatoxin, midkine, hefutoxin, potato carboxypeptidase inhibitor, bubble protein, attractin, a-Cik ccGID, μ-ΡΙΙΙΑ, ω-MVIIA, ω-CVID, χ-MrIA, p-TIA, conantokin G, contulakin G, GsMTx4, margatoxin, shK, toxin K, chymotrypsin inhibitor (CTI), and EGF epiregulin core.
[0167] In some embodiments, the peptide sequences of the disclosure are flanked by additional amino acids. One or more additional amino acids can, for example, confer a desired in vivo charge, isoelectric point, chemical conjugation site, stability, or physiologic property to a peptide.
[0168] Identifying sequence homology can be important for determining key residues that preserve cartilage homing function. For example, in some embodiments identification of conserved positively charged residues can be important in preserving cartilage homing in any homologous variants that are made. In other embodiments, identification of basic or aromatic dyads, can be important in preserving interaction and activity with Kv ion channels in homologous variants.
[0169] Two or more peptides can share a degree of homology and share similar properties in vivo. For instance, a peptide can share a degree of homology with a peptide of the present disclosure. In some cases, a peptide of the disclosure can have up to about 20% pairwise homology, up to about 25% pairwise homology, up to about 30% pairwise homology, up to about 35% pairwise homology, up to about 40% pairwise homology, up to about 45% pairwise homology, up to about 50% pairwise homology, up to about 55% pairwise homology, up to about 60% pairwise homology, up to about 65% pairwise homology, up to about 70% pairwise homology, up to about 75% pairwise homology, up to about 80% pairwise homology, up to about 85% pairwise homology, up to about 90% pairwise homology, up to about 95% pairwise homology, up to about 96% pairwise homology, up to about 97% pairwise homology, up to about 98% pairwise homology, up to about 99% pairwise homology, up to about 99.5% pairwise homology, or up to about 99.9% pairwise homology with a second peptide. In some cases, a peptide of the disclosure can have at least about 20% pairwise homology, at least about 25% pairwise homology, at least about 30%
- 61 WO 2017/044894
PCT/US2016/051166 pairwise homology, at least about 35% pairwise homology, at least about 40% pairwise homology, at least about 45% pairwise homology, at least about 50% pairwise homology, at least about 55% pairwise homology, at least about 60% pairwise homology, at least about 65% pairwise homology, at least about 70% pairwise homology, at least about 75% pairwise homology, at least about 80% pairwise homology, at least about 85% pairwise homology, at least about 90% pairwise homology, at least about 95% pairwise homology, at least about 96% pairwise homology, at least about 97% pairwise homology, at least about 98% pairwise homology, at least about 99% pairwise homology, at least about 99.5% pairwise homology, at least about 99.9% pairwise homology with a second peptide. Various methods and software programs can be used to determine the homology between two or more peptides, such as NCBI BLAST, Clustal W, MAFFT, Clustal Omega, AlignMe, Praline, or another suitable method or algorithm.
[0170] In still other instances, the variant nucleic acid molecules of a peptide of any one of SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198-216, SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, or SEQ ID NO: 414 - SEQ ID NO: 432 can be identified by either a determination of the sequence identity or homology of the encoded peptide amino acid sequence with the amino acid sequence of any one of SEQ ID NO: 21 SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198-216, SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, or SEQ ID NO: 414 - SEQ ID NO: 432, or by a nucleic acid hybridization assay. Such peptide variants can include nucleic acid molecules (1) that remain hybridized with a nucleic acid molecule having the nucleotide sequence of any one of SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198-216, SEQ ID NO: 237 SEQ ID NO: 410, SEQ ID NO: 412, or SEQ ID NO: 414 - SEQ ID NO: 432 (or any complement of the previous sequences) under stringent washing conditions, in which the wash stringency is equivalent to 0.5x-2xSSC with 0.1% SDS at 55-65° C, and (2) that encode a peptide having at least 70%, at least 80%, at least 90%, at least 95% or greater than 95% sequence identity or homology to the amino acid sequence of any one SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198-216, SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, or SEQ ID NO: 414 - SEQ ID NO: 432. Alternatively, peptide variants of any one SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198-216, SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, or SEQ ID NO: 414 - SEQ ID NO: 432 can be characterized as nucleic acid molecules (1) that remain hybridized with a nucleic acid molecule having the nucleotide sequence of any one SEQ ID NO: 21 - SEQ ID NO: 194,
SEQ ID NO: 196, SEQ ID NO: 198-216, SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO:
- 62WO 2017/044894
PCT/US2016/051166
412, or SEQ ID NO: 414 - SEQ ID NO: 432 (or any complement of the previous sequences) under highly stringent washing conditions, in which the wash stringency is equivalent to
0.1x-0.2xSSC with 0.1% SDS at 50-65° C., and (2) that encode a peptide having at least
70%, at least 80%, at least 90%, at least 95% or greater than 95% sequence identity or homology to the amino acid sequence of any one of SEQ ID NO: 21 - SEQ ID NO: 194,
SEQ ID NO: 196, SEQ ID NO: 198-216, SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, or SEQ ID NO: 414 - SEQ ID NO: 432.
[0171] Percent sequence identity or homology can be determined by conventional methods. See, for example, Altschul et al., Bull. Math. Bio. 48:603 (1986), and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1992). Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the “BLOSUM62” scoring matrix of Henikoff and Henikoff (Id.). The sequence identity or homology is then calculated as: ([Total number of identical matches]/[length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences])(100).
[0172] Additionally, there are many established algorithms available to align two amino acid sequences. For example, the “FASTA” similarity search algorithm of Pearson and Lipman is a suitable protein alignment method for examining the level of sequence identity or homology shared by an amino acid sequence of a peptide disclosed herein and the amino acid sequence of a peptide variant. The FASTA algorithm is described by Pearson and Lipman, Proc. Nat'l Acad. Sci. USA 85:2444 (1988), and by Pearson, Meth. Enzymol. 183:63 (1990). Briefly, FASTA first characterizes sequence similarity by identifying regions shared by the query sequence (e.g., SEQ ID NO: 1) and a test sequence that has either the highest density of identities (if the ktup variable is 1) or pairs of identities (if ktup=2), without considering conservative amino acid substitutions, insertions, or deletions. The ten regions with the highest density of identities are then rescored by comparing the similarity of all paired amino acids using an amino acid substitution matrix, and the ends of the regions are “trimmed” to include only those residues that contribute to the highest score. If there are several regions with scores greater than the “cutoff’ value (calculated by a predetermined formula based upon the length of the sequence and the ktup value), then the trimmed initial regions are examined to determine whether the regions can be joined to form an approximate alignment with gaps. Finally, the highest scoring regions of the two amino acid sequences are aligned using a modification of the Needleman-Wunsch-Sellers algorithm (Needleman and Wunsch, J. Mol. Biol. 48:444 (1970); Sellers, Siam J. Appl. Math. 26:787 (1974)), which
- 63 WO 2017/044894
PCT/US2016/051166 allows for amino acid insertions and deletions. Illustrative parameters for FASTA analysis are: ktup=l, gap opening penalty=10, gap extension penalty=l, and substitution matrix=BLOSUM62. These parameters can be introduced into a FASTA program by modifying the scoring matrix file (“SMATRIX”), as explained in Appendix 2 of
Pearson, Meth. Enzytnol.l&3:63 (1990).
[0173] FASTA can also be used to determine the sequence identity or homology of nucleic acid molecules using a ratio as disclosed above. For nucleotide sequence comparisons, the ktup value can range between one to six, preferably from three to six, most preferably three, with other parameters set as described above.
[0174] Some examples of common amino acids that are a “conservative amino acid substitution” are illustrated by a substitution among amino acids within each of the following groups: (1) glycine, alanine, valine, leucine, and isoleucine, (2) phenylalanine, tyrosine, and tryptophan, (3) serine and threonine, (4) aspartate and glutamate, (5) glutamine and asparagine, and (6) lysine, arginine and histidine. The BLOSUM62 table is an amino acid substitution matrix derived from about 2,000 local multiple alignments of protein sequence segments, representing highly conserved regions of more than 500 groups of related proteins (Henikoff and Henikoff, Proc. Nat'l Acad. Sci. USA 89:10915 (1992)). Accordingly, the BLOSUM62 substitution frequencies can be used to define conservative amino acid substitutions that may be introduced into the amino acid sequences of the present invention. Although it is possible to design amino acid substitutions based solely upon chemical properties (as discussed above), the language “conservative amino acid substitution” preferably refers to a substitution represented by a BLOSUM62 value of greater than -1. For example, an amino acid substitution is conservative if the substitution is characterized by a BLOSUM62 value of 0, 1, 2, or 3. According to this system, preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 1 (e.g., 1, 2 or 3), while more preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 2 (e.g., 2 or 3).
[0175] Determination of amino acid residues that are within regions or domains that are critical to maintaining structural integrity can be determined. Within these regions one can determine specific residues that can be more or less tolerant of change and maintain the overall tertiary structure of the molecule. Methods for analyzing sequence structure include, but are not limited to, alignment of multiple sequences with high amino acid or nucleotide identity or homology and computer analysis using available software (e.g., the Insight
II.RTM. viewer and homology modeling tools; MSI, San Diego, Calif.), secondary structure
- 64WO 2017/044894
PCT/US2016/051166 propensities, binary patterns, complementary packing and buried polar interactions (Barton,
G.J., Current Opin. Struct. Biol. 5:372-6 (1995) and Cordes, M.H. et al., Current Opin.
Struct. Biol. 6:3-10 (1996)). In general, when designing modifications to molecules or identifying specific fragments determination of structure can typically be accompanied by evaluating activity of modified molecules.
[0176] Pairwise sequence alignment is used to identify regions of similarity that may indicate functional, structural and/or evolutionary relationships between two biological sequences (protein or nucleic acid). By contrast, multiple sequence alignment (MSA) is the alignment of three or more biological sequences. From the output of MSA applications, homology can be inferred and the evolutionary relationship between the sequences assessed. One of skill in the art would recognize as used herein, “sequence homology” and “sequence identity” and “percent (%) sequence identity” and “percent (%) sequence homology” have been used interchangeably to mean the sequence relatedness or variation, as appropriate, to a reference polynucleotide or amino acid sequence.
Chemical Modifications [0177] A peptide can be chemically modified one or more of a variety of ways. In some embodiments, the peptide can be mutated to add function, delete function, or modify the in vivo behavior. One or more loops between the disulfide linkages can be modified or replaced to include active elements from other peptides (such as described in Moore and Cochran, Methods in Enzymology, 503, p.223-251, 2012). Amino acids can also be mutated, such as to increase half-life, modify, add or delete binding behavior in vivo, add new targeting function, modify surface charge and hydrophobicity, or allow conjugation sites. N-methylation is one example of methylation that can occur in a peptide of the disclosure. In some embodiments, the peptide can be modified by methylation on free amines. For example, full methylation can be accomplished through the use of reductive methylation with formaldehyde and sodium cyanoborohydride.
[0178] A chemical modification can, for instance, extend the half-life of a peptide or change the biodistribution or pharmacokinetic profile. A chemical modification can comprise a polymer, a polyether, polyethylene glycol, a biopolymer, a polyamino acid, a fatty acid, a dendrimer, an Fc region, a simple saturated carbon chain such as palmitate or myristolate, or albumin. The chemical modification of a peptide with an Fc region can be a fusion Fcpeptide. A polyamino acid can include, for example, a polyamino acid sequence with repeated single amino acids (e.g., polyglycine), and a polyamino acid sequence with mixed
-65WO 2017/044894
PCT/US2016/051166 polyamino acid sequences (e.g., gly-ala-gly-ala) that can or can not follow a pattern , or any combination of the foregoing.
[0179] In some embodiments, the peptides of the present disclosure may be modified such that the modification increases the stability and/or the half-life of the peptides. In some embodiments, the attachment of a hydrophobic moiety, such as to the N-terminus, the Cterminus, or an internal amino acid, can be used to extend half-life of a peptide of the present disclosure. In other embodiments, the peptide of the present disclosure can include posttranslational modifications (e.g., methylation and/or amidation), which can affect, e.g., serum half-life. In some embodiments, simple carbon chains (e.g., by myristoylation and/or palmitylation) can be conjugated to the fusion proteins or peptides. In some embodiments, the simple carbon chains may render the fusion proteins or peptides easily separable from the unconjugated material. For example, methods that may be used to separate the fusion proteins or peptides from the unconjugated material include, but are not limited to, solvent extraction and reverse phase chromatography. The lipophilic moieties can extend half-life through reversible binding to serum albumin. The conjugated moieties can, e.g., be lipophilic moieties that extend half-life of the peptides through reversible binding to serum albumin. In some embodiments, the lipophilic moiety can be cholesterol or a cholesterol derivative including cholestenes, cholestanes, cholestadienes and oxysterols. In some embodiments, the peptides can be conjugated to myristic acid (tetradecanoic acid) or a derivative thereof. In other embodiments, the peptides of the present disclosure are coupled (e.g., conjugated) to a halflife modifying agent. Examples of half-life modifying agents include but are not limited to: a polymer, a polyethylene glycol (PEG), a hydroxyethyl starch, polyvinyl alcohol, a water soluble polymer, a zwitterionic water soluble polymer, a water soluble poly(amino acid), a water soluble polymer of proline, alanine and serine, a water soluble polymer containing glycine, glutamic acid, and serine, an Fc region, a fatty acid, palmitic acid, or a molecule that binds to albumin.
[0180] In some embodiments, the first two N-terminal amino acids (GS) of SEQ ID NO: 1 SEQ ID NO: 194, SEQ ID NO: 196, or SEQ ID NO: 198 - SEQ ID NO: 216 can serve as a spacer or linker in order to facilitate conjugation or fusion to another molecule, as well as to facilitate cleavage of the peptide from such conjugated or fused molecules. In some embodiments, the fusion proteins or peptides of the present disclosure can be conjugated to other moieties that, e.g., can modify or effect changes to the properties of the peptides.
- 66WO 2017/044894
PCT/US2016/051166
Active Agent Conjugates [0181] Peptides according to the present disclosure can be conjugated or fused to an agent for use in the treatment of cartilage diseases, disorders, or injuries. For example, in certain embodiments, a peptide as described herein can be fused to another molecule, such as an active agent that provides a functional capability. A peptide can be fused with an active agent through expression of a vector containing the sequence of the peptide with the sequence of the active agent. In various embodiments, the sequence of the peptide and the sequence of the active agent are expressed from the same Open Reading Frame (ORF). In various embodiments, the sequence of the peptide and the sequence of the active agent can comprise a contiguous sequence. The peptide and the active agent can each retain similar functional capabilities in the fusion peptide compared with their functional capabilities when expressed separately.
[0182] Furthermore, for example, in certain embodiments, the peptides described herein are attached to another molecule, such as an active agent that provides a functional capability. In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 active agents can be linked to a peptide. Multiple active agents can be attached by methods such as conjugating to multiple lysine residues and/or the N-terminus, or by linking the multiple active agents to a scaffold, such as a polymer or dendrimer and then attaching that agent-scaffold to the peptide (such as described in Yurkovetskiy, A. V., Cancer Res 75(16): 3365-72 (2015). Examples of active agents include but are not limited to: a peptide, an oligopeptide, a polypeptide, a peptidomimetic, a polynucleotide, a polyribonucleotide, a DNA, a cDNA, a ssDNA, a RNA, a dsRNA, a micro RNA, an oligonucleotide, an antibody, a single chain variable fragment (scFv), an antibody fragment, an aptamer, a cytokine, an interferon, a hormone, an enzyme, a growth factor, a checkpoint inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA4 inhibitor, a CD antigen, aa chemokine, a neurotransmitter, an ion channel inhibitor, a G-protein coupled receptor inhibitor, a G-protein coupled receptor activator, a chemical agent, a radio sensitizer, a radioprotectant, a radionuclide, a therapeutic small molecule, a steroid, a corticosteroid, an anti-inflammatory agent, an immune modulator, a complement fixing peptide or protein, a tumor necrosis factor inhibitor, a tumor necrosis factor activator, a tumor necrosis factor receptor family agonist, a tumor necrosis receptor antagonist,, a tumor necrosis factor (TNF) soluble receptor or antibody, caspase protease activator or inhibitor, an NF-κΒ a RIPK1 and/or RIPK3 inhibitor or activator (e.g., through Toll-like receptors (TLRs) TLR-3 and/or TLR-4, or T-cell receptor (TCR) and the like), a death-receptor ligand (E.g.,
Fas ligand) activator or inhibitor, TNF receptor family (e.g., TNFR1, TNFR2, lymphotoxin β
-67WO 2017/044894
PCT/US2016/051166 receptor/TNFRS3, OX40/TNFRSF4, CD40/TNFRSF5, Fas/TNFRSF6, decoy receptor
3/TNFRSF6B, CD27/TNFRSF7, CD3O/TNFRSF8, 4-1BB/TNFRSF9, DR4 (death receptor
4/TNFRS10A), DR5 (death receptor 5/TNFRSF10B), decoy receptor 1/TNFRSF10C, decoy receptor 2/TNFRSF10D, RANK (receptor activator of NF-kappa B/TNFRSF11A), OPG (osteoprotegerin/TNFRSFUB), DR3 (death receptor 3/TNFRSF25), TWEAK receptor/TNFRSF 12 A, TAC1/TNFRSF13B, BAFF-R (BAFF receptor/TNFRSF13C), HVEM (herpes virus entry mediator/TNFRSF14), nerve growth factor receptor/TNFRSF 16, BCMA (B cell maturation antigen/TNFRSF17), GITR (glucocorticoid-induced TNF receptor/TNFRSF 18), TAJ (toxicity and JNK inducer/TNFRSF19), RELT/TNFRSF19L,
DR6 (death receptor 6/TNFRSF21), TNFRSF22, TNFRSF23, ectodysplasin A2 isoform receptor/TNFRS27, ectodysplasin 1, and anhidrotic receptor, a TNF receptor superfamily ligand including - TNF alpha, lymphotoxin-α, tumor necrosis factor membrane form, tumor necrosis factor shed form, LIGHT, lymphotoxin β2αι heterotrimer, OX-40 ligand, compound 1 [PMID: 24930776], CD40 ligand, Fas ligand, TL1A, CD70, CD30 ligand, TRAF1, TRAF2, TRAF3, TRAIL, RANK ligand, APRIL, BAFF, B and T lymphocyte attenuator, NGF,
BDNF, neurotrophin-3, neurotrophin-4, TL6, ectodysplasin A2, ectodysplasin Al - a TIMP3 inhibitor, a BCL-2 family inhibitor, an IAP disruptor, a protease inhibitor, an amino sugar, a chemotherapeutic (whether acting through an apoptotic or non-apoptotic pathway) (Ricci et al. Oncologist 11(4):342-57 (2006)), a cytotoxic chemical, a toxin, a tyrosine kinase inhibitor (e.g. imatinib mesylate), protons, bevacuzimab (antivascular agent), erlotinib (EGFR inhibitor), an anti-infective agent, an antibiotic, an anti-viral agent, an anti-fungal agent, an aminoglycoside, a nonsteroidal anti-inflammatory drug (NSAID), a statin, a nanoparticle, a liposome, a polymer, a biopolymer, a polysaccharide, a proteoglycan, a glycosaminoglycan, polyethylene glycol, a lipid, a dendrimer, a fatty acid, or an Fc domain or an Fc region, or an active fragment or a modification thereof. Any combination of the above active agents can be co-delivered with peptides or peptide conjugates of this disclosure. Additionally, in some embodiments, other co-therapies such as proton therapy or ablative radiotherapy can be administered to a subject in need thereof along with peptides or peptide conjugates of this disclosure. In some embodiments, the peptide is covalently or non-covalently linked to an active agent, e.g., directly or via a linker. TNF blockers suppress the immune system by blocking the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases, such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. The drugs in this class include Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab
-68WO 2017/044894
PCT/US2016/051166 pegol) and Simponi (golimumab). The peptide disclosed herein can be used to home, distribute to, target, directed to, is retained by, accumulate in, migrate to, and/or bind to cartilage, and thus also be used for localizing the attached or fused active agent. Furthermore, knotted chlorotoxin peptide can be internalized in cells (Wiranowska, M., Cancer Cell Int., 11: 27 (2011)). Therefore, cellular internalization, subcellular localization, and intracellular trafficking after internalization of the active agent peptide conjugate or fusion peptide can be important factors in the efficacy of an active agent conjugate or fusion. (Ducry, L., Antibody Drug Conjugates (2013); and Singh, S. K., Pharm Res. 32(11): 3541-3571 (2015)). Exemplary linkers suitable for use with the embodiments herein are discussed in further detail below.
[0183] The peptides or fusion peptides of the present disclosure can also be conjugated to other moieties that can serve other roles, such as providing an affinity handle (e.g., biotin) for retrieval of the peptides from tissues or fluids. For example, peptides or fusion peptides of the present disclosure can also be conjugated to biotin. In addition to extension of half-life, biotin could also act as an affinity handle for retrieval of peptides or fusion peptides from tissues or other locations. In some embodiments, fluorescent biotin conjugates that can act both as a detectable label and an affinity handle can be used. Non limiting examples of commercially available fluorescent biotin conjugates include Atto 425-Biotin, Atto 488-Biotin, Atto 520Biotin, Atto-550 Biotin, Atto 565-Biotin, Atto 590-Biotin, Atto 610-Biotin, Atto 620-Biotin, Atto 655-Biotin, Atto 680-Biotin, Atto 700-Biotin, Atto 725-Biotin, Atto 740-Biotin, fluorescein biotin, biotin-4-fluorescein, biotin-(5-fluorescein) conjugate, and biotin-Bphycoerythrin, Alexa fluor 488 biocytin, Alexa flour 546, Alexa Fluor 549, lucifer yellow cadaverine biotin-X, Lucifer yellow biocytin, Oregon green 488 biocytin, biotin-rhodamine and tetramethylrhodamine biocytin. In some other examples, the conjugates could include chemiluminescent compounds, colloidal metals, luminescent compounds, enzymes, radioisotopes, and paramagnetic labels. In some embodiments, the peptide described herein can be attached to another molecule. For example, the peptide sequence also can be attached to another active agent (e.g., small molecule, peptide, polypeptide, polynucleotide, antibody, aptamer, cytokine, growth factor, neurotransmitter, an active fragment or modification of any of the preceding, fluorophore, radioisotope, radionuclide chelator, acyl adduct, chemical linker, or sugar, etc.). In some embodiments, the peptide can be fused with, or covalently or non-covalently linked to an active agent.
[0184] Additionally, more than one peptide sequence derived from a toxin or venom can be present on or fused with a particular peptide. A peptide can be incorporated into a
- 69WO 2017/044894
PCT/US2016/051166 biomolecule by various techniques. A peptide can be incorporated by a chemical transformation, such as the formation of a covalent bond, such as an amide bond. A peptide can be incorporated, for example, by solid phase or solution phase peptide synthesis. A peptide can be incorporated by preparing a nucleic acid sequence encoding the biomolecule, wherein the nucleic acid sequence includes a subsequence that encodes the peptide. The subsequence can be in addition to the sequence that encodes the biomolecule, or can substitute for a subsequence of the sequence that encodes the biomolecule.
Detectable Agent Conjugates [0185] A peptide can be conjugated to an agent used in imaging, research, therapeutics, theranostics, pharmaceuticals, chemotherapy, chelation therapy, targeted drug delivery, and radiotherapy. The agent can be a detectable agent. In some embodiments, a knottin peptide is conjugated to detectble agents, such as a metal, a radioisotope, a dye, fluorophore, or another suitable material that can be used in imaging. Non-limiting examples of radioisotopes include alpha emitters, beta emitters, positron emitters, and gamma emitters. In some embodiments, the metal or radioisotope is selected from the group consisting of actinium, americium, bismuth, cadmium, cesium, cobalt, europium, gadolinium, iridium, lead, lutetium, manganese, palladium, polonium, radium, ruthenium, samarium, strontium, technetium, thallium, and yttrium. In some embodiments, the metal is actinium, bismuth, lead, radium, strontium, samarium, or yttrium. In some embodiments, the radioisotope is actinium-225 or lead-212. In some embodiments, the fluorophore is a fluorescent agent emitting electromagnetic radiation at a wavelength between 650 nm and 4000 nm, such emissions being used to detect such agent. In some embodiments the fluorophore is a fluorescent agent is selected from the group consisting of Non-limiting examples of fluorescent dyes that could be used as a conjugating molecule in the present disclosure include DyLight-680, DyLight750, VivoTag-750, DyLight-800, IRDye-800, VivoTag-680, Cy5.5, or indocyanine green (ICG). In some embodiments, near infrared dyes often include cyanine dyes. Additional nonlimiting examples of fluorescent dyes for use as a conjugating molecule in the present disclosure include acradine orange or yellow, Alexa Fluors and any derivative thereof, 7actinomycin D, 8-anilinonaphthalene-l-sulfonic acid, ATTO dye and any derivative thereof, auramine-rhodamine stain and any derivative thereof, bensantrhone, bimane, 9-10bis(phenylethynyl)anthracene, 5,12 - bis(phenylethynyl)naththacene, bisbenzimide, brainbow, calcein, carbodyfluorescein and any derivative thereof, l-chloro-9,10bis(phenylethynyl)anthracene and any derivative thereof, DAPI, DiOC6, DyLight Fluors and
-70WO 2017/044894
PCT/US2016/051166 any derivative thereof, epicocconone, ethidium bromide, FlAsH-EDT2, Fluo dye and any derivative thereof, FluoProbe and any derivative thereof, Fluorescein and any derivative thereof, Fura and any derivative thereof, GelGreen and any derivative thereof, GelRed and any derivative thereof, fluorescent proteins and any derivative thereof, m isoform proteins and any derivative thereof such as for example mCherry, hetamethine dye and any derivative thereof, hoeschst stain, iminocoumarin, indian yellow, indo-1 and any derivative thereof, laurdan, lucifer yellow and any derivative thereof, luciferin and any derivative thereof, luciferase and any derivative thereof, mercocyanine and any derivative thereof, nile dyes and any derivative thereof, perylene, phloxine, phyco dye and any derivative thereof, propium iodide, pyranine, rhodamine and any derivative thereof, ribogreen, RoGFP, rubrene, stilbene and any derivative thereof, sulforhodamine and any derivative thereof, SYBR and any derivative thereof, synapto-pHluorin, tetraphenyl butadiene, tetrasodium tris, Texas Red, Titan Yellow, TSQ, umbelliferone, violanthrone, yellow fluroescent protein and YOYO-1. Other Suitable fluorescent dyes include, but are not limited to, fluorescein and fluorescein dyes (e.g., fluorescein isothiocyanine or FITC, naphthofluorescein, 4', 5'-dichloro-2',7' dimethoxyfluorescein, 6-carboxyfluorescein or FAM, etc.), carbocyanine, merocyanine, styryl dyes, oxonol dyes, phycoerythrin, erythrosin, eosin, rhodamine dyes (e.g., carboxytetramethyl-rhodamine or TAMRA, carboxyrhodamine 6G, carboxy-X-rhodamine (ROX), lissamine rhodamine B, rhodamine 6G, rhodamine Green, rhodamine Red, tetramethylrhodamine (TMR), etc.), coumarin and coumarin dyes (e.g., methoxycoumarin, dialkylaminocoumarin, hydroxycoumarin, aminomethylcoumarin (AMCA), etc.), Oregon Green Dyes (e.g., Oregon Green 488, Oregon Green 500, Oregon Green 514., etc.), Texas Red, Texas Red-X, SPECTRUM RED, SPECTRUM GREEN, cyanine dyes (e.g., CY-3, Cy5, CY-3.5, CY-5.5, etc.), ALEXA FLUOR dyes (e.g., ALEXA FLUOR 350, ALEXA FLUOR 488, ALEXA FLUOR 532, ALEXA FLUOR 546, ALEXA FLUOR 568, ALEXA FLUOR 594, ALEXA FLUOR 633, ALEXA FLUOR 660, ALEXA FLUOR 680, etc.), BODIPY dyes (e.g., BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR, BODIPY 530/550, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY 630/650, BODIPY 650/665, etc.), IRDyes (e.g., IRD40, IRD 700, IRD 800, etc.), and the like. Additional suitable detectable agents are described in PCT/US14/56177. Nonlimiting examples of radioisotopes include alpha emitters, beta emitters, positron emitters, and gamma emitters. In some embodiments, the metal or radioisotope is selected from the group consisting of actinium, americium, bismuth, cadmium, cesium, cobalt, europium, gadolinium, iridium, lead, lutetium, manganese, palladium, polonium, radium, ruthenium,
-71 WO 2017/044894
PCT/US2016/051166 samarium, strontium, technetium, thallium, and yttrium. In some embodiments, the metal is actinium, bismuth, lead, radium, strontium, samarium, or yttrium. In some embodiments, the radioisotope is actinium-225 or lead-212.
[0186] Other embodiments of the present disclosure provide peptides conjugated to a radio sensitizer or photo sensitizer. Examples of radio sensitizers include but are not limited to: ABT-263, ABT-199, WEHI-539, paclitaxel, carboplatin, cisplatin, oxaliplatin, gemcitabine, etanidazole, misonidazole, tirapazamine, and nucleic acid base derivatives (e.g., halogenated purines or pyrimidines, such as 5-fluorodeoxyuridine). Examples of photo sensitizers include but are not limited to: fluorescent molecules or beads that generate heat when illuminated, porphyrins and porphyrin derivatives (e.g., chlorins, bacteriochlorins, isobacteriochlorins, phthalocyanines, and naphthalocyanines), metalloporphyrins, metallophthalocyanines, angelicins, chalcogenapyrrillium dyes, chlorophylls, coumarins, flavins and related compounds such as alloxazine and riboflavin, fullerenes, pheophorbides, pyropheophorbides, cyanines (e.g., merocyanine 540), pheophytins, sapphyrins, texaphyrins, purpurins, porphycenes, phenothiaziniums, methylene blue derivatives, naphthalimides, nile blue derivatives, quinones, perylenequinones (e.g., hypericins, hypocrellins, and cercosporins), psoralens, quinones, retinoids, rhodamines, thiophenes, verdins, xanthene dyes (e.g., eosins, erythrosins, rose bengals), dimeric and oligomeric forms of porphyrins, and prodrugs such as 5-aminolevulmrc acid. Advantageously, this approach allows for highly specific targeting of diseased cells (e.g., cancer cells) using both a therapeutic agent (e.g., drug) and electromagnetic energy (e.g., radiation or light) concurrently. In some embodiments, the peptide is covalently or non-covalently linked to the agent, e.g., directly or via a linker. Exemplary linkers suitable for use with the embodiments herein are discussed in further detail below
Linkers [0187] Peptides according to the present disclosure that home, target, migrate to, are retained by, accumulate in, and/or bind to, or are directed to the cartilage can be attached to another moiety (e.g., an active agent), such as a small molecule, a second peptide, a protein, an antibody, an antibody fragment, an aptamer, polypeptide, polynucleotide, a fluorophore, a radioisotope, a radionuclide chelator, a polymer, a biopolymer, a fatty acid, an acyl adduct, a chemical linker, or sugar or other active agent described herein through a linker, or directly in the absence of a linker.
-72WO 2017/044894
PCT/US2016/051166 [0188] A peptide can be directly attached to another molecule by a covalent attachment. For example, the peptide is attached to a terminus of the amino acid sequence of a larger polypeptide or peptide molecule, or is attached to a side chain, such as the side chain of a lysine, serine, threonine, cysteine, tyrosine, aspartic acid, a non-natural amino acid residue, or glutamic acid residue. The attachment can be via an amide bond, an ester bond, an ether bond, a carbamate bond, a carbon-nitrogen bond, a triazole, a macrocycle, an oxime bond, a hydrazone bond, a carbon-carbon single double or triple bond, a disulfide bond, or a thioether bond. In some embodiments, similar regions of the disclosed peptide(s) itself (such as a terminus of the amino acid sequence, an amino acid side chain, such as the side chain of a lysine, serine, threonine, cysteine, tyrosine, aspartic acid, a non-natural amino acid residue, or glutamic acid residue, via an amide bond, an ester bond, an ether bond, a carbamate bond, a carbon-nitrogen bond, a triazole, a macrocycle, an oxime bond, a hydrazone bond, a carboncarbon single double or triple bond, a disulfide bond, or a thioether bond, or linker as described herein) can be used to link other molecules.
[0189] Attachment via a linker can involve incorporation of a linker moiety between the other molecule and the peptide. The peptide and the other molecule can both be covalently attached to the linker. The linker can be cleavable, non-cleavable, self-immolating, hydrophilic, or hydrophobic. The linker can have at least two functional groups with one bonded to the peptide, the other bonded to the other molecule, and a linking portion between the two functional groups.
[0190] Non-limiting examples of the functional groups for attachment can include functional groups capable of forming an amide bond, an ester bond, an ether bond, a carbonate bond, a carbamate bond, or a thioether bond. Non-limiting examples of functional groups capable of forming such bonds can include amino groups; carboxyl groups; hydroxyl groups; aldehyde groups; azide groups; alkyne and alkene groups; ketones; hydrazides; acid halides such as acid fluorides, chlorides, bromides, and iodides; acid anhydrides, including symmetrical, mixed, and cyclic anhydrides; carbonates; carbonyl functionalities bonded to leaving groups such as cyano, succinimidyl, and A-hydroxysuccinimidyl; hydroxyl groups; sulfhydryl groups; and molecules possessing, for example, alkyl, alkenyl, alkynyl, allylic, or benzylic leaving groups, such as halides, mesylates, tosylates, triflates, epoxides, phosphate esters, sulfate esters, and besylates.
[0191] Non-limiting examples of the linking portion can include alkylene, alkenylene, alkynylene, polyether, such as polyethylene glycol (PEG), hydroxy carboxylic acids, polyester, polyamide, polyamino acids, polypeptides, cleavable peptides, valine-citrulline,
-73WO 2017/044894
PCT/US2016/051166 aminobenzylcarbamates, D-amino acids, and polyamine, any of which being unsubstituted or substituted with any number of substituents, such as halogens, hydroxyl groups, sulfhydryl groups, amino groups, nitro groups, nitroso groups, cyano groups, azido groups, sulfoxide groups, sulfone groups, sulfonamide groups, carboxyl groups, carboxaldehyde groups, imine groups, alkyl groups, halo-alkyl groups, alkenyl groups, halo-alkenyl groups, alkynyl groups, halo-alkynyl groups, alkoxy groups, aryl groups, aryloxy groups, aralkyl groups, arylalkoxy groups, heterocyclyl groups, acyl groups, acyloxy groups, carbamate groups, amide groups, urethane groups, epoxides, and ester groups.
[0192] Non-limiting examples of linkers include:
Figure AU2016321342A1_D0001
1,000; 1 to about 1,000; 0 to about 500; 1 to about 500; 0 to about 250; 1 to about 250; 0 to about 200; 1 to about 200; 0 to about 150; 1 to about 150; 0 to about 100; 1 to about 100; 0 to about 50; 1 to about 50; 0 to about 40; 1 to about 40; 0 to about 30; 1 to about 30; 0 to about
-74WO 2017/044894
PCT/US2016/051166
25; 1 to about 25; 0 to about 20; 1 to about 20; 0 to about 15; 1 to about 15; 0 to about 10; 1 to about 10; 0 to about 5; or 1 to about 5. In some embodiments, each n is independently 0, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about
11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, or about 50. In some embodiments, m is 1 to about 1,000; 1 to about 500; 1 to about 250; 1 to about 200; 1 to about 150; 1 to about 100; 1 to about 50; 1 to about 40; 1 to about 30; 1 to about 25; 1 to about 20; 1 to about 15; 1 to about 10; or 1 to about 5. In some embodiments, m is 0, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, or about 50.
[0193] In some cases a linker can be a succinic linker, and a drug can be attached to a peptide via an ester bond or an amide bond with two methylene carbons in between. In other cases, a linker can be any linker with both a hydroxyl group and a carboxylic acid, such as hydroxy hexanoic acid or lactic acid.
[0194] The linker can be a cleavable or a noncleavable linker. The use of a cleavable linker permits release of the conjugated moiety (e.g., a therapeutic agent) from the peptide, e.g., after targeting to the cartilage. In some cases the linker is enzyme cleavable, e.g., a valinecitrulline linker. In some embodiments, the linker contains a self-immolating portion. In other embodiments, the linker includes one or more cleavage sites for a specific protease, such as a cleavage site for matrix metalloproteases (MMPs), thrombin, or cathepsin. Alternatively or in combination, the linker is cleavable by other mechanisms, such as via pH, reduction, or hydrolysis. A hydrolytically labile linker, (amongst other cleavable linkers described herein) can be advantageous in terms of releasing active agents from the peptide. For example, an active agent in a conjugate form with the peptide may not be active, but upon release from the conjugate after targeting to the cartilage, the active agent is active.
[0195] The rate of hydrolysis of the linker can be tuned. For example, the rate of hydrolysis of linkers with unhindered esters is faster compared to the hydrolysis of linkers with bulky groups next an ester carbonyl. A bulky group can be a methyl group, an ethyl group, a phenyl
-75WO 2017/044894
PCT/US2016/051166 group, a ring, or an isopropyl group, or any group that provides steric bulk. In some cases, the steric bulk can be provided by the drug itself, such as by ketorolac when conjugated via its carboxylic acid. The rate of hydrolysis of the linker can be tuned according to the residency time of the conjugate in the cartilage. For example, when a peptide is cleared from the cartilage relatively quickly, the linker can be tuned to rapidly hydrolyze. In contrast, for example, when a peptide has a longer residence time in the cartilage, a slower hydrolysis rate can allow for extended delivery of an active agent. This can be important when the peptide is used to deliver a drug to the cartilage. “Programmed hydrolysis in designing paclitaxel prodrug for nanocarrier assembly” Sci Rep 2015, 5, 12023 Fu et al., provides an example of modified hydrolysis rates.
Peptide Stability [0196] A peptide of the present disclosure can be stable in various biological conditions. For example, any peptide of SEQ ID NO: 1 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432 can exhibit resistance to reducing agents, proteases, oxidative conditions, or acidic conditions.
[0197] In some cases, biologic molecules (such as peptides and proteins) can provide therapeutic functions, but such therapeutic functions are decreased or impeded by instability caused by the in vivo environment. (Moroz et al. Adv Drug Deliv Rev 101:108-21 (2016), Mitragotri et al. Nat Rev Drug Discov 13(9):655-72 (2014), Bruno et al. Ther Deliv (11):1443-67 (2013), Sinha et al. Crit Rev Ther Drug Carrier Syst. 24(1):63-92 (2007), Hamman et al. BioDrugs 19(3):165-77 (2005)). For instance, the GI tract can contain a region of low pH (e.g. pH ~1), a reducing environment, or a protease-rich environment that can degrade peptides and proteins. Proteolytic activity in other areas of the body, such as the mouth, eye, lung, intranasal cavity, joint, skin, vaginal tract, mucous membranes, and serum, can also be an obstacle to the delivery of functionally active peptides and polypeptides. Additionally, the half-life of peptides in serum can be very short, in part due to proteases, such that the peptide can be degraded too quickly to have a lasting therapeutic effect when administering reasonable dosing regimens. Likewise, proteolytic activity in cellular compartments such as lysosomes and reduction activity in lysosomes and the cytosol can degrade peptides and proteins such that they may be unable to provide a therapeutic function on intracellular targets. Therefore, peptides that are resistant to reducing agents, proteases, and low pH may be able to provide enhanced therapeutic effects or enhance the therapeutic efficacy of co-formulated or conjugated active agents in vivo.
-76WO 2017/044894
PCT/US2016/051166 [0198] Additionally, oral delivery of drugs can be desirable in order to target certain areas of the body (e.g., disease in the GI tract such as colon cancer, irritable bowel disorder, infections, metabolic disorders, and constipation) despite the obstacles to the delivery of functionally active peptides and polypeptides presented by this method of administration. For example, oral delivery of drugs can increase compliance by providing a dosage form that is more convenient for patients to take as compared to parenteral delivery. Oral delivery can be useful in treatment regimens that have a large therapeutic window. Therefore, peptides that are resistant to reducing agents, proteases, and low pH can allow for oral delivery of peptides without nullifying their therapeutic function.
Peptide Resistance to Reducing Agents [0199] Peptides of this disclosure can contain one or more cysteines, which can participate in disulfide bridges that can be integral to preserving the folded state of the peptide. Exposure of peptides to biological environments with reducing agents can result in unfolding of the peptide and loss of functionality and bioactivity. For example, glutathione (GSH) is a reducing agent that can be present in many areas of the body and in cells, and can reduce disulfide bonds. As another example, a peptide can become reduced upon cellular internalization during trafficking of a peptide across the gastrointestinal epithelium after oral administration A peptide can become reduced upon exposure to various parts of the GI tract. The GI tract can be a reducing environment, which can inhibit the ability of therapeutic molecules with disulfide bonds to have optimal therapeutic efficacy, due to reduction of the disulfide bonds. A peptide can also be reduced upon entry into a cell, such as after internalization by endosomes or lysosomes or into the cytosol, or other cellular compartments. Reduction of the disulfide bonds and unfolding of the peptide can lead to loss of functionality or affect key pharmacokinetic parameters such as bio availability, peak plasma concentration, bioactivity, and half-life. Reduction of the disulfide bonds can also lead to increased susceptibility of the peptide to subsequent degradation by proteases, resulting in rapid loss of intact peptide after administration. In some embodiments, a peptide that is resistant to reduction can remain intact and can impart a functional activity for a longer period of time in various compartments of the body and in cells, as compared to a peptide that is more readily reduced. .
[0200] In certain embodiments, the peptides of this disclosure can be analyzed for the characteristic of resistance to reducing agents to identify stable peptides. In some embodiments, the peptides of this disclosure can remain intact after being exposed to different molarities of reducing agents such as 0.00001M - 0.0001M, 0.0001M - 0.001M,
- 77 WO 2017/044894
PCT/US2016/051166
0.001M - 0.01M, 0.01 M - 0.05 M, 0.05 M - 0.1 M, for greater 15 minutes or more. In some embodiments, the reducing agent used to determine peptide stability can be dithiothreitol (DTT), Tris(2-carboxyethyl)phosphine HCI (TCEP), 2-Mercaptoethanol, (reduced) glutathione (GSH), or any combination thereof. In some embodiments, at least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to a reducing agent.
Peptide Resistance to Proteases [0201] The stability of peptides of this disclosure can be determined by resistance to degradation by proteases. Proteases, also referred to as peptidases or proteinases, can be enzymes that can degrade peptides and proteins by breaking bonds between adjacent amino acids. Families of proteases with specificity for targeting specific amino acids can include serine proteases, cysteine proteases, threonine proteases, aspartic proteases, glutamic proteases, esterases, serum proteases, and asparagine proteases. Additionally, metalloproteases, matrix metalloproteases, elastase, carboxypeptidases, Cytochrome P450 enzymes, and cathepsins can also digest peptides and proteins. Proteases can be present at high concentration in blood, in mucous membranes, lungs, skin, the GI tract, the mouth, nose, eye, and in compartments of the cell. Misregulation of proteases can also be present in various diseases such as rheumatoid arthritis and other immune disorders. Degradation by proteases can reduce bio availability, biodistribution, half-life, and bioactivity of therapeutic molecules such that they are unable to perform their therapeutic function. In some embodiments, peptides that are resistant to proteases can better provide therapeutic activity at reasonably tolerated concentrations in vivo.
[0202] In some embodiments, peptides of this disclosure can resist degradation by any class of protease. In certain embodiments, peptides of this disclosure resist degradation by pepsin (which can be found in the stomach), trypsin (which can be found in the duodenum), serum proteases, or any combination thereof. In certain embodiments, peptides of this disclosure can resist degradation by lung proteases (e.g., serine, cysteinyl, and aspartyl proteases, metalloproteases, neutrophil elastase, alpha-1 antitrypsin, secretory leucoprotease inhibitor, elafin), or any combination thereof. In some embodiments, the proteases used to determine peptide stability can be pepsin, trypsin, chymotrypsin, or any combination thereof. In some embodiments, at least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to a protease. Peptides of
-78WO 2017/044894
PCT/US2016/051166
SEQ ID NO: 212, SEQ ID NO: 24, and SEQ ID NO: 111 can have particular structural qualities, which make them more resistant to protease degradation. For example, peptide of
SEQ ID NO: 24 and SEQ ID NO: 112 exhibit the “hitchin” topology as described previously, which can be associated with resistance to protease and chemical degradation.
Peptide Stability in Acidic Conditions [0203] Peptides of this disclosure can be administered in biological environments that are acidic. For example, after oral administration, peptides can experience acidic environmental conditions in the gastric fluids of the stomach and gastrointestinal (GI) tract. The pH of the stomach can range from ~l-4 and the pH of the GI tract ranges from acidic to normal physiological pH descending from the upper GI tract to the colon. In addition, the vagina, late endosomes, and lysosomes can also hav acidic pH values, such as less than pH 7. These acidic conditions can lead to denaturation of peptides and proteins into unfolded states. Unfolding of peptides and proteins can lead to increased susceptibility to subsequent digestion by other enzymes as well as loss of biological activity of the peptide.
[0204] In certain embodiments, the peptides of this disclosure can resist denaturation and degradation in acidic conditions and in buffers, which simulate acidic conditions. In certain embodiments, peptides of this disclosure can resist denaturation or degradation in buffer with a pH less than 1, a pH less than 2, a pH less than 3, a pH less than 4, a pH less than 5, a pH less than 6, a pH less than 7, or a pH less than 8. In some embodiments, peptides of this disclosure remain intact at a pH of 1-3. In certain embodiments, at least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to a buffer with a pH less than 1, a pH less than 2, a pH less than 3, a pH less than 4, a pH less than 5, a pH less than 6, a pH less than 7, or a pH less than 8. In other embodiments, at least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to a buffer with a pH of 13. In other embodiments, the peptides of this disclosure can be resistant to denaturation or degradation in simulated gastric fluid (pH 1-2). In some embodiments, at least 5-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90-100% of the peptide remains intact after exposure to simulated gastric fluid. In some embodiments, low pH solutions such as simulated gastric fluid or citrate buffers can be used to determine peptide stability.
-79WO 2017/044894
PCT/US2016/051166
Peptide Stability at High Temperatures [0205] Peptides of this disclosure can be administered in biological environments with high temperatures. For example, after oral administration, peptides can experience high temperatures in the body. Body temperature can range from 36°C to 40°C. High temperatures can lead to denaturation of peptides and proteins into unfolded states. Unfolding of peptides and proteins can lead to increased susceptibility to subsequent digestion by other enzymes as well as loss of biological activity of the peptide. In some embodiments, a peptide of this disclosure can remain intact at temperatures from 25°C to 100°C. High temperatures can lead to faster degradation of peptides. Stability at a higher temperature can allow for storage of the peptide in tropical environments or areas where access to refrigeration is limited. In certain embodiments, 5%-100% of the peptide can remain intact after exposure to 25°C for 6 months to 5 years. 5%-100% of a peptide can remain intact after exposure to 70°C for 15 minutes to 1 hour. 5%-100% of a peptide can remain intact after exposure to 100°C for 15 minutes to 1 hour. In other embodiments, at least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to 25°C for 6 months to 5 years. In other embodiments, at least 5%-10%, at least 10%-20%, at least 20%30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to 70°C for 15 minutes to 1 hour. In other embodiments, at least 5%-10%, at least 10%-20%, at least 20%-30%, at least 30%-40%, at least 40%-50%, at least 50%-60%, at least 60%-70%, at least 70%-80%, at least 80%-90%, or at least 90%-100% of the peptide remains intact after exposure to 100°C for 15 minutes to 1 hour.
Pharmacokinetics of Peptides [0206] The pharmacokinetics of any of the peptides of this disclosure can be determined after administration of the peptide via different routes of administration. For example, the pharmacokinetic parameters of a peptide of this disclosure can be quantified after intravenous, subcutaneous, intramuscular, rectal, aerosol, parenteral, ophthalmic, pulmonary, transdermal, vaginal, optic, nasal, oral, sublingual, inhalation, dermal, intrathecal, intranasal, intra-articular, peritoneal, buccal, synovial, or topical administration. Peptides of the present disclosure can be analyzed by using tracking agents such as radiolabels or fluorophores. For example, a radiolabeled peptides of this disclosure can be administered via various routes of administration. Peptide concentration or dose recovery in various biological samples such as
- 80WO 2017/044894
PCT/US2016/051166 plasma, urine, feces, any organ, skin, muscle, and other tissues can be determined using a range of methods including HPLC, fluorescence detection techniques (TECAN quantification, flow cytometry, iVIS), or liquid scintillation counting.
[0207] The methods and compositions described herein can relate to pharmacokinetics of peptide administration via any route to a subject. Pharmacokinetics can be described using methods and models, for example, compartmental models or noncompartmental methods. Compartmental models include but are not limited to monocompartmental model, the two compartmental model, the multicompartmental model or the like. Models can be divided into different compartments and can be described by the corresponding scheme. For example, one scheme is the absorption, distribution, metabolism and excretion (ADME) scheme. For another example, another scheme is the liberation, absorption, distribution, metabolism and excretion (LADME) scheme. In some aspects, metabolism and excretion can be grouped into one compartment referred to as the elimination compartment. For example, liberation can include liberation of the active portion of the composition from the delivery system, absorption includes absorption of the active portion of the composition by the subject, distribution includes distribution of the composition through the blood plasma and to different tissues, metabolism, which includes metabolism or inactivation of the composition and finally excretion, which includes excretion or elimination of the composition or the products of metabolism of the composition. Compositions administered intravenously to a subject can be subject to multiphasic pharmacokinetic profiles, which can include but are not limited to aspects of tissue distribution and metabolism/excretion. As such, the decrease in plasma or serum concentration of the composition is often biphasic, including, for example an alpha phase and a beta phase, occasionally a gamma, delta or other phase is observed [0208] Pharmacokinetics includes determining at least one parameter associated with administration of a peptide to a subject. In some aspects, parameters include at least the dose (D), dosing interval (τ), area under curve (AUC), maximum concentration (Cmax), minimum concentration reached before a subsequent dose is administered (Cmin), minimum time (Tmin), maximum time to reach Cmax (Tmax), volume of distribution (Vd), steady-state volume of distribution (Vss), back-extrapolated concentration at time 0 (Co), steady state concentration (Css), elimination rate constant (ke), infusion rate (kjn), clearance (CL), bio availability (f), fluctuation (%PTF) and elimination half-life (ti/2).
[0209] In certain embodiments, the peptides of any of SEQ ID NO: 1 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432 exhibit optimal pharmacokinetic parameters after oral administration. In
- 81 WO 2017/044894
PCT/US2016/051166 other embodiments, the peptides of any of SEQ ID NO: 1 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432 exhibit optimal pharmacokinetic parameters after any route of administration, such as oral administration, inhalation, intranasal administration, topical administration, intravenous administration, subcutaneous administration, intra-articular administration, intramuscular administration, intraperitoneal administration, or any combination thereof. [0210] In some embodiments any peptide of SEQ ID NO: 1 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432 exhibits an average Tmax of 0.5 - 12 hours, or 1-48 hours at which the Cmax is reached, an average bio availability in serum of 0.1% - 10% in the subject after administering the peptide to the subject by an oral route, an average bio availability in serum of less than 0.1% after oral administration to a subject for delivery to the Gl tract, an average bio availability in serum of 10-100% after parenteral administration, an average h/2 of 0.1 hours - 168 hours, or 0.25 hours - 48 hours in a subject after administering the peptide to the subject, an average clearance (CL) of 0.5-100 L/hour or 0.5 - 50 L/hour of the peptide after administering the peptide to a subject, an average volume of distribution (Vd) of 200 - 20,000 mL in the subject after systemically administering the peptide to the subject, or optionally no systemic uptake, any combination thereof.
Methods of Manufacture [0211] Various expression vector/host systems can be utilized for the production of the recombinant expression of peptides described herein. Non-limiting examples of such systems include microorganisms such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing a nucleic acid sequence encoding peptides or peptide fusion proteins/chimeric proteins described herein, yeast transformed with recombinant yeast expression vectors containing the aforementioned nucleic acid sequence, insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the aforementioned nucleic acid sequence, plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus (CaMV), tobacco mosaic virus (TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing the aforementioned nucleic acid sequence, or animal cell systems infected with recombinant virus expression vectors (e.g., adenovirus, vaccinia virus) including cell lines engineered to contain multiple copies of the aforementioned nucleic acid sequence, either stably amplified (e.g., CHO/dhfr, CHO/glutamine synthetase) or unstably
- 82WO 2017/044894
PCT/US2016/051166 amplified in double-minute chromosomes (e.g., murine cell lines). Disulfide bond formation and folding of the peptide could occur during expression or after expression or both.
[0212] A host cell can be adapted to express one or more peptides described herein. The host cells can be prokaryotic, eukaryotic, or insect cells. In some cases, host cells are capable of modulating the expression of the inserted sequences, or modifying and processing the gene or protein product in the specific fashion desired. For example, expression from certain promoters can be elevated in the presence of certain inducers (e.g., zinc and cadmium ions for metallothionine promoters). In some cases, modifications (e.g., phosphorylation) and processing (e.g., cleavage) of peptide products can be important for the function of the peptide. Host cells can have characteristic and specific mechanisms for the post-translational processing and modification of a peptide. In some cases, the host cells used to express the peptides secretes minimal amounts of proteolytic enzymes.
[0213] In the case of cell- or viral-based samples, organisms can be treated prior to purification to preserve and/or release a target polypeptide. In some embodiments, the cells are fixed using a fixing agent. In some embodiments, the cells are lysed. The cellular material can be treated in a manner that does not disrupt a significant proportion of cells, but which removes proteins from the surface of the cellular material, and/or from the interstices between cells. For example, cellular material can be soaked in a liquid buffer or, in the case of plant material, can be subjected to a vacuum, in order to remove proteins located in the intercellular spaces and/or in the plant cell wall. If the cellular material is a microorganism, proteins can be extracted from the microorganism culture medium. Alternatively, the peptides can be packed in inclusion bodies. The inclusion bodies can further be separated from the cellular components in the medium. In some embodiments, the cells are not disrupted. A cellular or viral peptide that is presented by a cell or virus can be used for the attachment and/or purification of intact cells or viral particles. In addition to recombinant systems, Peptides can also be synthesized in a cell-free system using a variety of known techniques employed in protein and peptide synthesis.
[0214] In some cases, a host cell produces a peptide that has an attachment point for a drug. An attachment point could comprise a lysine residue, an N-terminus, a cysteine residue, a cysteine disulfide bond, or a non-natural amino acid. The peptide could also be produced synthetically, such as by solid-phase peptide synthesis, or solution-phase peptide synthesis. The peptide could be folded (formation of disulfide bonds) during synthesis or after synthesis or both. Peptide fragments could be produced synthetically or recombinantly and then joined together synthetically, recombinantly, or via an enzyme.
- 83 WO 2017/044894
PCT/US2016/051166 [0215] FIG. 10 illustrates a schematic of a method of manufacturing a construct that expresses a peptide of the disclosure, such as the constructs illustrated in FIG. 9 and as described throughout the disclosure and in SEQ ID NO: 1 - SEQ ID NO: 194, SEQ ID NO:
196, SEQ ID NO: 198 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID
NO: 432 provided herein.
[0216] In other aspects, the peptides of the present disclosure can be prepared by conventional solid phase chemical synthesis techniques, for example according to the Fmoc solid phase peptide synthesis method (“Fmoc solid phase peptide synthesis, a practical approach,” edited by W. C. Chan and P. D. White, Oxford University Press, 2000).
Pharmaceutical Compositions of Peptides [0217] A pharmaceutical composition of the disclosure can be a combination of any peptide described herein with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, antioxidants, solubilizers, buffers, osmolytes, salts, surfactants, amino acids, encapsulating agents, bulking agents, cryoprotectants, and/or excipients. The pharmaceutical composition facilitates administration of a peptide described herein to an organism. Pharmaceutical compositions can be administered in therapeutically-effective amounts as pharmaceutical compositions by various forms and routes including, for example, intravenous, subcutaneous, intramuscular, rectal, aerosol, parenteral, ophthalmic, pulmonary, transdermal, vaginal, optic, nasal, oral, sublingual, inhalation, dermal, intrathecal, intranasal, and topical administration. A pharmaceutical composition can be administered in a local or systemic manner, for example, via injection of the peptide described herein directly into an organ, optionally in a depot. [0218] Parenteral injections can be formulated for bolus injection or continuous infusion. The pharmaceutical compositions can be in a form suitable for parenteral injection as a sterile suspension, solution or emulsion in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Pharmaceutical formulations for parenteral administration include aqueous solutions of a peptide described herein in water soluble form. Suspensions of peptides described herein can be prepared as oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. The suspension can also contain suitable stabilizers or agents which increase the solubility and/or reduces the
- 84WO 2017/044894
PCT/US2016/051166 aggregation of such peptides described herein to allow for the preparation of highly concentrated solutions. Alternatively, the peptides described herein can be lyophilized or in powder form for re-constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. In some embodiments, a purified peptide is administered intravenously.
[0219] A peptide of the disclosure can be applied directly to an organ, or an organ tissue or cells, such as brain or brain tissue or cancer cells, during a surgical procedure. The recombinant peptides described herein can be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams, and ointments. Such pharmaceutical compositions can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
[0220] In practicing the methods of treatment or use provided herein, therapeuticallyeffective amounts of the peptide described herein described herein can be administered in pharmaceutical compositions to a subject suffering from a condition that affects the immune system. In some embodiments, the subject is a mammal such as a human. A therapeuticallyeffective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compounds used, and other factors.
[0221] Pharmaceutical compositions can be formulated using one or more physiologicallyacceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations that can be used pharmaceutically. Formulation can be modified depending upon the route of administration chosen. Pharmaceutical compositions comprising a peptide described herein can be manufactured, for example, by expressing the peptide in a recombinant system, purifying the peptide, lyophilizing the peptide, mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or compression processes. The pharmaceutical compositions can include at least one pharmaceutically acceptable carrier, diluent, or excipient and compounds described herein as free-base or pharmaceutically-acceptable salt form.
[0222] Methods for the preparation of peptides described herein comprising the compounds described herein include formulating the peptide described herein with one or more inert, pharmaceutically-acceptable excipients or carriers to form a solid, semi-solid, or liquid composition. Solid compositions include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories. These compositions can also contain minor amounts of nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and other pharmaceutically-acceptable additives.
- 85WO 2017/044894
PCT/US2016/051166 [0223] Non-limiting examples of pharmaceutically-acceptable excipients can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington’s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkinsl999), each of which is incorporated by reference in its entirety.
Administration of Pharmaceutical Compositions [0224] A pharmaceutical composition of the disclosure can be a combination of any venom or toxin derived peptide described herein with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients. The pharmaceutical composition facilitates administration of a peptide described herein to an organism. Pharmaceutical compositions can be administered in therapeuticallyeffective amounts as pharmaceutical compositions by various forms and routes including, for example, intravenous, subcutaneous, intramuscular, rectal, aerosol, parenteral, ophthalmic, pulmonary, transdermal, vaginal, optic, nasal, oral, inhalation, dermal, intra-articular, intrathecal, intranasal, and topical administration. A pharmaceutical composition can be administered in a local or systemic manner, for example, via injection of the peptide described herein directly into an organ, optionally in a depot.
[0225] Parenteral injections can be formulated for bolus injection or continuous infusion. The pharmaceutical compositions can be in a form suitable for parenteral injection as a sterile suspension, solution or emulsion in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Pharmaceutical formulations for parenteral administration include aqueous solutions of a peptide described herein in water-soluble form. Suspensions of peptides described herein can be prepared as oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. The suspension can also contain suitable stabilizers or agents which increase the solubility and/or reduces the aggregation of such peptides described herein to allow for the preparation of highly concentrated solutions. Alternatively, the peptides described herein can be lyophilized or in powder form for re-constitution with a suitable vehicle, e.g., sterile pyrogen-free water,
- 86WO 2017/044894
PCT/US2016/051166 before use. In some embodiments, a purified peptide is administered intravenously. A peptide described herein can be administered to a subject, home, target, migrates to, is retained by, and/or binds to, or be directed to an organ, e.g., the cartilage.
[0226] A peptide of the disclosure can be applied directly to an organ, or an organ tissue or cells, such as cartilage or cartilage tissue or cells, during a surgical procedure. The recombinant peptides described herein can be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams, and ointments. Such pharmaceutical compositions can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
[0227] In practicing the methods of treatment or use provided herein, therapeuticallyeffective amounts of the peptide described herein described herein are administered in pharmaceutical compositions to a subject suffering from a condition. In some instances the pharmaceutical composition will affect the physiology of the animal, such as the immune system, inflammatory response, or other physiologic affect. In some embodiments, the subject is a mammal such as a human. A therapeutically-effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compounds used, and other factors.
[0228] Pharmaceutical compositions can be formulated using one or more physiologicallyacceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations that can be used pharmaceutically. Formulation can be modified depending upon the route of administration chosen. Pharmaceutical compositions comprising a peptide described herein can be manufactured, for example, by expressing the peptide in a recombinant system, purifying the peptide, lyophilizing the peptide, mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or compression processes. The pharmaceutical compositions can include at least one pharmaceutically acceptable carrier, diluent, or excipient and compounds described herein as free-base or pharmaceutically-acceptable salt form.
[0229] Methods for the preparation of peptides described herein comprising the compounds described herein include formulating the peptide described herein with one or more inert, pharmaceutically-acceptable excipients or carriers to form a solid, semi-solid, or liquid composition. Solid compositions include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories. These compositions can also contain minor amounts of
- 87WO 2017/044894
PCT/US2016/051166 nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and other pharmaceutically-acceptable additives.
[0230] Non-limiting examples of pharmaceutically-acceptable excipients can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington’s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkinsl999), each of which is incorporated by reference in its entirety.
Use of Peptide in Imaging and Surgical Methods [0231] The present disclosure generally relates to peptides that home, target, migrate to, are retained by, accumulate in, and/or bind to, or are directed to specific regions, tissues, structures, or cells within the body and methods of using such peptides. These peptides have the ability to contact the cartilage, which makes them useful for a variety of applications. In particular, the peptides can have applications in site-specific modulation of biomolecules to which the peptides are directed to. End uses of such peptides can include, for example, imaging, research, therapeutics, theranostics, pharmaceuticals, chemotherapy, chelation therapy, targeted drug delivery, and radiotherapy. Some uses can include targeted drug delivery and imaging.
[0232] In some embodiments, the present disclosure provides a method for detecting a cancer, cancerous tissue, or tumor tissue, the method comprising the steps of contacting a tissue of interest with a peptide of the present disclosure, wherein the peptide is conjugated to a detectable agent and measuring the level of binding of the peptide, wherein an elevated level of binding, relative to normal tissue, is indicative that the tissue is a cancer, cancerous tissue or tumor tissue.
[0233] In some embodiments, the disclosure provides a method of imaging an organ or body region or region, tissue or structure of a subject, the method comprising administrating to the subject the peptide or a pharmaceutical composition disclosed herein and imaging the subject. In some embodiments such imaging is used to detect a condition associated with a function of the cartilage. In some cases the condition is an inflammation, a cancer, a degradation, a growth disturbance, genetic, a tear or an injury, or another suitable condition. In some cases the condition is a chondrodystrophy, a traumatic rupture or detachment, pain following surgery in regions of the body containing cartilage, costochondritis, herniation,
- 88WO 2017/044894
PCT/US2016/051166 polychondritis, arthritis, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis (AS), Systemic Lupus Erythematosus (SLE or “Lupus”), Psoriatic Arthritis (PsA), gout, achondroplasia, or another suitable condition. In some case the condition is associated with a cancer or tumor of the cartilage. In some cases the condition is a type of chondroma or chondrosarcoma, whether metastatic or not, or another suitable condition. In some embodiments, such as those associated with cancers, the imaging may be associated with surgical removal of the diseased region, tissue, structure or cell of a subject.
[0234] Furthermore, the present disclosure provides methods for intraoperative imaging and resection of a diseased or inflamed tissue, cancer, cancerous tissue, or tumor tissue using a peptide of the present disclosure conjugated with a detectable agent. In some embodiments, the diseased or inflamed tissue, cancer, cancerous tissue, or tumor tissue is detectable by fluorescence imaging that allows for intraoperative visualization of the cancer, cancerous tissue, or tumor tissue using a peptide of the present disclosure. In some embodiments, the peptide of the present disclosure is conjugated to one or more detectable agents. In a further embodiment, the detectable agent comprises a fluorescent moiety coupled to the peptide. In another embodiment, the detectable agent comprises a radionuclide. In some embodiments, imaging is achieved during open surgery. In further embodiments, imaging is accomplished using endoscopy or other non-invasive surgical techniques.
Treatment of Cartilage Disorders [0235] The term “effective amount,” as used herein, can refer to a sufficient amount of an agent or a compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. Compositions containing such agents or compounds can be administered for prophylactic, enhancing, and/or therapeutic treatments. An appropriate “effective” amount in any individual case can be determined using techniques, such as a dose escalation study. [0236] The methods, compositions, and kits of this disclosure can comprise a method to prevent, treat, arrest, reverse, or ameliorate the symptoms of a condition. The treatment can comprise treating a subject (e.g., an individual, a domestic animal, a wild animal or a lab animal afflicted with a disease or condition) with a peptide of the disclosure. In treating a disease, the peptide can contact the cartilage of a subject. The subject can be a human. A subject can be a human; a non-human primate such as a chimpanzee, or other ape or monkey species; a farm animal such as a cattle, horse, sheep, goat, swine; a domestic animal such as a
- 89WO 2017/044894
PCT/US2016/051166 rabbit, dog, and cat; a laboratory animal including a rodent, such as a rat, mouse and guinea pig, or the like. A subject can be of any age. A subject can be, for example, an elderly adult, adult, adolescent, pre-adolescens, child, toddler, infant, or fetus in utero.
[0237] Treatment can be provided to the subject before clinical onset of disease. Treatment can be provided to the subject after clinical onset of disease. Treatment can be provided to the subject after 1 day, 1 week, 6 months, 12 months, or 2 years or more after clinical onset of the disease. Treatment may be provided to the subject for more than 1 day, 1 week, 1 month, months, 12 months, 2 years or more after clinical onset of disease. Treatment may be provided to the subject for less than 1 day, 1 week, 1 month, 6 months, 12 months, or 2 years after clinical onset of the disease. Treatment can also include treating a human in a clinical trial. A treatment can comprise administering to a subject a pharmaceutical composition, such as one or more of the pharmaceutical compositions described throughout the disclosure. A treatment can comprise a once daily dosing. A treatment can comprise delivering a peptide of the disclosure to a subject, either intravenously, subcutaneously, intramuscularly, by inhalation, dermally, intra-articular injection, orally, intrathecally, transdermally, intranasally, via a peritoneal route, or directly onto or into a joint, e.g., via topical, intra-articular injection route or injection route of application. A treatment can comprise administering a peptideactive agent complex to a subject, either intravenously, intra-articular injection, parenterally, orally, via a peritoneal route, or directly onto, near or into the cartilage.
[0238] Types of cartilage diseases or conditions that can be treated with a peptide of the disclosure can include inflammation, pain management, anti-infective, pain relief, anticytokine, cancer, injury, degradation, genetic basis, remodeling, hyperplasia, surgical injury/trauma, or the like. Examples of cartilage diseases or conditions that can be treated with a peptide of the disclosure include Costochondritis, Spinal disc herniation, Relapsing polychondritis, Injury to the articular cartilage, any manner of rheumatic disease (e.g., Rheumatoid Arthritis (RA), ankylosing spondylitis (AS), Systemic Lupus Erythematosus (SLE or “Lupus”), Psoriatic Arthritis (PsA), Osteoarthritis, Gout, and the like), Herniation, Achondroplasia, Benign or non-cancerous chondroma, Malignant or cancerous chondrosarcoma, Chondriodystrophies, Chondromalacia patella, Costochondritis, Halus rigidus, Hip labral tear, Osteochondritis dssecans, Osteochondrodysplasias, Torn meniscus, Pectus carinatum, Pectus excavatum, Chondropathy, Chondromalacia, Polychondritis, Relapsing Polychondritis, Slipped epiphysis, Osteochondritis Dissecans, Chondrodysplasia, Costochondritis, Perichondritis, Osteochondroma, Knee osteoarthritis, Finger osteoarthritis, Wrist osteoarthritis, Hip osteoarthritis, Spine osteoarthritis, Chondromalacia, Osteoarthritis
- 90WO 2017/044894
PCT/US2016/051166
Susceptibility, Ankle Osteoarthritis, Spondylosis, Secondary chondrosarcoma, Small and unstable nodules as seen in osteoarthritis, Osteochondroses, Primary chondrosarcoma, Cartilage disorders, scleroderma, collagen disorders, Chondrodysplasia, Tietze syndrome, Dermochondrocorneal dystrophy of Francois, Epiphyseal dysplasia multiple 1, Epiphyseal dysplasia multiple 2, Epiphyseal dysplasia multiple 3, Epiphyseal dysplasia multiple 4, Epiphyseal dysplasia multiple 5, Ossified Ear cartilages with Mental deficiency, Muscle Wasting and Bony Changes, Periosteal chondrosarcoma, Carpotarsal osteochondromatosis, Achondroplasia, Genochondromatosis II, Genochondromatosis, Chondrodysplasia — disorder of sex development, Chondroma, Chordoma, Atelosteogenesis, type 1, Atelosteogenesis Type III, Atelosteogenesis, type 2, Pyknoachondrogenesis, Osteoarthropathy of fingers familial, Dyschondrosteosis - nephritis, Coloboma of Alar-nasal cartilages with telecanthus, Alar cartilages hypoplasia - coloboma - telecanthus, Pierre Robin syndrome - fetal chondrodysplasia, Dysspondyloenchondromatosis, Achondroplasia regional - dysplasia abdominal muscle, Osteochondritis Dissecans, Familial Articular Chondrocalcinosis, Tracheobronchomalacia, Chondritis, Dyschondrosteosis, Jequier-Kozlowski-skeletal dysplasia, Chondrodystrophy, Cranio osteoarthropathy, Tietze's syndrome, Hip dysplasia ecchondromata, Bessel-Hagen disease, Chondromatosis (benign), Enchondromatosis (benign), Chondrocalcinosis due to apatite crystal deposition, Meyenburg-Altherr-ETehlinger syndrome, Enchondromatosis-dwarfism-deafness, premature growth plate closure (e.g., due to dwarfism, injury, therapy such as retinoid therapy for adolescent acne, or ACL repair), Astley-Kendall syndrome, Synovial osteochondromatosis, Severe achondroplasia with developmental delay and acanthosis nigricans, Chondrocalcinosis, Stanescu syndrome, Familial osteochondritis dissecans, Achondrogenesis type 1A, Achondrogenesis type 2, Achondrogenesis, Langer-Saldino Type, Achondrogenesis type IB, Achondrogenesis type 1A and IB, Type II Achondrogenesis-Hypochondrogenesis, Achondrogenesis, Achondrogenesis type 3, Achondrogenesis type 4, Chondrocalcinosis 1, Chondrocalcinosis 2, Chondrocalcinosis familial articular, Diastrophic dysplasia, Fibrochondrogenesis, Hypochondroplasia, Keutel syndrome, Maffucci Syndrome, Osteoarthritis Susceptibility 6, Osteoarthritis Susceptibility 5, Osteoarthritis Susceptibility 4, Osteoarthritis Susceptibility 3, Osteoarthritis Susceptibility 2, Osteoarthritis Susceptibility 1, Pseudoachondroplasia, Cauliflower ear, Costochondritis, Growth plate fractures, Pectus excavatum, septic arthritis, gout, pseudogout (calcium pyrophosphate deposition disease or CPPD), gouty arthritis, bacterial, viral, or fungal infections in or near the joint, bursitis, tendinitis, arthropathies, or another cartilage or joint disease or condition.
- 91 WO 2017/044894
PCT/US2016/051166 [0239] In some embodiments, a peptide or peptide conjugate of this disclosure can be administered to a subject in order to target,an arthritic joint. In other embodiments, a peptide or peptide conjugate of this disclosure can be administered to a subject in order to treat an arthritic joint.
[0240] In some embodiments, the present disclosure provides a method for treating a cancer, the method comprising administering to a subject in need thereof an effective amount of a peptide of the present disclosure.
[0241] In some embodiments, the present disclosure provides a method for treating a cancer, the method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a peptide of the present disclosure and a pharmaceutically acceptable carrier.
[0242] In some embodiments, the peptides of the present disclosure can be used to treat chondrosarcoma. Chondrosarcoma is a cancer of cartilage producing cells and is often found in bones and joints. It falls within the family of bone and soft-tissue sarcomas. In certain embodiments, administration of a peptide or peptide conjugate of the present disclosure can be used to image and diagnose or target and treat a subject with chondrosarcoma. The adminstration of a peptide or peptide conjugate of the present disclosure can be used in combination with ablative radiotherapy or proton therapy to treat chondrosarcoma.The subject can be a human or an animal.
[0243] In some embodiments, a peptide or peptide conjugate of this disclosure can be used to treat Chordoma. In certain embodiments, administration of a peptide or peptide conjugate of the present disclosure can be used to image and diagnose or target and treat a subject with chordoma. The adminstration of a peptide or peptide conjugate of the present disclosure can be used in combination with a tyrosine kinase inhibitor, such as imatinib mesylate, and ablative radiotherapy or proton therapy to treat chordoma. The adminstration of a peptide or peptide conjugate of the present disclosure can be used in combination with an antivascular agent such as bevacizumab and an epidermal growth factor receptor inhibitor such as erlotinib to treat chordoma. The subject can be a human or an animal.
[0244] In some embodiments, the present disclosure provides a method for inhibiting invasive activity of cells, the method comprising administering an effective amount of a peptide of the present disclosure to a subject.
[0245] In some embodiments, the peptides of the present disclosure are conjugated to one or more therapeutic agents. In further embodiments, the therapeutic agent is a chemotherapeutic, anti-cancer drug, or anti-cancer agent selected from, but are not limited to: anti- 92WO 2017/044894
PCT/US2016/051166 inflammatories, such as for example a glucocorticoid, a corticosteroid, a protease inhibitor, such as for example collagenase inhibitor or a matrix metalloprotease inhibitor (i.e., MMP-13 inhibitor), an amino sugar, vitamin (e.g., Vitamin D), and antibiotics, antiviral, or antifungal, a statin, an immune modulator, radioisotopes, toxins, enzymes, sensitizing drugs, nucleic acids, including interfering RNAs, antibodies, anti-angiogenic agents, cisplatin, antimetabolites, mitotic inhibitors, growth factor inhibitors, paclitaxel, temozolomide, topotecan, fluorouracil, vincristine, vinblastine, procarbazine, decarbazine, altretamine, methotrexate, mercaptopurine, thioguanine, fludarabine phosphate, cladribine, pentostatin, cytarabine, azacitidine, etoposide, teniposide, irinotecan, docetaxel, doxorubicin, daunorubicin, dactinomycin, idarubicin, plicamycin, mitomycin, bleomycin, tamoxifen, flutamide, leuprolide, goserelin, aminogluthimide, anastrozole, amsacrine, asparaginase, mitoxantrone, mitotane and amifostine, and their equivalents, as well as photo-ablation. Some of these active agents induce programmed cell death such as apoptosis in target cells and thereby improve symptoms or ameliorate disease. Apoptosis can be induced by many active agents, including, for example, chemotherapeutics, anti-inflammatories, corticosteroids, NSAIDS, tumor necrosis factor alpha (TNF-α) modulators, tumor necrosis factor receptor (TNFR) family modulators. In some embodiments, peptides of this disclosure can be used to target active agents to pathways of cell death or cell killing, such as caspases, apoptsis activators and inhibitors, XBP-1, Bcl-2, Bcl-Xl, Bcl-w, and other disclosed herein. In other embodiments, the therapeutic agent is any nonsteroidal anti-inflammatory drug (NSAID).
The NSAID can be any heterocyclic acetic acid derivatives such as ketorolac, indomethacin, etodolac, or tolemetin, any propionic acid derivatives such as naproxen, any enolic acid derivatives, any anthranilic acid derivatives, any selective COX-2 inhibitors such as celecoxib, any sulfonanilides, any salicylates, aceclofenac, nabumetone, sulindac, diclofenac, or ibuprofen. In other embodiments, the therapeutic agent is any steroid, such as dexamethasone, budesonide, triamcinolone, cortisone, prednisone, rednisolone, triamcinolone hexacetonide, or methylprednisolone. In other embodiments, the therapeutic agent is a pain reliever, such as acetaminophen, opioids, local anesthetics, anti-depressants, glutamate receptor anatagonists, adenosine, or neuropetides. In some embodiments, a treatment consists of administering a combination of any of the above therapeutic agents and a peptide conjugate, such as a treatment in which both a dexamethasone-peptide conjugate and an NSAID are administered to a patient. Peptides of the current disclosure that target the cartilage can be used to treat the diseases conditions as described herein, for example, any diseases or conditions including tears, injuries (i.e., sports injuries), genetic factors,
- 93 WO 2017/044894
PCT/US2016/051166 degradation, thinning, inflammation, cancer or any other disease or condition of the cartilage or to target therapeutically-active substances to treat these diseases amongst others. In other cases, a peptide of the disclosure can be used to treat traumatic rupture, detachment, chostochondritis, spinal disc herniation, relapsing and non-relapsing polychondritis, injury to the articular cartilage, osteoarthritis, arthritis or achondroplasia. In some cases, the peptide or peptide-active agent can be used to target cancer in the cartilage, for example benign chondroma or malignant chondrosarcoma, by contacting the cartilage by diffusion into chondrocytes and then having antitumor function, targeted toxicity, inhibiting metastases, etc. As well, such peptide or peptide-active agent can be used to label, detect, or image such cartilage lesions, including tumors and metastases amongst other lesions, which may be removed through various surgical techniques or by targeting with peptide-active agents that induce programmed cell death or kill cells.
[0246] Venom or toxin derived peptide(s), peptides, modified peptides, labeled peptides, peptide-active agent conjugates and pharmaceutical compositions described herein can be administered for prophylactic and/or therapeutic treatments. In therapeutic applications, the composition can be administered to a subject already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest the symptoms of the disease or condition, or to cure, heal, improve, or ameliorate the condition. Such peptides described herein can also be administered to prevent (either in whole or in part), lessen a likelihood of developing, contracting, or worsening a condition. Amounts effective for this use can vary based on the severity and course of the disease or condition, previous therapy, the subject’s health status, weight, response to the drugs, and the judgment of the treating physician. Venom or toxin derived peptide(s), peptides, modified peptides, labeled peptides, peptideactive agent conjugates and pharmaceutical compositions described herein can allow for targeted homing of the peptide and local delivery of any conjugate. For example, a peptide conjugated to a steroid allows for local delivery of the steroid, which is significantly more effective and less toxic than traditional systemic steroids. A peptide conjugated to an NSAID is another example. In this case, the peptide conjugated to an NSAID allows for local delivery of the NSAID, which allows for administration of a lower NSAID dose and is subsequently less toxic. By delivering an active agent to the joint, pain relief can be more rapid, may be more long lasting, and can be obtained with a lower systemic dose and off-site undesired effects than with systemic dosing without targeting.
[0247] Peptides of the current disclosure that target the cartilage can be used to treat or manage pain associated with a cartilage injury or disorder, or any other cartilage or joint
- 94WO 2017/044894
PCT/US2016/051166 condition as described herein. The peptides can be used either directly or as carriers of active drugs, peptides, or molecules. For example, since ion channels can be associated with pain and can be activated in disease states such as arthritis, peptides that interact with ion channels can be used directly to reduce pain. In another embodiment, the peptide is conjugated to an active agent with anti-inflammatory activity, in which the peptide acts as a carrier for the local delivery of the active agent to reduce pain.
[0248] In some embodiments, the peptides described herein provide a method of treating a cartilage condition of a subject, the method comprising administering to the subject a therapeutically-effective amount of a peptide comprising the sequence SEQ ID NO: 1 or fragment thereof. In some embodiments, the peptides described herein provide a method of treating a cartilage condition of a subject, the method comprising administering to the subject a peptide of any one of SEQ ID NO: 2 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432 or fragment thereof.
[0249] Multiple peptides described herein can be administered in any order or simultaneously. In some cases, multiple functional fragments of peptides derived from toxins or venom can be administered in any order or simultaneously. If simultaneously, the multiple peptides described herein can be provided in a single, unified form, such as an intravenous injection, or in multiple forms, such as subsequent intravenous dosages.
[0250] Peptides can be packaged as a kit. In some embodiments, a kit includes written instructions on the use or administration of the peptides.
EXAMPLES [0251] The following examples are included to further describe some embodiments of the present disclosure, and should not be used to limit the scope of the disclosure.
EXAMPLE 1 Manufacture of Peptides [0252] This example provides a method for generating knottin peptides. Peptides derived from knottin peptides of scorpions and spiders were generated in mammalian cell culture using a published methodology. (A.D. Bandaranayke, C. Correnti, B.Y. Ryu, M. Brault, R.K. Strong, D. Rawlings. 2011. Daedalus: a robust, turnkey platform for rapid production of decigram quantities of active recombinant proteins in human cell lines using novel lentiviral vectors. Nucleic Acids Research. (39)21, e!43).
-95WO 2017/044894
PCT/US2016/051166 [0253] The peptide sequence was reverse-translated into DNA, synthesized, and cloned inframe with siderocalin using standard molecular biology techniques. (M.R. Green, Joseph Sambrook. Molecular Cloning. 2012 Cold Spring Harbor Press.). The resulting construct was packaged into a lentivirus, transfected into HEK293 cells, expanded, isolated by immobilized metal affinity chromatography (IMAC), cleaved with tobacco etch virus protease, and purified to homogeneity by reverse-phase chromatography. Following purification, each peptide was lyophilized and stored frozen.
EXAMPLE 2 Radiolabeling of Peptide [0254] This example describes radiolabelling of knottin peptides. Several knottins (some sequences derived from spiders and scorpions) were radiolabeled by reductive methylation with 14C formaldehyde and sodium cyanoborohydride with standard techniques. See J Biol Chem. 254(11):4359-65 (1979). The sequences were engineered to have the amino acids, “G” and “S” at the N terminus. See Methods in Enzymology V91:1983 p.570 and Journal of Biological Chemistry 254(11):1979 p. 4359. An excess of formaldehyde was used to ensure complete methylation (dimethylation of every free amine). The labeled peptides were isolated via solid-phase extraction on Strata-X columns (Phenomenex 8B-S100-AAK), rinsed with water with 5% methanol, and recovered in methanol with 2% formic acid. Solvent was subsequently removed in a blowdown evaporator with gentle heat and a stream of nitrogen gas.
EXAMPLE 3
Dosing of Peptide with Kidney Ligation [0255] This example describes a dosing scheme for administering knottin peptides to mice in conjunction with kidney ligation. Different dosages of the peptides were administered to Female Harlan athymic nude mice, weighing 20g - 25g, via tail vein injection (n = 2 mice per knottin). The sequence of thirteen cartilage homing peptides of SEQ ID NO: 21 - SEQ ID NO: 33 are shown in TABLE 1. The experiment was done in duplicates. The kidneys were ligated to prevent renal filtration of the peptides. Each peptide was radiolabeled by methylating lysines and the N-terminus, so the actual binding agent may contain methyl or dimethyl lysine(s) and a methylated or dimethylated amino terminus.
[0256] A target dosage of 50-100 nmol of each peptide carrying 10-25 uCi of 14C was administered to Female Harlan athymic nude mice while anesthetized. Each peptide was
- 96WO 2017/044894
PCT/US2016/051166 allowed to freely circulate within the animal before the animals were euthanized and sectioned.
EXAMPLE 4
Peptide Homing with Kidney Ligation [0257] This example illustrates peptide homing to cartilage of mice with kidneys that were ligated prior to peptide administration. At the end of the dosing period in EXAMPLE 3, mice were frozen in a hexane/dry ice bath and then frozen in a block of carboxymethylcellulose. Whole animal sagittal slices were prepared that resulted in thin frozen sections being available for imaging. Thin, frozen sections of animal including imaging of tissues such as brain, tumor, liver, kidney, lung, heart, spleen, pancreas, muscle, adipose, gall bladder, upper gastrointestinal tract, lower gastrointestinal tract, bone, bone marrow, reproductive track, eye, cartilage, stomach, skin, spinal cord, bladder, salivary gland, and other types of tissues were obtained with a microtome, allowed to desiccate in a freezer, and exposed to phosphoimager plates for about ten days.
[0258] These plates were developed, and the signal (densitometry) from each organ was normalized to the signal found in the heart blood of each animal. A signal in tissue darker than the signal expected from blood in that tissue indicates peptide accumulation in a region, tissue, structure or cell. For instance, the cartilage is avascular and contains minute amounts of blood. A ratio of at least 170% signal in the cartilage versus heart ventricle was chosen as a reference level for significant targeting to cartilage, which also correlated with clear accumulation in cartilaginous tissues in the images of the slices. FIG. 1 illustrates the tissue distribution in the cartilage for the peptides SEQ ID NO: 21 - SEQ ID NO: 33, 3 hours after administration in animals with ligated kidneys. FIG. 2 identifies the locations of the SEQ ID NO: 24 peptide distribution in joint and other cartilage. FIG. 3 identifies the locations of the SEQ ID NO: 24 peptide distribution in rib, spinal, and other cartilage. FIG. 4 identifies the locations of the SEQ ID NO: 24 peptide distribution in nasal, spinal, tracheal, and other cartilage. FIGURES 3-4 illustrate the homing of SEQ ID NO: 24 to hyaline cartilage such as articular cartilage and physeal cartilage, as well as fibrocartilage.
[0259] Additionally, the peptide can be retained in cartilage for hours after treatment. The SEQ ID NO: 24 peptide was radiolabeled as in Example 3 and 100 nmol of peptide was injected into a mouse with intact kidneys. FIG. 5 illustrates the retention of and the tissue distribution in the cartilage of a peptide of SEQ ID NO: 24, 24 hours after administration. For comparison, FIG. 11 shows white light and corresponding autoradiographic images from a
-97WO 2017/044894
PCT/US2016/051166 section of a mouse 24 hours after administration of 100 nmol of radiolabeled SEQ ID NO: 433 peptide, which did not home to cartilage and was seen in the bone marrow. FIG. 11A illustrates a white light image of a frozen section of a mouse 24 hours after administration of 100 nmol of SEQ ID NO: 433. FIG. 11B shows an autoradiographic image corresponding to FIG. 11A in which the 14C signal identifies the radiolabeled SEQ ID NO: 433 peptide.
[0260] TABLE 2 summarizes the net charge at neutral pH and migration of the peptides of SEQ ID NO: 21 - SEQ ID NO: 33 to the cartilage (C) and muscle (M) compared to the level in the blood 3 hours after administration. The “cartilage” entries reflect the percentage of signal in the cartilage compared to the blood signal in the heart ventricle within the tissue slices. Peptides that are cartilage homers have a cartilage signal of >170%, peptides that are efficient cartilage homers can have a cartilage signal of >300%, and peptides that are strong cartilage homers have a cartilage signal of >500%. SEQ ID NO: 484 corresponds to an amino acid sequence of
GSECLGFGKGCNPSNDQCCKSSNLVCSRKHRWCKYEIGK.
-98WO 2017/044894
PCT/US2016/051166
TABLE 2
SEQ ID NO Charge Cartilage (C) Muscle (M)
21 8.7 270 36
22 7 337 27
23 6 497 26
24 6 624 34
25 5.7 358 24
26 5.7 413 38
27 4.7 448 31
28 4.7 361 17
29 4 243 26
30 4 221 26
31 3.7 306 68
32 2 194 44
33 3.7 179 28
196 6 291 30
198 4 276 26
483 1 67 24
485 2.7 92 21
484 4 93 20
433 3 156 20
[0261] As shown in TABLE 2, sequences with significant positive charge at physiological pH exhibited higher accumulation in cartilage. Many of these sequences share common elements. These common elements may represent parts of the sequence that confer cartilage homing to the peptide by locating positive charge or other binding elements into certain parts of the three dimensional structure of the folded peptide. For instance, K or R residues might be preferentially located in certain parts of the sequence in order to locate positive charge on the correct surface areas for homing, especially with respect to the C residues which determine folding and loop location of the folded peptide. However, only parts of these sequences may be important for homing or other aspects of the sequences may be important for homing.
- 99WO 2017/044894
PCT/US2016/051166 [0262] Two example sequences containing common elements are
GSXVXXXVKCXGSKQCXXPCKRXXGXRXGKCINKKXCKCYXXX (SEQ ID NO: 9) and GSXXXGCVXXXXKCRPGXKXCCXPXKRCSRRFGXXXXKKCKXXXXXX (SEQ ID NO: 10), where X can independently be any number of any amino acid or no amino acid. FIG. 12 shows a sequence alignment of SEQ ID NO: 9 with the peptide sequences from which the common element sequences were based on and a sequence alignment of SEQ ID NO: 10 with the peptide sequences from which the common element sequences were based on. Sequence GSXVXXXVKCXGSKQCXXPCKRXXGXRXGKCINKKXCKCYXXX (SEQ ID NO: 9) is a sequence based on the most common elements found in the following sequences:
GSGVPINVKCRGSRDCLDPCKKA-GMRFGKCINSK-CHCTP— (SEQ ID NO: 24), GS-VRIPVSCKHSGQCLKPCKDA-GMRFGKCMNGK-CDCTPK- (SEQ ID NO: 23), GSQVQTNVKCQGGS-CASVCRREIGVAAGKCINGK-CVCYRN- (SEQ ID NO: 27), GS——ISCTGSKQCYDPCKRKTGCPNAKCMNKS-CKCYGCG (SEQ ID NO: 26), GSEV—IRCSGSKQCYGPCKQQTGCTNSKCMNKV-CKCYGCG (SEQ ID NO: 28),
GSAVCVYRT------CDKDCKRR-GYRSGKCINNA-CKCYPYG (SEQ ID NO: 25),
GS—-GIVC—KVCKIICGMQ-GKKVNICKAPIKCKCKKG- (SEQ ID NO: 21), and GSQIYTSKECNGSSECYSHCEGITGKRSGKCINKK-CYCYR-(SEQ ID NO: 30). Sequence GSXXXGCVXXXXKCRPGXKXCCXPXKRCSRRFGXXXXKKCKXXXXXX (SEQ ID NO: 10) is a sequence based on the most common elements found in the following sequences:
GS—ACKGVFDACTPGKNECC-PNRVCSDK-H—-KWCKWKL- (SEQ ID NO: 29),
GS—GCLEFWWKCNPNDDKCCRPKLKCSKLF——KLCNFSFG (SEQ ID NO: 31), GSSEKDCIKHLQRCR-ENKDCC—SKKCSRR-GTNPEKRCR- (SEQ ID NO: 22), and GS—GCFGY—KCDYY-KGCCSGYV-CSPTW——KWCVRPGPGR (SEQ ID NO: 33). A dash, indicates that no amino acid is in that position. The following residues may be independently interchanged in SEQ ID NO: 9 or SEQ ID NO: 10: any K and any R; any M, any I, any L, and any V; any G and any A; any S and any T; and any Q and any N. These sets of interchangeable amino acids have similarities in properties that can allow for them to be interchangeable without inhibiting homing to cartilage. For example, any K can be interchanged with any R because K and R both provide a positive charge at physiological pH and thus may provide necessary charge for homing to cartilage, and any S can be interchanged with any T because S and T both have a hydroxyl group available for hydrogen
- 100WO 2017/044894
PCT/US2016/051166 bonding. The N-terminal GS sequence may or may not be included between the peptides of the present disclosure.
[0263] Particular fragments with common elements were also noted, such as the GKCINKKCKC (SEQ ID NO: 316) fragment with the internal fragments KCIN (SEQ ID NO: 317) and KKCK (SEQ ID NO: 318), PCKR (SEQ ID NO: 319), KRCSRR (SEQ ID NO: 320), and GSKQC (SEQ ID NO: 321). The following residues may be independently interchanged in SEQ ID NO: 101 - SEQ ID NO: 105 or SEQ ID NO: 316 - SEQ ID NO:
321: any K and any R; any M, any I, any L, and any V; and G and any A; any S and any T; and any Q and any N.
[0264] A predominance of R and K residues were noted in the C-terminal parts of the peptides as well as in the fragments, correlating with the high positive charge of the peptides. [0265] The peptides of SEQ ID NO: 21 and SEQ ID NO: 33 in TABLE 1 are derived from a scorpion toxin (e.g., Buthus martensii Karsh) that was found to migrate specifically to a region, tissue, structure or cells in the cartilage, potentially by diffusion. FIGS. 6A and 6B illustrate the HPLC profiles of a peptide of SEQ ID NO: 23 and SEQ ID NO: 24.
EXAMPLE 5
Peptide Homing with Therapeutic Agents [0266] This example describes certain exemplary therapeutic agents that are conjugated to a knottin peptide. A peptide of the disclosure is expressed recombinantly or chemically synthesized and then is conjugated to an exemplary drug, such as paclitaxel or triamcinolone acetonide using techniques known in the art, such as those described in Bioconjugate Techniques by Greg Hermanson. One or more drugs is conjugated per peptide, or an average of less than one drug is conjugated per peptide.
[0267] Coupling of these drugs to a peptide of any of SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216 or SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432 targets the drug to the cartilage of the subject. One or more drug-peptide conjugates are administered to a human or animal.
EXAMPLE 6
Treatment of Osteoarthritis [0268] This example describes a method for treating osteoarthritis using peptides of the present disclosure. This method is used as a treatment for acute and/or chronic symptoms associated with osteoarthritis. A peptide of the present disclosure is expressed recombinantly
- 101 WO 2017/044894
PCT/US2016/051166 or chemically synthesized and then is used directly or conjugated to an anti-inflammatory compound, such as triamcinolone acetonide and dexamethasone. The resulting peptide or peptide-drug conjugate is administered in a pharmaceutical composition subcutaneously, intravenously, or orally, or is injected directly into a joint of a patient and targeted to cartilage. The formulation can be modified physically or chemically to increase the time of exposure in the cartilage. The peptide is selected from SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216 or SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432. One or more anti-inflammatory peptide conjugates are administered to a human or animal.
EXAMPLE 7
Treatment of Cartilage Degradation [0269] This example describes a method for treating and/or preventing cartilage degradation using a peptide of the present disclosure. This method is used as a treatment for acute and/or chronic symptoms associated with cartilage degradation. Progressive degradation or thinning of the cartilage is difficult to treat in part because molecules such as small molecule drugs and antibodies typically do not reach the avascular cartilage. A peptide of the present disclosure is used for its homing and/or native activity, or is mutated to generate activity such as MMP protease inhibition. It is expressed recombinantly or chemically synthesized and then is used directly or conjugated to an extracellular matrix targeting compound, such as an inhibitor of MMP activity (e.g., MMP13, collagenase (MMP-1), or other agent as described herein). The resulting peptide or peptide-drug conjugate is administered in a pharmaceutical composition subcutaneously, intravenously, or orally, or is injected directly into a joint of a patient and targeted to extracellular matrix. The peptide is selected from SEQ ID NO: 21 SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216 or SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432. One or more extracellular matrix targeting conjugates are administered to a human or animal.
EXAMPLE 8
Treatment of a Cartilage Injury [0270] This example describes a method for treating a cartilage injury using a peptide of the present disclosure. A peptide of the present disclosure is expressed recombinantly or chemically synthesized and then is used directly or conjugated to a therapeutic compound, such as those described herein, including, but not limited to triamcinolone and
- 102WO 2017/044894
PCT/US2016/051166 dexamethasone. The resulting peptide or peptide-drug conjugate is administered in a pharmaceutical composition to a patient and targeted to cartilage. The peptide is selected from S SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216 or SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432. One or more therapeutic compound-peptide conjugates are administered to a human or animal.
EXAMPLE 9
Treatment of Rheumatoid Arthritis [0271] This example describes a method for treating rheumatoid arthritis. This method is used as a treatment for acute and/or chronic symptoms associated with rheumatoid arthritis. A peptide of the present disclosure is expressed recombinantly or chemically synthesized and then is used directly, or is conjugated to an anti-inflammatory compound, such as triamcinolone and dexamethasone. When the peptide is used directly, the peptide can, for example, bind or inhibit ion channels such as Kv 1.3. The resulting peptide or peptide-drug conjugate is administered in a pharmaceutical composition to a patient and is targeted to cartilage. The peptide is selected from SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216 or SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432. One or more anti-inflammatory compoundpeptide conjugates are administered to a human or animal subcutaneously, intravenously, or orally, or is injected directly into a joint
EXAMPLE 10 Treatment of Gout [0272] This example describes a method for treating gout using peptides of the present disclosure. This method is used as a treatment for acute and/or chronic symptoms associated with gout. A peptide of the present disclosure is expressed and administered in a pharmaceutical composition to a patient as a therapeutic for gout. A peptide of the disclosure is recombinantly or chemically synthesized and then is used directly or conjugated to a nonsteroidal anti-inflammatory drugs, colchicine, a steroid, or uricase. The peptide selected from SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216 or SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432 is administered in a pharmaceutical composition to a patient and the peptide is
- 103 WO 2017/044894
PCT/US2016/051166 targeted to the cartilage affected by gout. One or more peptides are administered to a human or animal subcutaneously, intravenously, or orally, or is injected directly into a joint.
EXAMPLE 11
Treatment or Management of Pain [0273] This example describes a method for treating or managing pain associated with a cartilage injury or disorder. This method is used as a treatment for acute and/or chronic symptoms associated with a cartilage injury or disorder. A peptide of the disclosure is expressed and administered in a pharmaceutical composition to a patient as a therapeutic for pain as a result of injury or other cartilage or joint condition as described herein. The peptide of the present disclosure inhibits ion channels, such as Nav 1.7. The peptide is expressed recombinantly or chemically synthesized, wherein the peptide selected from SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216 or SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432. Alternatively, the peptides of SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216 or SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432 are mutated to maintain the cartilage homing function, but to add or increase ion channel inhibition, such as to Nav 1.7. Following expression or synthesis, the peptide is used directly or conjugated to an NSAID. Following administration of the peptide, the peptide targets to the cartilage affected by pain. One or more peptides are administered to a human or animal subcutaneously, intravenously, or orally, or is injected directly into a joint.
EXAMPLE 12 Immunogenicity of Peptides [0274] This example describes the evaluation of immunogenicity for certain peptides of the present disclosure. Immunogenicity was predicted using the network-based alignment algorithm (“NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide biding prediction”, Nielsen et. al. BMC Bioinformatics 2009 Vol 10, p296). The algorithm was applied to intact knottin proteins with sequences SEQ ID NO: 21 - SEQ ID NO: 33 against 24 alleles of HFA-DR, HFA-DP, HFA-DQ and H2-IAb MHCII classes. FIG. 7 shows the MHC class II peptide binding prediction of peptides with the sequences SEQ ID NO: 21 - SEQ ID NO: 33 as listed in TABLE 1. The y-axis shows the predicted affinity of MHC class II peptide binding prediction for a peptide with units of log(nM), where affinity
- 104WO 2017/044894
PCT/US2016/051166 <50 nM predicts strong binding. Among the peptides with SEQ ID NO: 21 - SEQ ID NO: 33,
82.3% (284/345) of the simulated bindings showed binding weaker than 50 nM between the peptide and MHC class II peptide. The high content of weak binders indicates that the peptides are predicted to have lower immunogenicity when administered to humans.
[0275] Immunogenicity was evaluated in silico for additional intact cartilage homing peptides. TABLE 3 illustrates the MHC class II peptide binding prediction of intact cartilage homing peptides sequences. The prediction values were obtained using network-based alignment algorithm. The algorithm was run using intact knottin peptides against 28 alleles of HLA-DR, HLA-DP, DLA-DQ, and H2-IAb MHC II classes. Some of the intact knottin peptides were predicted to be strong binders of MHC class II, however excluding certain sequences known to have high immunogenicity such as C-terminal proline in a peptide of SEQ ID NO: 111 or glycine in a peptide of SEQ ID NO: 199 reduced binding to MHC II alleles. As an example, peptides of SEQ ID NO: 209 - SEQ ID NO: 210 have 90% homology to a peptide of SEQ ID NO: 111 and SEQ ID NO: 110, respectively, and are less immunogenic due to reduced binding to MHC II alleles. In another example, a peptide of SEQ ID NO: 211 has 83% homology to a peptide of SEQ ID NO: 114 and is less immunogenic due to reduced binding to MHC II alleles.
TABLE 3
SEQ ID NO Number of alleles that compounds bind at < 50 nM Number of alleles that compounds bind at <500 nM
111 7 11
199 10 12
109 2 11
110 8 11
114 6 12
200 2 5
EXAMPLE 13 Ketorolac Peptide Conjugate [0276] This example describes the conjugation of ketorolac to a knottin peptide using a lactic acid linker. As shown below in reaction scheme (I), a conjugate is produced from a mixture of (//.Sj-ketorolac, lactic acid, and a knottin peptide:
- 105WO 2017/044894
PCT/US2016/051166
Figure AU2016321342A1_D0002
’< J N
/.....%J
Ketorolac
OH o
OH
OH
..-OH tactic acid iintef
O
Ketorolac-lactic acid linker conjugate ./ o
Figure AU2016321342A1_D0003
NH-peptide _
O
NH-peptide
Ketorolac-lactic acid-peptide conjugate qj [0277] The ketorolac-lactic acid linker conjugate depicted above is then reacted with a lysine or the N-terminus of a knottin peptide to create a ketorolac-lactic acid- peptide conjugate.
The knottin peptide is selected from the peptides of SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216, SEQ ID NO: 237 - SEQ ID NO: 410,
SEQ ID NO: 412, or SEQ ID NO: 414 - SEQ ID NO: 432.
[0278] Ketorolac is currently dosed as an enantiomeric mixture, in which enantiomers with a single racemic stereocenter are very difficult to separate. As in the reaction scheme (I), a diastereomer with two chiral centers is created by the addition of a chiral linker such as Llactic acid. Since diastereomers are easily separated, the active enantiomer of ketorolac conjugated to the lactic acid linker can be purified prior to conjugation to a knottin peptide. The chemical synthesis can use any conjugation techniques known in the art, such as described in Bioconjugate Techniques by Greg Hermanson and in “Ketorolac-dextran conjugates: synthesis, in vitro, and in vivo evaluation:” Acta Pharm. 57 (2007) 441-450,
Vyas, Trivedi, and Chaturvedi. The conjugate can display anti-inflammatory activity, or free ketorolac is released from the conjugate to provide anti-inflammatory activity. The free ketorolac can result from hydrolysis that occurs after administration, such as hydrolysis at the ester bond. By dosing the conjugate containing the cartilage homing peptide, a higher AUC of ketorolac delivery to the joint may be achieved than would be achieved by systemic dosing of ketorolac alone.
EXAMPLE 14
Ibuprofen Peptide Conjugate [0279] This example describes the conjugation of ibuprofen to a knottin peptide using a PEG linker. A conjugate is produced using ibuprofen and a PEG linker, which forms an ester bond that can hydrolyze as described in “In vitro and in vivo study of poly(ethylene glycol) conjugated ibuprofen to extend the duration of action,” Scientia Pharmaceutica, 2011,
- 106WO 2017/044894
PCT/US2016/051166
79:359-373, Nayak and Jain. Fischer esterification is used to conjugate ibuprofen with a short
PEG, e.g., with triethylene glycol, to yield ibuprofen-ester-PEG-OH.
[0280] Following preparation of the PEG-ibuprofen conjugate as shown above, the hydroxyl moiety of PEG is activated with Ν,Ν’-disuccinimidyl carbonate (DSC) to form ibuprofenester-PEG-succinimidyl carbonate, which is then reacted with a lysine or the N-terminus of a knottin peptide to form an ibuprofen-ester-PEG-peptide conjugate. The knottin peptide is selected from any one of the peptides of sequence SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216, SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, or SEQ ID NO: 414 - SEQ ID NO: 432. The conjugate can display antiinflammatory activity, or free ibuprofen is released from the conjugate to provide antiinflammatory activity. The free ibuprofen can result from hydrolysis that occurs after administration, such as hydrolysis at the ester bond.
[0281] Ibuprofen-peptide conjugates are administered to a subject in need thereof. The subject can be a human or a non-human animal.
EXAMPLE 15
Dexamethasone Peptide Conjugate [0282] This example describes different methods of conjugating dexamethasone with a peptide of this disclosure. A peptide of SEQ ID NO: 111 was recombinantly expressed. Dexamethasone was readily conjugated to a peptide of this disclosure using a dicarboxylic acid linker. The peptide-dexamethasone conjugate was made by first converting dexamethasone to a hemisuccinate by reacting it with succinic anhydride. The hemisuccinate was then converted to a succinate carboxylic acid containing an active ester, using dicyclohexyl carbodiimide (DCC) or l-ethyl-3-(3-dimethylamninopropyl)carbodiimide (EDO) in the presence of N-hydroxy succinimide (NHS). This active ester was then reacted with a lysine or the N-terminus of a knottin peptide to create a dexamethasone-carboxylic acid-peptide conjugate. Methods such as those described in “Functionalized derivatives of hyaluronic acid oligosaccharides: drug carriers and novel biomaterials” Bioconjugate Chemistry 1994, 5, 339-347, Pouyani and Prestwich, and Bioconjugate Techniques by Greg Hermanson can be used.
[0283] Peptide-dexamethasone conjugates were prepared by coupling dexamethasone to the peptides of this disclosure using standard coupling-reagent chemistry. For example, dexamethasone conjugates were made by reacting dexamethasone hemigluterate with 1.05 molar equivalents of l,l’-carbonyldiimidazole in anhydrous DMSO in an inert atmosphere.
- 107WO 2017/044894
PCT/US2016/051166
After 30 minutes, excess dexamethasone in anhydrous DMSO was added along with two molar equivalents of anhydrous trimethylamine. The N-hydroxysuccinimide ester of the peptide-dexamethasone conjugate was generated to form a shelf-stable intermediate for later reaction with an amine-containing carrier. The N-terminal dexamethasone-peptide conjugate (SEQ ID NO: 11 IB) was verified by electrospray mass spectrometry (ES-MS) within a 10 ppm error.
[0284] A knottin peptide of any of the sequences of this disclosure including SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216, SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, or SEQ ID NO: 414 - SEQ ID NO: 432, are conjugated to dexamethasone using the methods described above.
EXAMPLE 16
Peptide Conjugate Hydrolysis [0285] This example describes preparation of knottin peptide conjugates having tunable hydrolysis rates. The dexamethasone conjugate described in EXAMPLE 15 is synthesized with the modification that instead of using succinic anhydride, other molecules are used to provide steric hindrance to hydrolysis at the carbon adjacent to the final hydrolyzable ester.
In one exemplary conjugate, the dexamethasone conjugate is synthesized with tetramethyl succinic anhydride to generate hindered esters, which causes a decreased rate of hydrolysis. In another exemplary conjugate, one methyl group is present at the adjacent carbon. In another exemplary conjugate, two methyl groups are present at the adjacent carbon. In another exemplary conjugate, one ethyl group is present at the adjacent carbon. In another exemplary conjugate, two ethyl groups are present at the adjacent carbon. The rate of hydrolysis in these exemplary conjugates is therefore adjusted as compared to the conjugates in EXAMPLE 15, preventing premature cleavage and ensuring that the majority of peptidedexamethasone conjugates accumulate in cartilage.
[0286] The resulting peptide conjugates are administered to a human or animal subcutaneously, intravenously, orally, or injected directly into a joint to treat disease.
EXAMPLE 17
Effects of Peptide on Ion Channels [0287] This example describes the interaction between knottin peptides of the present disclosure and ion channels. Ion channels can be associated with pain and can be activated in disease states such as arthritis. A peptide of the disclosure is expressed and administered in a
- 108WO 2017/044894
PCT/US2016/051166 pharmaceutical composition to a patient to treat a joint condition or disease associated with an ion channel and treatable by binding, blocking, or interacting with the ion channel. Ion channels, such as Nav 1.7, are inhibited by peptides of the present disclosure. A given peptide is expressed recombinantly or chemically synthesized, wherein the peptide selected from SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216, SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, or SEQ ID NO: 414 - SEQ ID NO: 432. Following expression or synthesis, the peptide is used directly or conjugated to a therapeutic compound, such as those described herein. A peptide of the present disclosure selectively interacts with ion channels, or is mutated in order to interact with ion channels.
For example, a peptide of this disclosure is bound to Nav 1.7 or Nav 1.7 is blocked by a peptide of this disclosure. When the peptide is administered to a human subject, Nav 1.7 signaling is reduced in the tissues in proximity to the joints, and pain relief is thereby provided.
EXAMPLE 18
Dosing of Peptide without Kidney Ligation [0288] This example describes a dosing scheme for administering knottin peptides to mice without kidney ligation. The peptide administered had the sequence of SEQ ID NO: 24 as shown in TABLE 1. The peptide was radiolabeled by methylating lysines and the Nterminus, so the actual binding agent may contain methyl or dimethyl lysine(s) and a methylated or dimethylated amino terminus.
[0289] A target dosage of 100 nmol of each peptide carrying 10-25 pCi of 14C was administered to Female Harlan athymic nude mice by a tail vein injection. Each peptide was allowed to freely circulate within the animal for either 4 hours or 24 hours before the animals were euthanized and sectioned.
EXAMPLE 19
Peptide Homing with Intact Kidneys [0290] This example illustrates peptide homing to cartilage in animals with intact kidneys. At the end of the 4 hour or 24 hour dosing periods in Example 18, mice were frozen in a hexane/dry ice bath and then frozen in a block of carboxymethylcellulose. Whole animal sagittal slices were prepared that resulted in thin frozen sections being available for imaging. Thin, frozen sections of animal including imaging of tissues such as brain, tumor, liver, kidney, lung, heart, spleen, pancreas, muscle, adipose, gall bladder, upper gastrointestinal
- 109WO 2017/044894
PCT/US2016/051166 track, lower gastrointestinal track, bone, bone marrow, reproductive track, eye, cartilage, stomach, skin, spinal cord, bladder, salivary gland, and other types of tissues were obtained with a microtome, allowed to desiccate in a freezer, and exposed to phosphoimager plates for about ten days.
[0291] These plates were developed. A signal in tissue darker than the signal expected from blood in that tissue indicates peptide accumulation in a region, tissue, structure or cell. For instance, the cartilage is avascular and contains minute amounts of blood. FIG. 13A illustrates a white light image of a frozen section of a mouse 4 hours after administration 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 13B illustrates an autoradiographic image corresponding to FIG. 13A in which the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the cartilage of a mouse 4 hours after administration of 100 nmol.
[0292] FIG. 14A illustrates a white light image of a frozen section of a mouse 24 hours after administration 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 14B illustrates an autoradiographic image corresponding to FIG. 14A in which the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the cartilage of a mouse 24 hours after administration of 100 nmol.
[0293] FIG. 15A illustrates a white light image of a frozen section of a hind limb of a mouse 4 hours after administration 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 15B illustrates an autoradiographic image corresponding to FIG. 15A in which the the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the ankle and digit cartilage of a mouse 4 hours after administration of 100 nmol. FIG. 15C illustrates an autoradiographic image in which the the 14C signal identifies the radiolabeled SEQ ID NO:
peptide distribution in the ankle and digit cartilage of a mouse 4 hours after administration of 100 nmol. FIG. 15D illustrates a white light image of a frozen section of a hind limb of a mouse 4 hours after administration 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 15E illustrates an autoradiographic image corresponding to FIG. 15D in which the the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the ankle and digit cartilage of a mouse 4 hours after administration of 100 nmol. FIG. 15F illustrates a white light image of a frozen section of a hind limb of a mouse 4 hours after administration 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 15G illustrates an autoradiographic image corresponding to FIG. 15F in which the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the ankle and digit cartilage of a mouse 4 hours after administration of 100 nmol.
- 110WO 2017/044894
PCT/US2016/051166 [0294] FIG. 16A illustrates a white light image of a frozen section of a hind limb of a mouse 24 hours after administration 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 16B illustrates an autoradiographic image corresponding to FIG. 16A in which the the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the ankle and digit cartilage of a mouse 24 hours after administration of 100 nmol. FIG. 16C illustrates a white light image of a frozen section of a hind limb of a mouse 24 hours after administration 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 16D illustrates an autoradiographic image corresponding to FIG. 16C in which the the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the ankle and digit cartilage of a mouse 24 hours after administration of 100 nmol. FIG. 16E illustrates a white light image of a frozen section of a hind limb of a mouse 24 hours after administration 100 nmol of radiolabeled SEQ ID NO: 24 peptide. FIG. 16F illustrates an autoradiographic image corresponding to FIG. 16E in which the the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the ankle and digit cartilage of a mouse 24 hours after administration of 100 nmol. FIG. 16G illustrates an autoradiographic image in which the the 14C signal identifies the radiolabeled SEQ ID NO: 24 peptide distribution in the ankle and digit cartilage of a mouse 24 hours after administration of 100 nmol.
EXAMPLE 20
Whole Body Fluorescence and Isolated Limb Fluorescence of Cartilage Homing Peptides [0295] This example illustrates peptide homing to cartilage mice after administration of a peptide fluorophore conjugate. A peptide of SEQ ID NO: 111 was chemically conjugated to one molecule of Cyanine 5.5, a near infrared fluorophore, at the N-terminus of the peptide via an active NHS ester on the dye. A dose of 10 nmol of each peptide of SEQ ID NO: 111 conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A) was administered to Female Haland athymic nude mice, weighing 20-25 g, and was administered via tail vein injection. Each experiment was done in duplicate (n=2 mice per group). The peptide of SEQ ID NO: 111 conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A) was allowed to freely circulate for the described time period before the mice were euthanized at various time points. Mice were evaluated for peptide distribution of the peptide of SEQ ID NO: 111 conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A) fluorescence in whole body imaging and in isolated hind limb imaging.
- Ill WO 2017/044894
PCT/US2016/051166 [0296] For Whole body fluorescence (WBF), at the end of the dosing period, mice were frozen in a hexane/dry ice bath and then embedded in a frozen block of carboxymethylcellulose. Whole animal sagittal slices were prepared that resulted in thin frozen sections for imaging. Thin frozen sections were obtained using a microtome and allowed visualization of tissues. Sections were allowed to dessicate in a freezer prior to imaging. WBF was then performed on fluorescent sections, which were scanned on a Fi-Cor Odyssey scanner at a setting of 169 pm resolution, medium quality, 700 channel, F-2.0 intensity.
[0297] For isolated hind limb fluorescence studies, mice were euthanized by CO2 asphyxiation at the end of the dosing period. The right hind limb was removed at the hip joint and imaged on a Sepctrum IVIS imager (ex/em: 675 nm.720 nm) with a 1 second exposure length and a focal height of 0.5 cm. Fimbs were imaged with skin removed and with muscle removed.
[0298] FIG. 17 shows white light images (left) and corresponding whole body fluorescence images (right) of a mouse 3 hours after administration of 10 nmol SEQ ID NO: 111 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). This experiment and results were reproduced in a second mouse (images not shown).
[0299] FIG. 18 shows white light images (left) and corresponding whole body fluorescence images (right) of a mouse 24 hours after administration of 10 nmol SEQ ID NO: 111 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). This experiment and results were reproduced in a second mouse (images not shown).
[0300] FIG. 19 shows white light images (left) and corresponding whole body fluorescence images (right) of a mouse 48 hours after administration of 10 nmol SEQ ID NO: 111 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). This experiment and results were reproduced in a second mouse (images not shown). FIG. 20 shows white light images (left) and corresponding whole body fluorescence images (right) of a mouse 72 hours after administration of SEQ ID NO: 111 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO:
111 A). This experiment and results were reproduced in a second mouse (images not shown). These WBF images showed SEQ ID NO: 112 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A) fluorescence distribution in intervertebral discs (IVD) and in joints and cartilaginous tissues at 3 hours and 24 hours.
[0301] FIG. 21 shows IVIS fluorescence imaging of an isolated hind limb from a first mouse and an isolated hind limb from a second mouse after administration of 10 nmol SEQ ID NO: 111 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A). FIG. 21A shows the
- 112WO 2017/044894
PCT/US2016/051166 right hind limb with skin removed from a first mouse and from a second mouse 3 hours after peptide administration. FIG. 21B shows the right hind limb with muscle removed from a first mouse and from a second mouse 3 hours after peptide administration. FIG. 21C shows the right hind limb with skin removed from a first mouse and from a second mouse 24 hours after peptide administration. FIG. 21D shows the right hind limb with muscle removed from a first moues and from a second mouse 24 hours after peptide administration. FIG. 21E shows the right hind limb with skin removed from a first mouse and from a second mouse 48 hours after peptide administration. FIG. 21F shows the right hind limb with muscle removed from a first mouse and from a second mouse 48 hours after peptide administration. FIG. 21G shows the right hind limb with skin removed from a first mouse and from a second mouse 72 hours after peptide administration. FIG. 21H shows the right hind limb with muscle removed from a first mouse and from a second mouse 72 hours after peptide administration. Peptide fluorescence was observed in the knee joints of isolated right hind limbs at all time points tested.
[0302] TABLE 4 summarizes fluorescence signal in IVD cartilage, at various time points after administration of SEQ ID NO: 111 peptide conjugated to a Cy5.5 fluorophore (SEQ ID NO: 111 A) in mice.
TABLE 4
SEQ ID NO Signal Observed Kidney Status Duration
111A Yes Intact 3hr
111A Yes Intact 24hr
111A No Intact 48hr
111A No Intact 72hr
EXAMPLE 21
Whole Body Autoradiography of Cartilage Homing Peptides [0303] This example illustrates peptide homing to cartilage mice 5 minutes to 48 hours after administration of a radiolabeled peptide. Signal from the radiolabeled peptides was found in all types of cartilage at each time point examined. Each peptide was radiolabeled by methylating lysines at the N-terminus as described in EXAMPLE 2. As such, the peptide may contain methyl or dimethyl lysines and a methylated or dimethlyated amino terminus. A dose of 100 nmol radiolabeled peptide was administered via tail vein injection in Female Harlan athymic nude mice, weighing 20-25 g. The experiment was done in duplicate (n=2 animals per group). In some animals, kidneys were ligated to prevent renal filtration of the
- 113 WO 2017/044894
PCT/US2016/051166 radiolabled peptides and extend plasma half-life. Each radiolabeled peptide was allowed to freely circulate within the animal for the described time period before the animals were euthanized and sectioned.
[0304] Whole body autoradiography (WBA) sagittal sectioning was performed as follows. At the end of the dosing period, mice were frozen in a hexane/dry ice bath and then embedded in a frozen block of carboxymethylcellulose. Whole animal sagittal slices were prepared that resulted in thin frozen sections for imaging. Thin frozen sections were obtained using a microtome and allowed visualization of tissues such as brain, tumor, liver, kidney, lung, heart, spleen, pancreas, muscle, adipose, gall bladder, upper gastrointestinal tract, lower gastrointestinal tract, bone, bone marrow, reproductive tract, eye, cartilage, stomach, skin, spinal cord, bladder, salivary gland, and more. Sections were allowed to dessicate in a freezer prior to imaging.
[0305] For the autoradiography imaging, tape mounted thin sections were freeze dried and radioactive samples were exposed to phophoimager plates for 7 days. These plates were developed and the signal (densitometry) from each organ was normalized to the signal found in the cardiac blood of each animal. A signal in tissue darker than the signal expected from blood in that tissue indicates accumulation in a region, tissue, structure, or cell.
[0306] FIG. 22 illustrates a white light image and a corresponding autoradiography image of frozen sections of a mouse, 5 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 22A illustrates a white light image of a frozen section of a mouse, 5 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
111. FIG. 22B illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 22A, 5 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 22C illustrates a white light image of a different frozen section of a mouse, 5 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 22D illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 22C, 5 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 22E illustrates a white light image of a different frozen section of a mouse, 5 minutes after administration of 100 nmol of a radiolabeled SEQ ID NO: 111. FIG. 22F illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 22E, 5 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the
- 114WO 2017/044894
PCT/US2016/051166 radiolabeled peptide distribution in the cartilage of the mouse. FIG. 22G illustrates a white light image of a different frozen section of a mouse, 5 minutes after administration of 100 nmol of a radiolabeled peptide of a SEQ ID NO: 111. FIG. 22H illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 22G, 5 minutes after administration of 100 nmol of a radiolabeled peptide of a SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0307] FIG. 23 illustrates a white light image and a corresponding autoradiography image of frozen sections of a mouse, 30 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 23A illustrates a white light image of a frozen section of a mouse, 30 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
111. FIG. 23B illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 23A, 30 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 23C illustrates a white light image of a different frozen section of a mouse, 30 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 23D illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 23C, 30 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 23E illustrates a white light image of a different frozen section of the mouse, 30 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 23F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 23E, 30 minutes after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0308] FIG. 24 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 24A illustrates a white light image of a frozen section of a mouse, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 24B illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 24A, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 24C illustrates a white light image of a different frozen section of a mouse, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 24D illustrates the 14C signal in a frozen section of a mouse, corresponding to the
- 115WO 2017/044894
PCT/US2016/051166 section shown in FIG. 24C, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 24E illustrates a white light image of a different frozen section of the mouse, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 24F illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 24E, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 24G illustrates a white light image of a different frozen section of the mouse, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 24H illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 24G, 1 hour after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0309] FIG. 25 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 25A illustrates a white light image of a frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
111. FIG. 25B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 25A, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 56C illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 25D illustrates the 14C signal in a different frozen section of the mouse, corresponding to the section shown in FIG. 25C, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 25E illustrates the 14C signal in a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0310] FIG. 26 illustrates a white light image and a corresponding autoradiography images of frozen sections from a mouse with ligated kidneys, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 26A illustrates a white light image of a frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 26B illustrates the 14C signal in a frozen
- 116WO 2017/044894
PCT/US2016/051166 section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 26A, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 26C illustrates a white light image of a different frozen section of the mouse with ligated kidneys, hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 26D illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 26C, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 26E illustrates a white light image of a different frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 26F illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to section shown in FIG. 26E, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. [0311] FIG. 27 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 27A illustrates a white light image of a frozen section of a mouse, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
111. FIG. 27B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 27A, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 27C illustrates an image of a different frozen section of a mouse, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
111. FIG. 27D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 27C, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 27E illustrates an image of a different frozen section of a mouse, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
111. FIG. 27F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 27E, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 27G illustrates a white light image of a different frozen section of a mouse, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 27H illustrates the 14C signal in a frozen section of a mouse,
- 117WO 2017/044894
PCT/US2016/051166 corresponding to the section shown in FIG. 27G, 8 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0312] FIG. 28 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 28A illustrates a white light image of a frozen section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 28B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 28A, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 28C illustrates a white light image of a different frozen section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 28D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 28C, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 28E illustrates a white light image of a different frozen section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 28F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 28E, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0313] FIG. 29 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 29A illustrates a white light image of a frozen section of a mouse, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 29B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 29A, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 29C illustrates a white light image of a different frozen section of a mouse, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 29D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 29C, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 29E illustrates a white light image of
- 118WO 2017/044894
PCT/US2016/051166 a different frozen section of the mouse, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 29F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 29E, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 29G illustrates a white light image of a different frozen section of a mouse, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. FIG. 29H illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 29G, 48 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 111. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0314] TABLE 5 shows the signal of radiolabeled peptides of SEQ ID NO: 24 and SEQ ID NO: 111 in IVD and knee joints as a percentage of the blood. Because the peptides may arrive at the joint within five minutes, a therapeutic effect from the peptide or a conjugated active agent may begin quickly. A therapeutic effect could be long lasting, due to continued presence of detected agents at 48 hours and/or due to long lasting pharmacodynamics effects.
TABLE 5
Hours SEQ ID NO: 24 IVD SEQ ID NO: 111 IVD SEQ ID NO: 111 Knee
0.08 164 404
0.5 369 510
1 961 1114
3 1779 3213 4059
8 3777 4990
24 833 5391 2137
48 3320 843
[0315] A radiolabeled peptide of SEQ ID NO: 111 was observed in the intervertebral disc (IVD) and synovial joints at all time points (5 minutes - 48 hours). The signal to background ratio in IVD peaked at 24 hours. The signal to background ratio in knee joints peaked at 8 hours. Signal in IVD was observed to progress from the periphery of the cartilage adjacent to the bone inwards.
[0316] FIG. 30 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse, 3 hours after administration of 100 nmol of a radiolabeled
- 119WO 2017/044894
PCT/US2016/051166 peptide of SEQ ID NO: 109. FIG. 30A illustrates a white light image of a frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
109. FIG. 30B illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 30A, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 30C illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. FIG. 30D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 30C, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 30E illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. FIG. 30F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 30E, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0317] FIG. 31 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. FIG. 31A illustrates a white light image of a frozen section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
109. FIG. 31B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 31A, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 31C illustrates a white light image of a different frozen section of the mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. FIG. 31D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 31C, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 31E illustrates a white light image of a different frozen section of the mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. FIG. 31F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 31E, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 109. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
- 120WO 2017/044894
PCT/US2016/051166 [0318] FIG. 32 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 32A illustrates a white light image of a frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
110. FIG. 32B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 32A, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 32C illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 32D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 32C, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 32E illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 32F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 32E, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 32G illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 32H illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 32G, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0319] FIG. 33 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 33A illustrates a white light image of a frozen section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
110. FIG. 33B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 33A, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 33C illustrates a white light image of a different frozen section of the mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 33D illustrates the 14C signal in a frozen section of the mouse,
- 121 WO 2017/044894
PCT/US2016/051166 corresponding to the section shown in FIG. 33C, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 33E illustrates a white light image of a different frozen section of the mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. FIG. 33F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 33E, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 110. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0320] FIG. 34 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 34A illustrates a white light image of a frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
114. FIG. 34B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 34A, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 34C illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 34D illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 34C, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 34E illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 34F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 34E, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0321] FIG. 35 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 35A illustrates a white light image of a frozen section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 35B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 35A, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 35C illustrates a white light image of a different frozen
- 122WO 2017/044894
PCT/US2016/051166 section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 35D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 35C, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 35E illustrates a white light image of a different frozen section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. FIG. 35F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 35E, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 114. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0322] FIG. 36 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 36A illustrates a white light image of a frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 36B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 36A, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 36C illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 36D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 36C, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 36E illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 36F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 36E, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0323] FIG. 37 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 37A illustrates a white light image of a frozen section of a mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 37B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 37A, 24 hours after administration of 100 nmol of a radiolabeled
- 123 WO 2017/044894
PCT/US2016/051166 peptide of SEQ ID NO: 200. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 37C illustrates a white light image of a different frozen section of the mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 37D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 37C, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 37E illustrates a white light image of a different frozen section of the mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 37F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 37E, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 37G illustrates a white light image of a different frozen section of the mouse, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. FIG. 37H illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 37G, 24 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 200. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0324] TABLE 6 shows the signal, as a percentage of signal in blood, of radiolabeled peptides of SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 114, and SEQ ID NO: 200in synovial joints.
TABLE 6
SEQ ID NO: 109 SEQ ID NO: 110 SEQ ID NO: 114 SEQ ID NO: 200
Average Std. Dev. Average Std. Dev. Average Std. Dev. Average Std. Dev.
3hr 5627 5121 3142 279 1175 366
24hr 5097 1874 981 326 4991 1764
[0325] TABLE 7 shows the signal of radiolabeled peptides of SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 114, and SEQ ID NO: 200 in the intervertebral disc (IVD).
- 124WO 2017/044894
PCT/US2016/051166
TABLE 7
SEQ ID NO: 109 SEQ ID NO: 110 SEQ ID NO: 114 SEQ ID NO: 200
Average Std. Dev. Average Std. Dev. Average Std. Dev. Average Std. Dev.
3hr 2758 1905 2374 795 1075 169 1809 649
24hr 4367 1218 1327 460 191 3542 848
[0326] Peptides signal for SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 114, and SEQ ID NO: 200 all showed signal in cartilage and exhibited cartilage homing properties. All peptides shown in TABLE 6 and TABLE 7 were variants of other peptides of this disclosure in which all lysine (K) residues were mutated to arginine (R)_residues. The peptide of SEQ ID NO: 109 is a K to R variant of a peptide of SEQ ID NO: 22, the peptide of SEQ ID NO:
110 is a K to R variant of a peptide of SEQ ID NO: 23, the peptide of SEQ ID NO: 114 is a K to R variant of a peptide of SEQ ID NO: 27, and the peptide of SEQ ID NO: 200 is a K to R variant of a peptide of SEQ ID NO: 86. These data show that K to R variants of cartilage homing peptides retain their cartilage homing properties. Radiolabeled peptide signals of SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 114, and SEQ ID NO: 200 exhibited accumulation in the IVD and joint cartilage at 3 hours after radiolabeled peptide administration. Radiolabeled peptide signals from SEQ ID NO: 109 and SEQ ID NO: 200 were maintained or increased in IVD and joint cartilage between 3 and 24 hours.
Radiolabeled peptide signal from SEQ ID NO: 110 decreased in joint and IVD cartilage between 3 and 24 hours. Radiolabeled peptide of SEQ ID NO: 114 exhibited reduced residence time with a signal near the limit of detection by 24 hours. SEQ ID NO: 110 was also present in the joint and IVD cartilage at 24 hours. SEQ ID NO: 109 exhibited the highest signal in cartilage, followed by SEQ ID NO: 200, SEQ ID NO: 110, and then SEQ ID NO:
114. The signal as a percentage of blood of a peptide of SEQ ID NO: 111 in the synovial joint (TABLE 5) at 3 hours and 24 hours ranked in intensity between peptides of SEQ ID NO: 200 and SEQ ID NO: 110 (TABLE 6). The signal as a percentage of blood of a peptide of SEQ ID NO: 111 in IVD (TABLE 5) at 3 hours and 24 hours was higher than any of the peptides of SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 114, and SEQ ID NO: 200 (TABLE 7). [0327] FIG. 38 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse with ligated kidneys, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 195 (GSNFKVEGACSKPCRKYCIDKGARNGKCINGRCHCYY). FIG. 38A illustrates a white light image of a frozen section of a mouse with ligated kidneys, 3 hours after administration
- 125WO 2017/044894
PCT/US2016/051166 of 100 nmol of a radiolabeled peptide of SEQ ID NO: 195. FIG. 38B illustrates the 14C signal in a frozen section of a mouse with ligated kidneys, corresponding to the section shown in FIG. 38A, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 195. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 38C illustrates a white light image of a different frozen section of the mouse with ligated kidneys, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 195. FIG. 38D illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 38C, 3 hours after administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 195. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0328] FIG. 39 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 196. FIG. 39A illustrates a white light image of a frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 196. FIG. 39B illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 39A, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 196. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 39C illustrates a white light image of a different frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 196. FIG. 39D illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 39C, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 196. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0329] FIG. 40 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 197 (GSDRDSCIDKSRCSKYGYYQECQDCCKKAGHNGGTCMFFKCKCA). FIG. 40A illustrates a white light image of a frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 197. FIG. 40B illustrates the 14C signal in a frozen section of a mouse with ligated kidneys, corresponding to the section shown in FIG. 40A, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 197. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 40C illustrates a white light image of a different frozen
- 126WO 2017/044894
PCT/US2016/051166 section of the mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 197. FIG. 40D illustrates the 14C signal in a frozen section of a mouse with ligated kidneys, corresponding to the section shown in FIG. 40C, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 197. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0330] FIG. 41 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 198. FIG. 41A illustrates a white light image of a frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 198. FIG. 41B illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 41A, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 198. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 41C illustrates a white light image of a different frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 198. FIG. 41D illustrates the 14C signal in a frozen section of a mouse with ligated kidneys, corresponding to the section shown in FIG. 41C, 3 hours after administration of 100 nmol a radiolabeled peptide of SEQ ID NO: 198. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0331] SEQ ID NO: 434 is a linearized version of SEQ ID NO: 111, where the knotted scaffold of the peptide has been removed by mutating out the cysteine residues that form the disulfide bonds of the peptide to serine residues, but retaining the rest of the sequence. FIG. 42 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 42A illustrates a white light image of a frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 42B illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 42A, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 42C illustrates a white light image of a different frozen section of the mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 42D illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 42C, 3 hours after
- 127WO 2017/044894
PCT/US2016/051166 administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 42E illustrates a white light image of a different frozen section of a mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 42F illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 42E, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 42G illustrates a white light image of a different frozen section of the mouse with ligated kidneys, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 42H illustrates the 14C signal in a frozen section of the mouse with ligated kidneys, corresponding to the section shown in FIG. 42G, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0332] FIG. 43 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 43A illustrates a white light image of a frozen section of a mouse, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 43B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 43A, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 43C illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 43D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 43C, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 43E illustrates a white light image of a different frozen section of the mouse, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 43F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 43E, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 43G illustrates a white light image of a different frozen section of a mouse, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ
- 128WO 2017/044894
PCT/US2016/051166
ID NO: 434. FIG. 43H illustrates the 14C signal in a frozen section of a mouse, corresponding to the section shown in FIG. 43G, 3 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0333] FIG. 44 illustrates a white light image and a corresponding autoradiography image of frozen sections from a mouse, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 44A illustrates a white light image of a frozen section of a mouse, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 44B illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 44A, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 44C illustrates a white light image of a different frozen section of a mouse, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 44D illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 44C, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 44E illustrates an image of a different frozen section of the mouse, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 44F illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 44E, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse. FIG. 44G illustrates a white light image of a different frozen section of a mouse, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. FIG. 44H illustrates the 14C signal in a frozen section of the mouse, corresponding to the section shown in FIG. 44G, 24 hours after administration of 100 nmol a radiolabeled linearized peptide of SEQ ID NO: 434. The 14C signal identifies the radiolabeled peptide distribution in the cartilage of the mouse.
[0334] TABLE 8 shows quantification of signal as a percentage of signal in blood from a linearized radiolabeled SEQ ID NO: 434 peptide in intervertebral discs (IVD).
TABLE 8
- 129WO 2017/044894
PCT/US2016/051166
3 hr Ligated Kidneys 3 hr Intact Kidneys 24 hr Intact Kidneys
IVD 117 177 104
[0335] The peptide of SEQ ID NO: 434, a linearized version of the peptide of SEQ ID NO: 111, homed to cartilage to a much lesser extent than the folded knotted peptide (SEQ ID NO:
111). The signal of the folded knotted peptide of SEQ ID NO: 111 was ~20-fold greater at 3 hours and ~50-fold greater at 24 hours (TABLE 5) as compared to the linearized peptide of SEQ ID NO: 434 (TABLE 8). These results indicate that in addition to changes in primary sequence or peptide charge, homing to cartilage can also be related to changes in conformation, or tertiary structure. Namely, in some cases, folded knottin peptides can be exemplary cartilage homers in comparison to unfolded, linearized peptides of the same primary sequence (except for the mutated cysteine residues).
EXAMPLE 22
Budesonide Peptide Conjugates [0336] This example describes conjugation of a peptide of this disclosure to budesonide. Budesonide is readily conjugated to any peptide disclosed herein via a dicarboxylic acid linker. The dicarboxylic acid linker is a linear dicarboxylic acid, such as succinic acid, or a related cyclic anhydride, such as succinic anhydride. Reactions with anhydrides can proceed under simple conditions. For example, the reaction of budesonide with five molar equivalents of glutaric anhydride is carried out in anhydrous pyridine at room temperature. Reactions with dicarboxylic acids can occur using standard carbodiimide coupling methods. For example, budesonide is reacted with one molar equivalent dimethylsuccinic acid, one molar equivalent l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (or another carbodiimide), and 0.2 molar equivalents of 40-dimethylamino pyridine.
[0337] The same methods as described in EXAMPLE 16 are used to adjust the rate of hydrolysis of peptide-budesonide conjugates, preventing premature cleavage and ensuring that the majority of peptide-budesonide conjugates accumulate in cartilage.
[0338] Peptide-budesonide conjugates are prepared by coupling budesonide to the peptides of this disclosure using standard coupling-reagent chemistry. The protocol for making the NHS succinic ester of budesonide is similar to that of dexamethasone, as described in EXAMPLE 15. The N-hydroxysuccinimide ester of the peptide-budesonide conjugate is generated to form a shelf-stable intermediate for later reaction with an amine-containing carrier.
- 130WO 2017/044894
PCT/US2016/051166 [0339] The knottin peptide can be any peptide with the sequence selected from SEQ ID NO:
- SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216 SEQ ID NO:
237 - SEQ ID NO: 410, SEQ ID NO: 412, or SEQ ID NO: 414 - SEQ ID NO: 432.
EXAMPLE 23
Peptide Charge and Cartilage Homing [0340] This example describes the charge of peptides of this disclosure and how it correlates to cartilage homing. TABLE 9 shows the number of lysines, and pi as calculated by various methods including Expasy pi and MYpI in peptides of this disclosure. The pi refers to the isoelectric point and is the pH at which the net charge of the peptide is zero.
TABLE 9
SEQ ID NO # Lysines Expasy pi Sillero pi
483 2 7.78 7.756
433 3 8.66 8.385
28 5 8.9 8.59
22 6 9.5 9.689
24 5 9.34 9.23
23 6 9.3 9.22
32 3 8.34 8.121
485 2 8.52 8.206
33 3 8.87 8.603
27 3 9.15 8.885
[0341] FIG. 45 shows cartilage homing of various peptides of this disclosure plotted against the calculated Expasy pi (calculated as described in Bjellqvist et al. Electrophoresis. 14(10):1023-31 (1993) and Bjellqvist et al. Electrophoresis. 15(3-4):529-39 (1994)). The yaxis C:B ratio indicates the cartilage to blood ratio. FIG. 46 shows cartilage homing of various peptides of this disclosure plotted against the calculated Sillero pi using R implementation (calculated as described in Sillero et al. Comput Biol Med. 36(2): 157-66 (2006) and Rice et al. Trends Genet. 16(6): 276-7 (2000)). These figures show that a peptide with a pi in the range of -8.5-9.5 by the Expasy or Sillero method can be desirable for cartilage homing.
[0342] A structure-based 3D modeling approach using a Poisson-Boltzmann distribution was also taken to identify the pi of various peptides of this disclosure. This approach identified
- 131 WO 2017/044894
PCT/US2016/051166 the charge at biological pH (pH 7) and the overall pi, as summarized in TABLE 10, of peptides in their unfolded and folded state. The 3D structures of verified cartilage homers were determined by x-ray crystallography or modeled using various homolog-based approaches. The structures were analyzed using the PDB2PQR package (1) and the Adaptive Posisson-Boltzmann Solver software package (2). These structures are shown in FIG. 48, where they are rendered as electrostatic surfaces (also see, Dolinsky et al. Nucleic Acids Res Jul;35(Web Server issue): W522-45 (2007) and Baker et al. Proc. Natl Acad Sci USA. 98(18): 10037-41 (2001)).
TABLE 10
SEQ ID NO Unfolded Peptide charge at pH 7 Folded Peptide charge at pH 7 Unfolded Peptide Overall Pl Folded Peptide Overall pi
28 4.91 4.90 10.49 10.49
111 5.15 4.88 12.38 12.30
23 6.15 6.13 11.16 11.05
27 4.91 4.85 11.53 11.50
EXAMPLE 24
Structure and Electrostatics of Cartilage Homing Peptides [0343] This example describes structural features and electrostatics of the cartilage homing peptides of this disclosure. Analysis of the primary sequences and predicted tertiary structure of multiple cartilage homing candidates (for example, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 27, and SEQ ID NO: 28) revealed interesting aspects of their structures that may be important for preserving biological function. Several cartilage homing candidates were grouped into a structural class identified herein as “hitchins.” FIG. 47 depicts the topology of the “hitchins” class of cartilage homing peptides, with disulfide connectivity labeled as ClC4, C2-C5, and C3-C6. Peptides of SEQ ID NO: 24, SEQ ID NO: 23, SEQ ID NO: 27, and SEQ ID NO: 28 are examples of the “hitchins” class of cartilage homing peptides. This information allowed for potential identification or prediction of cartilage homing proteins based on either primary sequence identity or similarly and/or structural homology. In addition to the “hitchins” peptides that were found to home to cartilage, other peptides such as the peptide of SEQ ID NO: 22 and SEQ ID NO: 205 home to cartilage and belong to a class of small proteins known as calcins. Data suggested that members of this calcin family may also
- 132WO 2017/044894
PCT/US2016/051166 home to cartilage despite having a distinct tertiary structure. Related members of this family include peptides of SEQ ID NO: 202 - SEQ ID NO: 205 and SEQ ID NO: 22 and may also home to cartilage. Members of this family may also be able to modulate intracellular targets in cartilage, such as ion channels and ryanodine receptors.
[0344] Upon further structural analysis, it was identified that many of the cartilage homing proteins have a contiguous surface of positive charge that accounts for most of the solvent accessible surface area as shown in FIG. 48. Positions of the positively charged residues on the surface of the protein and their localization can be important for maintaining this function.
[0345] Other peptides that share the “hitchins” or calcin topology, that have large contiguous areas of positive surface charge, and/or that have pi values similar to other cartilage homing peptides as shown in EXAMPLE 24, may also be predicted to home to cartilage. For example, in some cases these include peptides of SEQ ID NO: 72 - SEQ ID NO: 75, SEQ ID NO: 206, SEQ ID NO: 208 - SEQ ID NO: 213, SEQ ID NO: 288 - SEQ ID NO: 291, SEQ ID NO: 422, or SEQ ID NO: 424 - SEQ ID NO: 429.
[0346] FIG. 49 illustrates HPLC chromatograms of peptides of SEQ ID NO: 24 and SEQ ID NO: 111 in different buffer conditions. FIG. 49A illustrates the HPLC trace of a peptide of SEQ ID NO: 24 in PBS. FIG. 49B illustrates the HPLC trace of a peptide of SEQ ID NO: 24 in DTT in PBS. FIG. 49C illustrates the HPLC trace of a peptide of SEQ ID NO: 24 in 50 U trypsin and 1 mg/ml inhibitor in PBS. FIG. 49D illustrates the HPLC trace of a peptide of SEQ ID NO: 24 in 50 U trypsin, 1 mg/ml inhibitor, and DTT in PBS. FIG. 49E illustrates the HPLC trace of a peptide of SEQ ID NO: 11 lin PBS. FIG. 49F illustrates the HPLC trace of a peptide of SEQ ID NO: 11 lin DTT in PBS. FIG. 49G illustrates the HPLC trace of a peptide of SEQ ID NO: 11 lin 50 U trypsin and 1 mg/ml inhibitor in PBS. FIG. 49H illustrates the HPLC trace of a peptide of SEQ ID NO: 11 lin 50 U trypsin, 1 mg/ml inhibitor, and DTT in PBS.
[0347] FIG. 71 illustrates HPLC chromatograms of two peptides after exposure to reducing agents, proteinases, and/or simulated gastric fluid conditions. FIG. 71A illustrates the HPLC trace of a peptide of SEQ ID NO: 24 incubated in PBS. FIG. 71B illustrates the HPLC trace of a peptide of SEQ ID NO: 24 incubated in DTT in PBS. FIG. 71C illustrates the HPLC trace of a peptide of SEQ ID NO: 24 incubated in simulated gastric fluid (SGF). FIG. 71D illustrates the HPLC trace of a peptide of SEQ ID NO: 24 incubated in 500 U pepsin in SGF. FIG. 71E illustrates the HPLC trace of a peptide of SEQ ID NO: 24 incubated in 500 U pepsin, 0.5 M Tris, and DTT in SGF. FIG. 71F illustrates the HPLC trace of a peptide of
- 133 WO 2017/044894
PCT/US2016/051166
SEQ ID NO: 11 lincubated in PBS. FIG. 71G illustrates the HPLC trace of a peptide of SEQ ID NO: 11 lincubated in DTT in PBS. FIG. 71H illustrates the HPLC trace of a peptide of SEQ ID NO: 11 lincubated in simulated gastric fluid (SGF). FIG. 711 illustrates the HPLC trace of a peptide of SEQ ID NO: 11 lincubated in 500 U pepsin in SGF. FIG. 71J illustrates the HPLC trace of a peptide of SEQ ID NO: 11 lincubated in 500 U pepsin, 0.5 M Tris, and DTT in SGF.
[0348] FIG. 72 illustrates HPLC chromatograms of peptides of SEQ ID NO: 111 and SEQ ID NO: 434 after exposure to a range of conditions including oxidative, reductive, and acidic conditions as well as after exposure to proteinases. The peptide of SEQ ID NO: 434 is a linearized version of the knottin peptide of SEQ ID NO: 111. The peptide of SEQ ID NO:
434 has the same amino acid sequence as the knottin peptide of SEQ ID NO: 111, but with all cysteines mutated to serines. FIG. 72A illustrates the HPLC trace of a peptide of SEQ ID NO: 111 under reducing and acidic conditions. FIG. 72B illustrates the HPLC trace of a peptide of SEQ ID NO: 111 under various combinations of reducing agents and proteases including 10 mM DTT in 500 U pepsin, 500 U pepsin, 10 mM DTT in 50 U trypsin, and 50 U trypsin. FIGS. 72A-B show that the peptide of SEQ ID NO: 111 is highly resistant to degradation at pH 1, reducing agents, trypsin, and pepsin. FIG. 72C illustrates the HPLC trace of a peptide of SEQ ID NO: 434 under various protease conditions including in 500 U pepsin, in 50 U trypsin, non-reducing (NR, oxidized conditions) in simulated gastric fluid (SGF) at pH 1.05, and NR. FIG. 72C shows that the linearized peptide is more susceptible to degradation at these different conditions. These data indicate that the knottin structure provided by the cysteine residues in the peptide of SEQ ID NO: 112 is an important factor in providing stability.
[0349] The structure of known cartilage homing peptides was also used to systematically vary key parameters and identify homologous sequences that are predicted to have cartilage homing properties using NCBI BLAST. Three criteria were modulated in NCBI BLAST to identify potential new sequences including setting the percentage of overall sequence identity, conservation of cysteines for preservation of disulfide bridges, and conservation of positively and/or negatively charged residues. Peptides of SEQ ID NO: 208 - SEQ ID NO: 213 were identified as homologous to SEQ ID NO: 24 and are predicted to have cartilage homing properties.
- 134WO 2017/044894
PCT/US2016/051166
EXAMPLE 25
Peptide Localization in Chondrocytes [0350] This example illustrates binding of peptides of this disclosure to chondrocytes within cartilage in animals with intact kidneys. In one embodiment, animals are dosed and are processed as described in EXAMPLE 20 and EXAMPLE 21. Whole animal sagittal slices are prepared that result in thin frozen sections being available for staining and imaging. At the end of the dosing period, animals are euthanized and cartilage is removed for use in staining and imaging procedures. One or more of the following cartilage components are identified in thin frozen sections or live cartilage explants using standard staining techniques: collagen fibrils, glycosaminoglycans, or chondrocytes. A peptide of this disclosure is found to localize to chondrocytes in cartilage. Localization is visualized and confirmed by microscopy.
[0351] In another embodiment, peptides or peptide-drug conjugates of this disclosure are administered in humans and are localized in chondrocytes in cartilage.
EXAMPLE 26
Peptide Localization in Cartilage Extracellular Matrix [0352] This example illustrates localization of peptides of this disclosure in cartilage extracellular matrix. Peptides of this disclosure are bound to extracellular matrix within cartilage in animals with intact kidneys. Thin frozen sections or live cartilage explants are acquired, stained, and visualized as described in EXAMPLE 25. A peptide of the present disclosure is found to localize to the extracellular matrix in cartilage. Localization is visualized and confirmed by microscopy.
[0353] In another embodiment, peptides or peptide-drug conjugates of this disclosure are administered in humans and are localized in cartilage extracellular matrix.
EXAMPLE 27
Peptide Binding to Cartilage Explants [0354] This example illustrates a peptide or peptide conjugation of this disclosure binding to human and animal cartilage explants in culture. A peptide is selected from any one of the peptides of SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216, SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 SEQ ID NO: 432. Peptides are recombinantly expressed or chemically synthesized and are used directly, after radiolabeling, or after conjugation to a fluorophore or therapeutic
- 135WO 2017/044894
PCT/US2016/051166 compound. A peptide of peptide conjugate of this disclosure is incubated with cartilage explants derived from humans or animals. Peptides of peptide conjugate are found to bind to cartilage explants. Binding is confirmed using various methods that include but are not limited to liquid scintillation counting, confocal microscopy, immunohistochemistry, HPLC, orLC/MS.
EXAMPLE 28
Peptide Homing to an Arthritic Joint [0355] This example illustrates peptide homing to cartilage in humans or animals with arthritis. A peptide of the present disclosure is expressed recombinantly or chemically synthesized and is used directly, after radiolabeling, or after conjugation to a fluorophore or therapeutic compound. A peptide is selected from any one of the peptides of SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216, SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432. The peptide or peptide conjugate is administered to a human or animal subcutaneously, intravenously, or orally, or is injected directly into a joint. The peptide or peptide conjugate homes to cartilage.
EXAMPLE 29
Peptide Homing to Cartilage in Non-Human Animals [0356] This example illustrates a peptide or peptide conjugate of this disclosure homing to cartilage in non-human animals. Non-human animals include but are not limited to guinea pigs, rabbits, dog, cats, horses, and other non-human animals. A peptide of the present disclosure is recombinantly expressed or chemically synthesized and are used directly, after radiolabeling, or after conjugation to a fluorophore or therapeutic compound. The peptide is selected from any one of the peptides of SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216, SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432. The resulting peptide or peptide conjugate is administered to a non-human animal subcutaneously, intravenously, or orally, or is injected directly into a joint. Biodistribution is assessed by LC/MS, autoradiography, positron emission tomography (PET), or fluorescence imaging. A peptide or peptide conjugate is homed to cartilage in non-human animals.
- 136WO 2017/044894
PCT/US2016/051166
EXAMPLE 30
Treatment of Chondrosarcoma [0357] This example illustrates treatment of chondrosarcoma using peptides of the present disclosure. A peptide of the present disclosure is recombinantly expressed or chemically synthesized and are used directly, after radiolabeling, or after conjugation to a fluorophore or therapeutic compound, such as paclitaxel or monomethyl auristatin E. The peptide or peptide conjugate is administered in a pharmaceutical composition to a subject as a therapeutic for chondrosarcoma. The peptide is selected from any one of the peptides of SEQ ID NO: 21 SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216, SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432. One or more peptides or peptide conjugates of the present disclosure are administered to a subject. A subject can be a human or an animal. The pharmaceutical composition is administered subcutaneously, intravenously, orally, or injected directly into a joint. The peptides or peptide conjugates target cartilage affected by chondrosarcoma.
EXAMPLE 31
Method to Determine Improved Peptide Variants [0358] This example shows a method for determining ways to improve peptide variants by comparing and analyzing the primary sequences and tertiary structures of scaffold peptides. FIG. 50A-50C show sequences of SEQ ID NO: 24 aligned with SEQ ID NO: 23, SEQ ID NO: 24 aligned with SEQ ID NO: 27, and SEQ ID NO: 24 aligned with SEQ ID NO: 206. The sequence alignment of the two scaffolds was used to identify conserved positively charged residues (shown in boxes) that may be important for cartilage homing. A peptide of SEQ ID NO: 206 homes to cartilage and other peptides with positively charged residues in similar positions or cysteines in similar positions are also predicted to home to cartilage. [0359] Many cartilage homing peptides that come from scorpions are predicted to modulate Kv ion channels. FIG. 51 shows sequences of SEQ ID NO: 27 aligned with SEQ ID NO:
207. The sequence alignment of the two scaffolds was used to identify the basic/aromatic dyad that may be involved in the interaction with the Kv ion channel (K27 and Y36 of SEQ ID NO: 207). The mutation of K27 to alanine, arginine, or glutamic acid destroyed activity against the squid KvlA ion channel. K27 and Y36 may be desirable to maintain or add to a cartilage homing peptide of this disclosure to maintain or improve homing, to maintain or improve residence time in cartilage, or to maintain or improve modulation of an ion channel such as Kv. In contrast, K37 and &36 may be desirable to mutate out of a cartilage homing
- 137WO 2017/044894
PCT/US2016/051166 peptide to reduce interaction with an ion channel such as Kv. Disruption of either the basic or aromatic residue eliminates ion channel activity. In another example, D amino acids are expected to reduce or eliminate binding.
EXAMPLE 32 Peptide-Fc Protein Fusions [0360] This example illustrates making and using peptide-Fc protein fusions. A peptide of SEQ ID NO: 111 was recombinantly expressed with the sequence for the human IgGl Fc protein in HEK293 cells to yield a sequence of SEQ ID NO: 435 (METDTLLLWVLLLWVPGSTGGSGVPINVRCRGSRDCLDPCRRAGMRFGRCINSRCH
CTPGGSGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV
SNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEW
ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT
QKSLSLSPGK).
[0361] The sequence of any peptide of this disclosure is expressed as a fusion protein with either murine or human Fc by adding a secretion signal sequence to the N-terminus and an Fc sequence to the C-terminus. This creates a bivalent molecule with improved secretion properties. The larger peptide-Fc fusion is expressed in different mammalian or insect cell lines and is useful as a research reagent and a therapeutic.
[0362] Fc fusion to a peptide of SEQ ID NO: 111 to yield a sequence of SEQ ID NO: 435 extends half-life and improves biodistribution of the peptide to cartilage. Any peptide of this disclosure is co-expressed with Fc protein to yield Fc-fusion peptides with longer half-life and improved homing to cartilage. In SEQ ID NO: 435, the secretion signal sequence METDTLLLWVLLLWVPGSTG is followed by the peptide of SEQ ID NO: 111, and is followed by the sequence for Fc protein. Cleaving can be imprecise, resulting in cleavage at position 20 or position 21 of SEQ ID NO: 435.
EXAMPLE 33
Treatment of Chordoma [0363] This example illustrates treatment of chordoma using peptides of the present disclosure. A peptide of the present disclosure is recombinantly expressed or chemically synthesized and are used directly, after radiolabeling, or after conjugation to a fluorophore or therapeutic compound, such as paclitaxel or monomethyl auristatin E. The peptide or peptide
- 138WO 2017/044894
PCT/US2016/051166 conjugate is administered in a pharmaceutical composition to a subject as a therapeutic for chordoma. The peptide is selected from any one of the peptides of SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216, SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432. One or more peptides or peptide conjugates of the present disclosure are administered to a subject. A subject can be a human or an animal. The pharmaceutical composition is administered subcutaneously, intravenously, orally, or injected directly into a joint. The peptides or peptide conjugates target cartilage affected by chordoma.
EXAMPLE 34
Peptide Detectable Agent Conjugates [0364] This example describes the dye labeling of peptides. A peptide of the disclosure is expressed recombinantly or chemically synthesized, and then the N-terminus of the peptide is conjugated to an detectable agent via an NHS ester using DCC or EDC to produce a peptidedetectable agent conjugate. The detectable agent is the fluorophore dye is a cyanine dye, such as Cy5.5 or an Alexa fluorophore, such as Alexa647.
[0365] The peptide detectable agent conjugates are administered to a subject. The subject can be a human or a non-human animal. After administration, the peptide detectable agent conjugates home to cartilage. The subject, or a biopsy from the subject, can be imaged to visualize localization of the peptide detectable agent conjugates to cartilage. In some aspects, visualization of the peptide detectable agent conjugates in cartilage after administration results in diagnosis of arthritis, cartilage damage, or any cartilage disorder.
EXAMPLE 35
Peptide Conjugates with Cleavable Linkers [0366] This example describes preparation of knottin peptide conjugates having cleavable linkers. A peptide of the disclosure is expressed recombinantly or chemically synthesized. The peptide is conjugated to a detectable agent or an active agent via a cleavable linker, such as an ester bond using standard l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) or dicylcohexylcarbodiimide (DCC) based chemistry or thionyl chloride or phosphorous chloride-based bioconjugation chemistries. The linker is cleaved by esterases, MMP, cathepsin B, a protease, or thrombin.
[0367] The resulting peptide conjugates are administered to a human or animal subcutaneously, intravenously, orally, or injected directly into a joint to treat disease. The
- 139WO 2017/044894
PCT/US2016/051166 peptide is cleaved from the detectable agent or active agent only by digestion by a cleaving agent.
EXAMPLE 36
Intra-articular Administration of Peptides and Peptide Conjugates [0368] This example illustrates intra-articular administration of peptides or peptide conjugates of this disclosure. A peptide of this disclosure is expressed recombinantly or chemically synthesized. In some cases, the peptide is subsequently conjugated to a detectable agent or an active agent. The peptide or peptide conjugate is administered to a subject in need thereof via intra-articular administration. The cartilage is penetrated by the peptide or peptide conjugate due to the small size of the peptide or peptide conjugate, and due to binding of cartilage components by the peptide or peptide conjugate. The peptide or peptide conjugate is bound to cartilage and the residence time in the cartilage is longer due to this binding. Optionally, the injected material is aggregated, is crystallized, or complexes are formed, further extending the depot effect and contributing to longer residence time.
EXAMPLE 37
Treatment for Rapid Pain Relief [0369] This example illustrates rapid pain relief in patients treated for rheumatoid arthritis or osteoarthritis with the peptides or peptide conjugates of this disclosure. A peptide of this disclosure is expressed recombinantly or chemically synthesized, and then the N-terminus of the peptide is conjugated to an active agent via an NHS ester to produce a peptide-active agent conjugate. In some aspects the active agent is lidocaine. In some cases, the peptide alone is administered to the subject.
[0370] The peptide or peptide-active agent conjugate is administered to a subject in need thereof. The subject is a human or non-human animal. The subject in need thereof has rheumatoid arthritis or osteoarthritis. The peptide or peptide conjugate is delivered via intravenous administration. Upon administration, the peptide or peptide conjugate rapidly homes to cartilage. Rapid pain relief within five minutes to an hour is experienced by the subject, and pain relieve can last as long as over 3 hours.
EXAMPLE 38
Selective Mutation of Residues to Produce Stable Peptides [0371] This example illustrates selective mutations of residues to produce peptides with enhanced stability, such as enhanced stability during manufacturing or storage. A peptide of
- 140WO 2017/044894
PCT/US2016/051166 this disclosure is expressed recombinantly or chemically synthesized. Met residues are mutated to valine, Ala, Leu, or He to prevent oxidation. Asn-Pro sequences are mutated to any other residue (except cysteine) to avoid cleavage reactions. Asn-Gly or Asn-Ser, and/or Asn-Pro are replaced with any other residue (except cysteine) to reduce deamidation. AspGly, Asp-Ser, or Asp-Pro are replaced with any other residue (except cysteine) to reduce cleavage reactions.
[0372] The above mutations in the primary sequence of peptides of this disclosure result in enhanced peptide stability during manufacturing, storage, and after administration to a subject in need thereof.
EXAMPLE 39
Peptide Resistance to Pepsin Digestion [0373] This example shows peptide resistance to pepsin. SEQ ID NO: 24 peptide and SEQ ID NO: 111 peptide were suspended in 500 pi of ddFEO at a stock concentration of 2 mg/ml. Reactions were prepared with 12.5 pg peptide and 20 pg pepsin in simulated gastric fluid (pH 1.05) and incubated for 30 minutes at 37.5°C. Reactions were quenched with a final concentration of 100 mM Tris base and 10 mM dithiothreitol (DTT). Reversed phase HPLC (RP-HPLC) was run on samples using an Agilent 1260 HPLC equipped with a C-18 Poroshell 120B column. Sample were analyzed by a gradient method with a mobile phase of Solvent A (water with 0.1% TFA) and Solvent B (acetonitrile with 0.1% TFA). Solvent B was ramped up from 5%-45% of the mobile phase over a period of 10 minutes. Peptides were detected at an absorbance of 214 nm and 280 nm.
[0374] FIG. 52 shows HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 24 suspended in various solutions including SPTD, simulated gastric fluid (SGF) at pH 1.05 and 20 pg pepsin (P), SGF, DTT, and non-reducing (NR) conditions . FIG. 53 shows HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 111 suspended in various solutions including SPTD, simulated gastric fluid (SGF) at pH 1.05 and 20 pg pepsin (P), SGF, DTT, and non-reducing (NR) conditions. FIG. 52 shows a peak eluting around 6.5 minutes, which was found to be the intact peptide of SEQ ID NO: 24, the peak eluting near 1.5 minutes was DTT, and the peak eluting near 2.5 minutes was oxidized DTT. Because an intact peptide peak was observed in the DTT solution, SGF solution, SGF and P solution, and the SPTD solution - it was determined that the peptide of SEQ ID NO: 24 was highly resistant to degradation. FIG. 53 showing a peptide of SEQ ID NO: 111 was also found to be similarly highly resistant in the various conditions tested.
- 141 WO 2017/044894
PCT/US2016/051166
EXAMPLE 40
Peptide Resistance to Trypsin Digestion [0375] This example shows peptide resistance to trypsin digestion. Various peptides were suspended in 500 plotddFLO at a stock concentration of 2 mg/ml. Reactions were prepared with 12.5 pg peptide and 5 pg trypsin in 25 mM Tris/75 mM NaCI buffer (pH 7.0) and incubated for 30 minutes at 37.5°C. Reactions were quenched with 5 pg of soybean trypsin inhibitor and 10 mM dithiothreitol (DTT). Reversed phase HPLC (RP-HPLC) was run on samples using an Agilent 1260 HPLC equipped with a C-18 Poroshell 120B column. Sample were analyzed by a gradient method with a mobile phase of Solvent A (water with 0.1%
TFA) and Solvent B (acetonitrile with 0.1% TFA). Solvent B was ramped up from 5%-45% of the mobile phase over a period of 10 minutes.
[0376] FIG. 54 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 483 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions (starting peptide, no treatment with DTT, T, or I). DTT eluted near 1.5 minutes and 2.5 minutes (reduced and oxidized) and the NR trace shows that the intact peptide eluted near 8.75 minutes. The trace showing the peptide in a DTT solution shows intact peptide at 8.75 minutes and some reduced peptide near 10 minutes, showing that this peptide of SEQ ID NO: 483 is partially resistant to reduction by DTT. The trace showing the peptide with trypsin shows intact peptide and degraded peptide, again demonstrating that the peptide of SEQ ID NO: 483 was partially resistant to degradation by trypsin. FIG. 55 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 22 suspended in various solutions including (T, I, DTT), (T,I),
DTT, and non-reducing (NR) conditions. FIG. 56 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 24 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions. FIG. 57 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 32 suspended in various solutions including (T, I, DTT), (T,I), DTT, and nonreducing (NR) conditions.
[0377] FIG. 58 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of
- 142WO 2017/044894
PCT/US2016/051166 a peptide of SEQ ID NO: 485 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions. FIG. 59 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 27 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions. FIG. 60 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 205 suspended in various solutions including (T, I, DTT), (T,I), DTT, and nonreducing (NR) conditions. FIG. 61 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 195 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions. FIG. 62 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 196 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions.
[0378] FIG. 63 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 197 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions. FIG. 64 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 198 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions. FIG. 65 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 206 suspended in various solutions including (T, I, DTT), (T,I), DTT, and nonreducing (NR) conditions. FIG. 66 shows an HPLC chromatogram of 5 pg trypsin in 25 mM Tris, 5 pg soybean trypsin inhibitor and 10 mM DTT (T, I, DTT) as well as HPLC chromatograms of 12.5 pg of a peptide of SEQ ID NO: 111 suspended in various solutions including (T, I, DTT), (T,I), DTT, and non-reducing (NR) conditions.
- 143 WO 2017/044894
PCT/US2016/051166
EXAMPLE 41
Peptide Resistance to Reducing Agents [0379] This example shows of peptide resistance to reducing agents. Several peptides were suspended in 500 μΐ of ddlUO to a stock concentration of 2 mg/ml. Reactions were prepared by adding 12.5 pg peptide from the stock solution to a 10 mM solution of DTT in PBS and allowed to incubate at room temperature for 30 minutes. RP-HPLC was run on samples using an Agilent 1260 HPLC equipped with a C-18 Poroshell 120B column. Samples were analyzed by a gradient method with a mobile phase of Solvent A (water with 0.1% TFA) and Solvent B (acetonitrile with 0.1% TFA). Solvent B was ramped up from 5%-45% of the mobile phase over a period of 10 minutes.
[0380] FIG. 67 shows the HPLC chromatograms of various peptides and the mass spectrometry results of various peptides after direct-infusion electrospray mass spectrometry (ES-MS) on a Thermo Orbi Classic® mass spectrometer. Peptides were fractionated by HPLC and without any further sample prep, 5 pi of the sample was injected into the mass spectrometer at 1 mg/ml using a CTCPAL® autosampler. Alternatively, if peptides were provided as a lyophilized powder, the sample was dissolved in 100% water to a concentration of 1 mg/ml a Millipore Ziptip Cl8® column was used to desalt the peptides prior to injection for ES-MS. The mass spectrometer was calibrated using 5 pmol of mixture of five standard peptides to achieve a high accuracy of mass determination with less than a 10 ppm error. Confirmation of peptide disulfide bond formation was achieved by analyzing the m/z isotopic distribution and the exact charge. All peptides tested are shown under reducing and nonreducing conditions. Traces for peptides after DTT reduction that show some or all of the peptide eluting at the same retention time as under non-reducing conditions indicated that the peptide was resistant to reduction by DTT. FIG. 67A shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 483. The peak near 9.5 minutes is the peptide under non-reducing conditions and the peak near 8.4 minutes shows reduced peptide. FIG. 67B shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 22. The peak near 6.4 minutes is the peptide under non-reducing conditions and the peak near 5.4 minutes shows reduced peptide. FIG. 67C shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 24. Peaks showing the peptide under non-reducing conditions and reducing conditions are overlapping. FIG. 67D shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 32. The peak near 9.4 minutes is the peptide under non-reducing conditions and the peak near 9.0 minutes shows reduced peptide. FIG. 67E shows the HPLC chromatogram and mass
- 144WO 2017/044894
PCT/US2016/051166 spectrometry results of a peptide of SEQ ID NO: 485. The peak near 9.4 minutes is the peptide under non-reducing conditions and the peak near 8.1 minutes shows reduced peptide. FIG. 67F shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 27. The peak near 8.2 minutes is the peptide under non-reducing conditions and the peak near 5.4 minutes shows reduced peptide. FIG. 67G shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 205. The peak near 6.6 minutes is the peptide under non-reducing conditions and the peak near 5.6 minutes shows reduced peptide. FIG. 67H shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 195. The peak near 9.5 minutes is the peptide under non-reducing conditions and the peak near 8.4 minutes shows reduced peptide. FIG. 671 shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 196. Peaks showing the peptide under non-reducing conditions and reducing conditions are overlapping. FIG. 67J shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 197. The peak near 8.5 minutes is the peptide under non-reducing conditions and the peak near 7.7 minutes shows reduced peptide. FIG. 67K shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 198. The peak near 9.7 minutes is the peptide under non-reducing conditions and the peak near 6.7 minutes shows reduced peptide. FIG. 67L shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 206. The peak near 8.2 minutes is the peptide under non-reducing conditions and the peak near 7.2 minutes shows reduced peptide. FIG. 67M shows the HPLC chromatogram and mass spectrometry results of a peptide of SEQ ID NO: 111. Peaks showing the peptide under non-reducing conditions and reducing conditions are fully overlapping.
EXAMPLE 42
Intravenous and Oral Administration of Peptides [0381] This example describes intravenous and oral administration of peptides of this disclosure, including transit of the intact peptide through the GI tract and to the feces after oral administration. A radiolabeled peptide of SEQ ID NO: 24 was administered intravenously or orally to female Harlan athymic nude mice, 6-8 weeks of age. Radiolabeled peptides of SEQ ID NO: 24was administered intravenously (IV) at a dose of 4.8 pCi / 20 nmol. Radiolabeled peptide of SEQ ID NO: 24was administered orally (PO) at a dose of 24 pCi / 100 nmol. Mice were euthanized at various time points by CO2 asphyxiation and biological fluids were collected, including blood, urine, and feces. ETrine was collected be abdominal palpitation immediately before CO2 asphyxiation. Blood was collected by cardiac
- 145WO 2017/044894
PCT/US2016/051166 puncture immediately after CO2 asphyxiation and centrifuged to separate plasma. Feces was collected either before or after CO2 asphyxiation by palpitation of the colon. Samples were analyzed by HPLC to quantify the concentration or dose of intact peptide recovered in plasma, urine, and feces. For HPLC analysis, urine samples were first diluted at a 1:20 ratio in water and plasma samples were diluted at a 1:5 ratio in water. Feces samples were dissolved in Tris buffer, centrifuged to remove the insoluble fraction, and supernatants were diluted at a 1:1 ratio in water.
[0382] TABLE 11 shows a summary of the study design.
TABLE 11
Group SEQ ID NO Route Peptide Dose 14C Dose Time Points (hr) Mice/time
1 24 IV 20 nmol 4.8 pCi 0.08,0.5, 1, 3, 8, 24, 48 3
2 24 Oral 100 nmol 24 pCi 0.08,0.5, 1, 3, 8, 24, 48 3
[0383] FIG. 68 shows the concentration of a radiolabeled peptide of SEQ ID NO: 24in plasma after administration to a mouse. FIG. 68A shows the concentration of peptide in plasma after intravenous (IV) administration of 20 nmol of a radiolabeled peptide of SEQ ID NO: 24and oral (PO) administration of 100 nmol the radiolabeled peptide of SEQ ID NO: 24, as quantified by measuring the 14C signal using liquid scintillation counting. The delivered dose of 14C was 4.8 pCi for intravenous administration and 24 pCi for oral administration. Time points examined included 0.08, 0.5, 1, 3, 8, 24, 48 hours and three mice were examined per time point. FIG. 68B shows the percent of administered peptide dose recovered in plasma after intravenous (IV) administration of 20 nmol of a radiolabeled peptide of SEQ ID NO: 24and oral (PO) administration of 100 nmol of a radiolabeled peptide of SEQ ID NO: 24, as quantified by measuring the 14C signal using liquid scintillation counting. The delivered dose of 14C was 4.8 pCi for intravenous administration and 24 pCi for oral administration. Time points examined included 0.08, 0.5, 1, 3, 8, 24, 48 hours and three mice were examined per time point. FIG. 68C shows the intensity of peptide and peptide fragment peaks in plasma as measured by tandem HPLC and liquid scintillation counting after oral administration by gavage of 100 nmol of a radiolabeled peptide of SEQ ID NO: 24. The delivered dose of 14C was 24 pCi for oral administration. Time points examined included 0.5, 1, and 3 hours. These
- 146WO 2017/044894
PCT/US2016/051166 data show detection of radioactive signal from the dosed peptide up to at least 50 hours in plasma, with plasma concentrations up to 10% of the dose by IV administration and plasma concentrations up to 1% of the dose by PO administration. The intact peptide was eluted near 6 minutes, whereas cleaved fragments - such as the N-terminal Gly residue - were eluted near 1 minute. Thus, nearly some of all of the radioactivity detected in plasma was due to fragments of the administered peptide.
[0384] FIG. 69 shows the concentration of a radiolabeled peptide of SEQ ID NO: 24in urine after administration of the peptide to a mouse. FIG. 69A shows the concentration of peptide in urine after intravenous (IV) administration of 20 nmol of a radiolabeled peptide of SEQ ID NO: 24and oral (PO) administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
24, as quantified by measuring the 14C signal using liquid scintillation counting. The delivered dose of 14C was 4.8 pCi for intravenous administration and 24 pCi for oral administration. Time points examined included 0.08, 0.5, 1, 3, 8, 24, 48 hours and three mice were examined per time point. FIG. 69B shows the intensity of peptide and peptide fragment peaks in urine as measured by tandem HPLC and liquid scintillation counting after oral administration by gavage of 100 nmol of a radiolabeled peptide of SEQ ID NO: 24. The delivered dose of 14C was 24 pCi for oral administration. Time points examined included 0.5, 1, 3, 8, 24, and 48 hours.
[0385] FIG. 70 shows the concentration of a radiolabeled peptide of SEQ ID NO: 24 in feces after administration of the peptide to a mouse. FIG. 70A shows the concentration of peptide in feces after intravenous (IV) administration of 20 nmol of a radiolabeled peptide of SEQ ID NO: 24and oral (PO) administration of 100 nmol of a radiolabeled peptide of SEQ ID NO:
24, as quantified by measuring the 14C signal using liquid scintillation counting. The delivered dose of 14C was 4.8 pCi for intravenous administration and 24 pCi for oral administration. Time points examined included 0.08, 0.5, 1, 3, 8, 24, 48 hours and three mice were examined per time point. FIG. 70B shows the intensity of peptide and peptide fragment peaks in feces as measured by tandem HPLC and liquid scintillation counting after oral administration by gavage of 100 nmol of a radiolabeled peptide of SEQ ID NO: 24. The delivered dose of 14C was 24 pCi for oral administration. Time points examined included 3 and 8 hours. These data showed that intact peptide of SEQ ID NO: 24 was detected in feces after oral dosing, indicating that some intact peptide transited through the GI tract.
- 147WO 2017/044894
PCT/US2016/051166
EXAMPLE 43
Sequence Alignment to pFam00451:toxin_2 Family to Identify Cartilage Homing Peptides [0386] This example describes a method for identifying new cartilage homing peptides by sequence alignment to the pFam00451:toxin_2 structural class family. The pFam00451:toxin_2 structural class is a family of peptides related by similarities in sequence identity. FIG. 73 illustrates alignment of peptides within the pfam00451:toxin_2 structural class family of SEQ ID NO: 436 - SEQ ID NO: 482. Boxed and bolded residues indicate relative conservation of sequence while non-boxed and non-bolded residues indicate areas of higher sequence variability. SEQ ID NO: 436 was identified as a cartilage homing candidate peptide based on its structural similarities with the pFam00451:toxin_structural class family. FIG. 74 illustrates the sequence alignment of a peptide of SEQ ID NO: 436 from the pfam0045 l:toxin 2 structural class family with the sequence of SEQ ID NO: 24. Asterisks indicate positions with a single, fully conserved residue, a colon indicates conservation between groups of strongly similar properties (scoring > 0.5 in the Gonnet point accepted mutation (PAM) 250 matrix), and a period indicates conservation between groups of weakly similar properties (scoring < 0.5 in the Gonnet PAM 250 matrix). SEQ ID NO: 111 was also identified as a cartilage homing candidate based on its structural similiarities with the pfam00451:toxin_2 structural class family of peptides.
[0387] The pFam00451:toxin_2 structural class family is used as a scaffold to identify variant peptides that have cartilage homing properties. Any member of the pFam00451:toxin_2 structural class family is used to predict new cartilage homing peptides based on homology, preserved residues, or a preserved cysteine residue.
EXAMPLE 44 Temperature Stable Peptides [0388] This example illustrates peptide stability at high temperatures. Peptides were first suspended in 500 pi of ddH2O to a stock concentration of 2mg/ml. Reactions were prepared by adding 6.25 pi of peptide from the stock solution with 95 μΐ ddH2O and incubated at room temperature, 70°C, or 100°C for one hour in a Thermocycler. RP-HPLC was then run on samples using an Agilent 1260 HPLC equipped with a C-18 Poroshell 120B column. Sample were analyzed by a gradient method with a mobile phase of Solvent A (water with 0.1%
TFA) and Solvent B (acetonitrile with 0.1% TFA). Solvent B was ramped up from 5%-45% of the mobile phase over a period of 10 minutes.
- 148WO 2017/044894
PCT/US2016/051166 [0389] Peptides of SEQ ID NO: 28 and SEQ ID NO: 483 were analyzed by HPLC after incubation at room temperature (25°C), 70°C, or 100°C for one hour. After incubation at 70°C for 1 hour, peptides of SEQ ID NO: 483 and SEQ ID NO: 28 showed approximately the same HPLC elution time and peak height as the samples incubated at room temperature, indicating the peptides were resistant to heat-induced degradation. After incubation at 100°C for 1 hour, peptides of SEQ ID NO: 483 and SEQ ID NO: 28 underwent various degrees of degradation as evidenced by the reduced amount of peptide eluting at the original elution time.
[0390] While preferred embodiments of the present disclosure have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the disclosure be limited by the specific examples provided within the specification. While the disclosure has been described with reference to the aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the disclosure. Furthermore, it shall be understood that all embodiments of the disclosure are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the disclosure described herein may be employed in practicing the disclosure. It is therefore contemplated that the disclosure shall also cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby.
- 149WO 2017/044894
PCT/US2016/051166

Claims (117)

  1. WHAT IS CLAIMED:
    1. A composition, comprising:
    a knotted peptide, wherein upon administration to a subject the knotted peptide homes, targets, migrates to, accumulates in, binds to, is retained by, or is directed to a cartilage of the subject.
  2. 2. The composition of claim 1, wherein the knotted peptide comprises a sequence of any one of SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216 or a fragment thereof.
  3. 3. The composition of claim 1, wherein the knotted peptide comprises a sequence that has at least 80% sequence identity with any one of SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216 or a fragment thereof.
  4. 4. The composition of claim 1, wherein the knotted peptide comprises a sequence that has at least 85%, at least 90%, or at least 95% sequence identity with any one of SEQ ID NO: 21 - SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198 - SEQ ID NO: 216 or a fragment thereof.
  5. 5. The composition of claim 1, wherein the knotted peptide comprises a sequence of any one of SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 SEQ ID NO: 432 or a fragment thereof.
  6. 6. The composition of claim 1, wherein the knotted peptide comprises a sequence that has at least 80% sequence identity with any one of SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432 or a fragment thereof.
  7. 7. The composition of claim 1, wherein the knotted peptide comprises a sequence that has at least 85%, at least 90%, or at least 95% sequence identity with any one of SEQ ID NO: 237 - SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414 - SEQ ID NO: 432 or a fragment thereof.
  8. 8. The composition of claim 1, wherein the knotted peptide comprises a sequence of any one of SEQ ID NO: 1 - SEQ ID NO: 20 or a fragment thereof.
  9. 9. The composition of claim 1, wherein the knotted peptide comprises a sequence of any one of SEQ ID NO: 217 - SEQ ID NO: 236 or a fragment thereof.
  10. 10. The composition of claim 1, wherein the knotted peptide is at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% identical to any one of SEQ ID NO: 436 - SEQ ID NO: 482.
    - 150WO 2017/044894
    PCT/US2016/051166
  11. 11. The knotted peptide of claim 10, wherein the knotted peptide is SEQ ID NO: 24.
  12. 12. The knotted peptide of claim 10, wherein the knotted peptide is SEQ ID NO:
    111.
  13. 13. The composition of any one of claims 1-12, wherein the knotted peptide comprises 4 or more cysteine residues.
  14. 14. The composition of any one of claims 1-13, wherein the knotted peptide comprises three or more disulfide bridges formed between cysteine residues, wherein one of the disulfide bridges passes through a loop formed by two other disulfide bridges.
  15. 15. The composition of any one of claims 1-14, wherein the knotted peptide comprises a plurality of disulfide bridges formed between cysteine residues.
  16. 16. The composition of any one of claims 1-15, wherein the knotted peptide comprises a disulfide through a disulfide knot.
  17. 17. The composition of any one of claims 1-16, wherein at least one amino acid residue of the knotted peptide is in an L configuration or, wherein at least one amino acid residue of the knotted peptide is in a D configuration.
  18. 18. The composition of any of claims 1-17, wherein the sequence comprises at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58 residues, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65, at least 66, at least 67, at least 68, at least 69, at least 70, at least 71, at least 72, at least 73, at least 74, at least 75, at least 76, at least 77, at least 78, at least 79, at least 80, or at least 81 residues.
  19. 19. The composition of any of claims 1-18, wherein any one or more K residues are replaced by an R residue or wherein any one or more R residues are replaced by for a K residue.
  20. 20. The composition of any of claims 1-19, wherein any one or more M residues are replaced by any one of the I, L, or V residues.
  21. 21. The composition of any of claims 1-20, wherein any one or more L residues are replaced by any one of the V, I, or M residues.
    - 151 WO 2017/044894
    PCT/US2016/05U66
  22. 22. The composition of any of claims 1-21, wherein any one or more I residues are replaced by any of the M, L, or V residues.
  23. 23. The composition of any of claims 1-22, wherein any one or more V residues are replaced by any of the Μ, I, or L residues.
  24. 24. The composition of any of claims 1-23, wherein any one or more G residues are replaced by an A residue or wherein any one or more A residues are replaced by a G residue.
  25. 25. The composition of any of claims 1-24, wherein any one or more S residues are replaced by a T residue or wherein any one or more T residues are replaced by for an S residue.
  26. 26. The composition of any of claims 1-25, wherein any one or more Q residues are replaced by an N residue or wherein any one or more N residues are replaced by a Q residue.
  27. 27. The composition of any of claims 1-26, wherein any one or more D residues are replaced by an E residue or wherein any one or more E residues are replaced by a D residue.
  28. 28. The knotted peptide of any of any one of claims 1-27, wherein the knotted peptide has a charge distribution comprising an acidic region and a basic region.
  29. 29. The knotted peptide of claim 28, wherein the acidic region is a nub.
  30. 30. The knotted peptide of claim 28, wherein the basic region is a patch.
    3E The composition of any of claims 1-29, wherein the knotted peptide comprises 6 or more basic residues and 2 or fewer acidic residues.
  31. 32. The composition of any of claims 1-31, wherein the knotted peptide comprises a 4 -19 amino acid residue fragment containing at least 2 cysteine residues, and at least 2 positively charged amino acid residues.
  32. 33. The composition of any of claims 1-32, wherein the knotted peptide comprises a 20-70 amino acid residue fragment containing at least 2 cysteine residues, no more than 2 basic residues and at least 2 positively charged amino acid residues.
  33. 34. The composition of any of claims 1-33, wherein the knotted peptide comprises at least 3 positively charged amino acid residues.
  34. 35. The composition of any of claims 32-34, wherein the positively charged amino acid residues are selected from K, R, or a combination thereof.
  35. 36. The composition of any one of claims 1-35, wherein the knotted peptide has a charge greater than 2 at physiological pH.
    - 152WO 2017/044894
    PCT/US2016/051166
  36. 37. The composition of any one of claims 1-35, wherein the knotted peptide has a charge greater than 3.5 at physiological pH.
  37. 38. The composition of any one of claims 1-35, wherein the knotted peptide has a charge greater than 4.5 at physiological pH.
  38. 39. The composition of any one of claims 1-35, wherein the knotted peptide has a charge greater than 5.5 at physiological pH.
  39. 40. The composition of any one of claims 1-35, wherein the knotted peptide has a charge greater than 6.5 at physiological pH.
  40. 41. The composition of any one of claims 1-35, wherein the knotted peptide has a charge greater than 7.5 at physiological pH.
  41. 42. The composition of any one of claims 1-41, wherein the knotted peptide is selected from a potassium channel agonist, a potassium channel antagonist, a portion of a potassium channel, a sodium channel agonist, a sodium channel antagonist, a calcium channel agonist, a calcium channel antagonist, a hadrucalcin, a theraphotoxin, a huwentoxin, a kaliotoxin, a cobatoxin or a lectin.
  42. 43. The composition of claim 42, wherein the lectin is SHL-Ib2.
  43. 44. The composition of any one of claims 1-43, wherein the knotted peptide is arranged in a multimeric structure with at least one other knotted peptide.
  44. 45. The composition of any one of claims 1-44, wherein at least one residue of the knotted peptide comprises a chemical modification.
  45. 46. The composition of claim 45, wherein the chemical modification is blocking the N-terminus of the knotted peptide.
  46. 47. The composition of claim 45, wherein the chemical modification is methylation, acetylation, or acylation.
  47. 48. The knotted peptide of claim 45, wherein the chemical modification is: methylation of one or more lysine residues or analogue thereof; methylation of the N-terminus; or methylation of one or more lysine residue or analogue thereof and methylation of the N-terminus.
  48. 49. The composition of any one of claims 1-48, wherein the knotted peptide is linked to an acyl adduct.
  49. 50. The composition of any one of claims 1-49, wherein the knotted peptide is linked to an active agent.
    - 153 WO 2017/044894
    PCT/US2016/051166
  50. 51. The composition of claim 50, wherein the active agent is fused with the knotted peptide at an N-terminus or a C-terminus of the knotted peptide.
  51. 52. The composition of claim 51, wherein the active agent is an antibody.
  52. 53. The composition of claim 51, wherein the active agent is an Fc domain.
  53. 54. The composition of any one of claims 51-53, wherein the knotted peptide fused with an Fc domain comprises a contiguous sequence.
  54. 55. The composition of any one of claims 51-54, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 active agents are linked to the knotted peptide.
  55. 56. The composition of any one of claims 51-55, wherein the knotted peptide is linked to the active agent via a cleavable linker.
  56. 57. The composition of any one of claims 51-56, wherein the knotted peptide is linked to the active agent at an N-terminus, at the epsilon amine of an internal lysine residue, at the carboxylic acid of an aspartic acid or glutamic acid residue, or a C-terminus of the knotted peptide by a linker.
  57. 58. The composition of any one of claims 51-57 further comprising a non-natural amino acid, wherein the non-natural amino acid is an insertion, appendage, or substitution for another amino acid.
  58. 59. The composition of claim 58, wherein the knotted peptide is linked to the active agent at the non-natural amino acid by a linker.
  59. 60. The composition of any one of claims 51-59, wherein the linker comprises an amide bond, an ester bond, a carbamate bond, a carbonate bond, a hydrazone bond, an oxime bond, a disulfide bond, a thioester bond, or a carbon-nitrogen bond.
  60. 61. The composition of claim 60, wherein the cleavable linker comprises a cleavage site for matrix metalloproteinases, thrombin, cathepsins, or beta-glucuronidase.
  61. 62. The composition of any one of claims 57-61, wherein the linker is a hydrolytically labile linker.
  62. 63. The composition of any one of claims 51-62, wherein the knotted peptide is linked to the active agent via a noncleavable linker.
  63. 64. The composition of any one of claims 51-63, wherein the active agent is: a peptide, an oligopeptide, a polypeptide, a polynucleotide, a polyribonucleotide, a DNA, a cDNA, a ssDNA, a RNA, a dsRNA, a micro RNA, an oligonucleotide, an antibody, an antibody fragment, an aptamer, a cytokine, an enzyme, a growth factor, a chemokine, a neurotransmitter, a chemical agent, a fluorophore, a metal, a metal chelate, an X-ray contrast agent, a PET agent, a radioisotope, a photo sensitizer, a radio sensitizer, a radionuclide
    - 154WO 2017/044894
    PCT/US2016/051166 chelator, a therapeutic small molecule, a steroid, a corticosteroid, an anti-inflammatory agent, an immune modulator, a protease inhibitor, an amino sugar, a chemotherapeutic agent, a cytotoxic chemical, a toxin, a tyrosine kinase inhibitor, an anti-infective agent, an antibiotic, an anti-viral agent, an anti-fungal agent, an aminoglycoside, a nonsteroidal anti-inflammatory drug (NSAID), a statin, a nanoparticle, a liposome, a polymer, a biopolymer, a polysaccharide, a proteoglycan, a glycosaminoglycan, a glucocorticoid, an anti-cytokine agent, a pain-reducing agent, a dendrimer, a fatty acid, an Fc region, or a combination thereof.
  64. 65. The composition of claim 64, wherein the NSAID is ketorolac.
  65. 66. The composition of claim 64, wherein the NSAID is ibuprofen.
  66. 67. The composition of claim 64, wherein the steroid is dexamethasone.
  67. 68. The composition of claim 64, wherein the steroid is budesonide.
  68. 69. The composition of any one of claims 53-64, wherein the active agent induces programmed cell death.
  69. 70. The composition of claim 69, wherein the programmed cell death is apoptosis.
  70. 71. The composition of any one of claims 69-70, wherein the active agent is a tumor necrosis factor alpha inhibitor.
  71. 72. The composition of any one of claims 69-71, wherein the active agent is a TNF receptor family activator.
  72. 73. The composition of any one of claims 69-71, wherein the active agent is a TNF alpha antibody.
  73. 74. The composition of claim 64, wherein the protease inhibitor is a collagenase inhibitor, elastase inhibitor, or a matrix metalloprotease inhibitor.
  74. 75. The composition of claim 74, wherein the matrix metalloprotease is MMP13.
  75. 76. The composition of any one of claims 1-75, wherein the knotted peptide is linked to a detectable agent.
  76. 77. The composition of claim 76, wherein the detectable agent is fused with the knotted peptide at an N-terminus or a C-terminus of the knotted peptide.
  77. 78. The composition any one of claims 76-77, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 detectable agents are linked to the knotted peptide.
  78. 79. The composition of any one of claims 76-78, wherein the knotted peptide is linked to the detectable agent via a cleavable linker.
    - 155WO 2017/044894
    PCT/US2016/051166
  79. 80. The composition of any one of claims 76-79, wherein the knotted peptide is linked to the detectable agent at an N-terminus, at the epsilon amine of an internal lysine residue, or a C-terminus of the knotted peptide by a linker.
  80. 81. The composition of any one of claims 76-80, further comprising a non-natural amino acid, wherein the non-natural amino acid is an insertion, appendage, or substitution for another amino acid.
  81. 82. The composition of claim 81, wherein the knotted peptide is linked to the active agent at the non-natural amino acid by a linker.
  82. 83. The composition of any one of claims 76-82, wherein the linker comprises an amide bond, an ester bond, a carbamate bond, a hydrazone bond, an oxime bond, or a carbonnitrogen bond.
  83. 84. The composition of claim 83, wherein the cleavable linker comprises a cleavage site for matrix metalloproteinases, thrombin, cathepsins, or beta-glucuronidase.
  84. 85. The composition of any one of claims 76-84, wherein the knotted peptide is linked to the detectable agent via a noncleavable linker.
  85. 86. The composition of any one of claims 76-85, wherein the detectable agent is a fluorophore, a near-infrared dye, a contrast agent, a nanoparticle, a metal-containing nanoparticle, a metal chelate, an X-ray contrast agent, a PET agent, a radioisotope, or a radionuclide chelator.
  86. 87. The composition of any one of claims 76-86, wherein the detectable agent is a fluorescent dye.
  87. 88. The composition of any one of claims 1-87, wherein the knotted peptide has an isoelectric point of about 9.
  88. 89. The composition of any one of claim 1-88, wherein the knotted peptide is SEQ ID NO: 24.
  89. 90. The composition of any one of claim 1-88, wherein the knotted peptide is SEQ ID NO: 111.
  90. 91. A pharmaceutical composition comprising the composition of any of the claims 1-90 or a salt thereof, and a pharmaceutically acceptable carrier.
  91. 92. The pharmaceutical composition of claim 91, wherein the pharmaceutical composition is formulated for administration to a subject.
  92. 93. The pharmaceutical composition of any of claims 91-92, wherein the pharmaceutical composition is formulated for inhalation, intranasal administration, oral administration, topical administration, intravenous administration, subcutaneous
    - 156WO 2017/044894
    PCT/US2016/051166 administration, intra-articular administration, intramuscular administration, intraperitoneal administration, or a combination thereof.
  93. 94. A method of treating a condition in a subject in need thereof, the method comprising: administering to the subject a knotted peptide comprising a composition of any one of claims 1-90 or a pharmaceutical composition of any one of claims 91-93.
  94. 95. The method of claim 94, wherein the composition is administered by inhalation, intranasally, orally, topically, intravenously, subcutaneously, intra-articularly, intramuscularly administration, intraperitoneally, or a combination thereof.
  95. 96. The method any one of claims 94-95, wherein the composition homes, targets, or migrates to cartilage of the subject following administration.
  96. 97. The method of any of claims 94-96, wherein the condition is associated with a function of cartilage.
  97. 98. The method of any of claims 94-97, wherein the condition is an inflammation, a cancer, a degradation, a growth disturbance, genetic, a tear, an infection, or an injury.
  98. 99. The method of any of claims 94-98, wherein the condition is a chondrodystrophy.
  99. 100. The method of any of claims 94-98, wherein the condition is a traumatic rupture or detachment.
  100. 101. The method of any of claims 94-98, wherein the condition is a costochondritis.
  101. 102. The method of any of claims 91-95, wherein the condition is a herniation.
  102. 103. The method of any of claims 94-98, wherein the condition is a polychondritis.
  103. 104. The method of any of claims 94-98, wherein the condition is a chordoma.
  104. 105. The method of any of claims 94-98, wherein the condition is a type of arthritis.
  105. 106. The method of claim 105, wherein the type of arthritis is rheumatoid arthritis.
  106. 107. The method of claim 105, wherein the type of arthritis is osteoarthritis.
  107. 108. The method of any of claims 94-98, wherein the condition is achondroplasia.
  108. 109. The method of any of claims 94-98, wherein the cancer is benign chondroma or malignant chondrosarcoma.
  109. 110. The method of any of claims 94-98, wherein the condition is bursitis, tendinitis, gout, pseudogout, an arthropathy, or an infection.
  110. 111. The method of any of claims 94-98, wherein the composition is administered to treat the injury, to repair a tissue damaged by the injury, or to treat a pain caused by the injury.
    - 157WO 2017/044894
    PCT/US2016/051166
  111. 112. The method of any of 94-98, wherein the composition is administered to treat the tear or to repair a tissue damaged by the tear.
  112. 113. A method of imaging an organ or body region of a subject, the method comprising:
    administering to the subject composition of any one of claims 1-90 or a pharmaceutical composition of any one of claims 91-93; and imaging the subject.
  113. 114. The method of claim 113, wherein further comprising detecting a cancer or diseased region, tissue, structure or cell.
  114. 115. The method of any one of claims 113-114, further comprising performing surgery on the subject.
  115. 116. The method of any one of claims 113-115, further comprising treating the cancer.
  116. 117. The method of any one of claims 113-116, wherein the surgery comprises removing the cancer or the diseased region, tissue, structure or cell of the subject.
  117. 118. The method of claim 117, further comprising imaging the cancer or diseased region, tissue, structure, or cell of the subject after surgical removal.
    - 158WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    Φ ¢1 y
    &J» <
    ¢/} . &
    ¢./} «3
    IS
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    6/75 mAU mAU
    FIG. 6A
    FIG. 6B
    FIG. 6
    WO 2017/044894
    PCT/US2016/051166
    7/75
    Immunogenicity Predictions by MHCii Peptide Binding Prediction
    OS
    O
    Ξ fc <
    Ό ®
    XS
    Φ
    ¢- · t- “· 4 f· i -: s f- !· t· -. t £
    /s η ό Γ<Ί m Λ\ *3“ <Ν <η ΓΊ ό 2; Ό 04 Λ\ Γ- <Ν /S 00 ΓΊ ό ζ 04 Λ\ Ο CC ό ό ζ (Ν C4 Ο CC <Ν ό o r--' G Q f*“4 ο Q Q f*“4 ο Q Q Q Q Q Q 4— 4—4 f4 4—< 1—4 •—4 4— 1—4 •—4 4—ι 1—4 4-4 4—ι σ σ σ σ ο σ σ ο σ σ ry Ο' σ G ti wj G G g G G g ω (jj W ω o7 07 ο7 07 07 CZ! 07 07 07 Q0 07 07
    Sequence Reference Number
    FIG. 7
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    9/75
    Construct 1
    IgK SP sFLAG
    HIS
    Sen
    TEV
    SEQ ID No: X
    WO 2017/044894
    PCT/US2016/051166
    10/75 c:
    ο
    Ό
    Ο
    5Σ .2 ο
    σ φ
    ίΣ co
    Ο ε:
    co ο.
    ^=3 φ fe ω > οω Ω2
    ΓΜ «*>
    Js£
    Φ
    Φ
    Purification
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    12/75
    2 ao X co CI X co cc ό o o O pc Ο*/ m Ϊ'-' Ό 00 in χ—1 o / / z z z Ch C4 CN X OI X X X cn cc !~w>J OQ Q Q Q o o Z“^, ”Z o H 02 o Z“^, ”Z O pc h 02 ?«wwwi pc/ a a 22 o 22 Q 22 UJ Cd LiJ LI.J Cd Q O Q Q Q Q Q CZ) CZ) CZ! CZ! CZ) !-—1 X—< σ σσσ ααα X Cd MJ UJ uu cd xi Cd UJ cd X i 1 1 CZ) CZ) CZj CZ) iZ! CZ) CZj CZ) iZ! X i 1 1 rjj X i CD 1 X X l-J U-! 1 X X I ! i X X CD 1 X X 00 1 X X I X X O u X X X Old! 1 x< X Pl | X X (D X X X X X X is > X H X >-i >-l X X X X co C ) CO1 ;) C ) co O () o o o ΐ 'i o X is H X s X X (__] X X X X X X X 20 X X CO x co X o co o C ϊ O X ! 1 20 ! X i i i i X ! X 1 1 G'< i t_i_| 1 X X X X X p> <; !-—i X X 1 1 20 1 X ω X Γ x X X X X X X i 1 —I i X X X X X X X 2 X D-' 1 X i H !-i 1-! Xi <-l 1-! X HI i CX-! 1 o x x co ϋ o CO x o X X H !——I H X K X >---l X X K .-4 >---l X X !—j X DO X X X X x X X cd X co CD X X co 00 00 X 00 X X X 0 H X X co co o o X CO X ffi iX X X X X X X Fix i> 2o X ! X SI H o X X X X X X ύ_Ί X > cd Ο X o C, D X r o C D X X H, ]\2 co ΪΗ X I ! H H X i 1 X D-l X Q , 1 X X <l X| X X Oi X OC H X ! X 1 00 X X X X X o X X o CO co C ) C ) X X X X X X X X H o co co X co co x co o o co o o CO X H X X CD X X X i> X X X !-—i jzizj X Js X ι2θ X X X 00 X CD X !-—i co X X 20 i X X X Fi.1 X X X X X X CD1 X >-i x ( ) C ) co X C ) co o C ) O-i X p , 1 >-i Of X o ! Oi Oi ! H X H D? X X X X X CO K .-4 >---l X 1 k X >---l CO co o CO u co C,O X X OD co co 1 1 co X A 2d DO X x X I-1--1 i~X X' X O i 1 X X X X».·. o ! X iX X Oi E-i co i 1 l~7 Zd X X is X ! o ) u o C ) O i o X X > Old! Ii:! X X co X 00 X X H X X Ijj X X [„> J> Kx.„ H H X H1 X J> X H H 2-t X X X X i X X 00 O co CO C CO X H-j !—j X i ‘> i X X X CD X CD X t, i t_i_| X Oi i o i >~f X 1 1 X 1 P> s> > I p> i> I 1—1 X 1 1 20 1 X x Oi I XI <; I o X i 1 X i CQ ω co 00 X co 00 X co X CO X X 00 O X o o X CD o X CD X CD1 o X CD1
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166 c
    Γ s~~ i
    Γ !
    Γ
    ΓΖΊΓ''1 Ί rlU. 1
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166 s~~ i
    Γ !
    WO 2017/044894
    PCT/US2016/051166
    21 /75 ©
    xz
    o o o eq co Vi o V-: O i l ( o o o WO co o o o
    o o o 03 co wo o o i E ! o o o i.q GO o o o
    o o o oq co Vi o o 1 s Ϊ O o o WO co o o o
    © xz
    CM η
    CM d
    I i
    CM
    o o o co co LO o ,...: o ! 1 i o O o in 03 o o O
    o
    CM d
    WO 2017/044894
    PCT/US2016/051166 ο
    x;
    ©ο
    S3
    Ο ο Ο co co CO ο χ...' ο 9 ! a ο ο Ο ιη οο G ο ο
    ο ο ο co co co ο ο a ϊ ? Ο ο Ο co οο Ο ο ο
    ο χ:
    «Μ δ’*'·'»
    ο ο ο GO co !Χ5 Ο Ο a a 1 Ο Ο Ο CO ΟΟ ο ο ο
    ο ο ο co co ιο ο ο 1 Ε a ο Ο ο co οο ο ο ο
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166 c
    Γ
    WO 2017/044894
    PCT/US2016/051166
    25/75
    WO 2017/044894
    PCT/US2016/051166
    EZ r
    EZ
    Γ
    WO 2017/044894
    PCT/US2016/051166
    s.....
    Γ
    WO 2017/044894
    PCT/US2016/051166
    28/75
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    FIG. SOC FIG. 30D
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    S.....
    Γ
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    Γ°°
    Γ
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    38/75
    ++A+;-,,,. · '<g ,+ ; '·7θ::ί ,/+,
    WO 2017/044894
    PCT/US2016/051166
    F
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    42/75
    s'' C .. x .·&: .fe: :·; |?V FIG. 41A Γ”° § Z°°^ & A F^ FIG. 41B Wife &V ' x s3tY4LV· ' »·*
    WO 2017/044894
    PCT/US2016/051166 . 42E FIG. 42F
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    45 / 75
    1 <, *'»1 ·.·,·. •ΧςΧ- ❖ Γ 10. ‘Η'Ή'/Λ Cu Γ in 44R 8 VuJs , ““tt* S—J - ϊ ·ί Χ χγ VK \ Γ” ί A A f''· PIG. 44G F IG. 44D . 1¾¾. s ·· S \S ' FIG. 44E c r 8 A & 8“ I{ ™s 44 f™ i KG* B 8 /-Mil? $ \
    ί—- 8
    Γ I
    WO 2017/044894
    PCT/US2016/051166
    46 / 75
    Cartilage Homing vs. Expasy pi
    WO 2017/044894
    PCT/US2016/051166
    47/75
    FIG. 46
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    -Λ- -λ- Ά' A- -λ- 4- 4- -k Ά Ά 4,· 4,·
    SEQ ID NO SEQ ID NO
    VPINVKC
    VRIPVSC |G S RDCL D PCK|KAGNWGKC IN SKCHCT P K PCKbAGLWG K CMNGK C DC T P K
    SEQ ID NO SEQ ID NO
    V PIN VlKfc RG S RD C L D P dWiA- GMRF
    VQTN
    S CASVCRREIGVAAG * * *
    KlCHCTP gCVCYRN k Ά’ f·' yr yr 'fy 'fy λ Ά Ά' 4’ 4.· ·*·
    Ewe S RDCLD PCplKA- GMRFG|K|C I NSiKlCHCT P k|c|r|g s p e C L P KCtCjE AI g k s AG[KJcMNg[pjCKC y p
    WO 2017/044894
    PCT/US2016/051166 + + + + + + + + + +
    KfcTNGKCVdYtoN KCMNGKCKqijp
    -,-J
    27 QVQTNVKCQGGS-CASVCRREIGVAAG ;207 VFINAKCRGSPECLPKCKEAIGKAAG
    WO 2017/044894
    PCT/US2016/051166
    53/75
    WO 2017/044894
    PCT/US2016/051166
    54/75
    WO 2017/044894
    PCT/US2016/051166
    co S co . π |λ»' V CO Ϊ co * Q ' s ; ’T ' z co 00 '•t o O 4 0 O H' Z “VW s Z z O o ά w Q o q Q s i Uj LU »> QJ </? 0 I
    WCw,
    .......>Χχ: '»»:·<;<··· NSSSSS^:^ r f. r 5HISS ifcis
    WO 2017/044894
    PCT/US2016/051166 .'Μ:·
    WO 2017/044894
    PCT/US2016/051166
    W i »ί;. Si
    I I I | ·* & ΑΪ §5
    WO 2017/044894
    PCT/US2016/051166
    S' <w ; <.<> ' fo fo fo ! 5 >-) v's CK z G 0 ', d c L~ Z z z 5 Z u i o 0 fo 5 fo Q S ™ 4 o :- ty s O ω 0 i 0 fo : fo f fo fo ' fo
    '·©
    TT
    5 ·>.:· *·;$
    Αχ.
    III!
    WO 2017/044894
    PCT/US2016/051166
    CO in co ^r
    Q tJU co i : S ''
    TT*??. .
    o 5 a a
    w co •’i
    Q uo co cn •Ss •>V
    WO 2017/044894
    PCT/US2016/051166
    60/75
    11 £3 ί ί ί ί t1 + S»> (! %· :· χχχχ η J ίκ' 1 l·· i !' ί Q 1 i+x $ +: + t+> 1 fXv ϊ £> ί +Λ <Ν ί £+ί + ί.+ί ί (5 1 + '· < ' . ς ·. + ί Q + Ο + d d t +55 < «+ #+: *S ! δ ; £ti Ο + < $++ 5+: 5S4; 1 ++++ 5
    Ο + :++++ +ήί· + ++ + ί+ί + + ι ο ι ο / α i ΰ ι . X- ϊ UU : ω 5 UJ ; LU ·
    F I fe? ί w ί $$ I; * ++' +5yx+\\yty+\,«+\y.x,^<x,\^\5yw,x\,+x\-£tyyx<v\^^^ ί $ ++ ++ +>
    χ·>
    + ;+
    WO 2017/044894
    PCT/US2016/051166
    fc ft i; ;<«· £ ft ft to : m in o o r O CM s CM 1 ™
    s $ i MU
    S to
    O ; CM i
    8 ' a
    A
    MU w
    I '1
    1 I
    WO 2017/044894
    PCT/US2016/051166 ί
    j .χ:* !»$:· ·<-·&
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    65/75
    3 t to j to i: $ to s Λ to / to· j sssx :<<<< to A j O | z I CO ω ; co $ CO ; σ> σ> } σ» ω 1 •5- :· V . :: κ· to; s · ) to 1 $ ; 'to d < χχ* 8 ! ; jSx\ to ] Θ 1 to s ; O' ΐ Ο * : θ' o to , to kU | to to 7)
    WO 2017/044894
    PCT/US2016/051166
    66/75
    1 fc 1 h- s 1 8· μ co r £3 § * U : g i CM > CM 1 o 0 1 o d 1 ? .z i Q S a ; O □ 3 i o 1 ; ω
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    68/75 ί» TO88 BfcQiW P0QW TO» t&fcgflviAA) W - ’ 3» 3®
    TOT? =5?
    O'r a’ O >
    C ’ '
    Ϊ >
    ss
    SCiiiSX»:·’ ’;C3 <δ!
    com ¢0
    S«nj»n urn 98SS (3)
    FIG. 67F ?S7 &&ω
    FIG, 67G
    FIG, 67E
    88XW38 PQCSS3
    ΛΑ' 44
    Ο^ηί^ϊι SisxpiiXi Sc®q>xjn xcsia'sar ?$r§smis>
    FIG. 671 FIG. 67J FIG. 67K FIG. 67LFIG. 67M
    A7KJ37
    Sawist?!
    FIG. 67H
    QSTVX3 Qsmgg £Κϊΐ 34 >3 ? 'o? ’-\V M) &2S> 3937 7
    FIG. 67
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    Urine (CiWof)
    WO 2017/044894
    PCT/US2016/051166
    WO 2017/044894
    PCT/US2016/051166
    SEQ ID NO: 24
    WO 2017/044894
    PCT/US2016/051166
    FIG. 72C FIG. 72
    WO 2017/044894
    PCT/US2016/051166
    74/75 ί ο
    SEQ ID NO 436 5 SEQ ID NO 4 37 [7 J SEQ ID NO 4 38 26 SEQ ID NO 4 3 9 c J SEQ ID NO 440 5 SEQ ID NO 441 4 SEQ ID NO 442 1 SEQ ID NO 443 1 SEQ ID NO 4 4 4 2 7 SEQ ID NO 4 45 9 SEQ ID NO 4 4 6 1 SEQ ID NO 447 3 SEQ ID NO 448 2 SEQ ID NO 449 27 SEQ ID NO 4 50 07 U SEQ ID NO 4 51 8 SEQ ID NO 452 5 SEQ ID NO 4 53 2 7 SEQ ID NO 4 54 28 SEQ ID NO 4 55 5 SEQ ID NO 4 5 6 5 SEQ ID NO 4 57 [7 J SEQ ID NO 4 58 5 SEQ ID NO 4 5 9 28 SEQ ID NO 4 60 2 8 SEQ ID NO 4 61 6 SEQ ID NO 4 62 28 SEQ ID NO 4 63 28 SEQ ID NO 4 64 1 SEQ ID NO 4 65 29 SEQ ID NO 4 66 1 SEQ ID NO 4 67 27 SEQ ID NO 4 68 28 SEQ ID NO 4 69 O p:. SEQ ID NO 4 7 0 2 9 SEQ ID NO 4 71 2 8 SEQ ID NO 4 72 28 SEQ ID NO 4 73 5 SEQ ID NO 4 7 4 5 SEQ ID NO 4 75 6 SEQ ID NO 47 6 5 SEQ ID NO 4 7 7 C7 J SEQ ID NO 4 7 8 5 SEQ ID NO 4 7 9 2 5 SEQ ID NO 4 80 2 8 SEQ ID NO 4 81 2 8 SEQ ID NO 4 82 28
    I
    VR v
    Ξ
    V
    RCSESYQCFPI QCLK
    CCSS gcRsrfgktng-pj PjCRAAFGI SAG ¢.jKCInJgKC'K Kklfgtyrg-r lhntnrg-r yntsrg-r bcqatgrpng-r PjCKRE T G C P RA- KC pIcRKQT G C PNA~ KC QKLTGCLNA.-R Rketgypna-r DC]AD F C RRE T GC Ρ Y G~ R EPCRAR-GCRHG-R N F|CRRN - KC T H G - R QTGCPHA-Ki .TGRAAG-R GRAHG-R BCRAIGSLQS-R R.RGT G SAQAy- RCQ: lRrgtgsgqg-rcq:
    cvtgrfeg-kcq: rrvtgstqg-rcq: afgvdrg-r IGRAAG-R cRrvigvaag-rc RT C Ε RVVGVAAG-R CI dp.yntrg.a-rc ri fgtrpa-kc itgrrsg-rc
    L~.....GLLG-RCI
    A—GLLG-RCI -GFSSG-RC GNPPSVK------CKYRK
    TPD------RCSYRT
    RRLRCLLPS-RC -jC[RRVTGRAFG“R PCR.GVTGRAHG-R AC RAAVGRAAG- R PCKDA-GEIRFG-R PCR.DA-GE1RFG-R PCBvAQFGIRAGa PCRFLYGSSAxGa PCBvEI YGRHAGa CRQMFGKPNG-R P C KRA- G MR F G - RC <CP---GNPS---C
    NCIREVNNRNG-KCeN^RCRC!
    PQQ
    SQ ^NQ
    K S
    KDClY aRDCC IRECIY
    B
    K PK PQH1
    K
    SCSASSQCUP7 SCTASNQCNSI SCTTSKECWS
    KECELVKICI? LS
    RPC! IK 1 I I .AS T
    KS <jCT
    RCSi
    RCSi vCB CUR
    VCEKL
    G G
    SC INI3
    SCRTP SCI Si G
    KECT ys: AMCp QClYPHCB
    CQCI 1C I
    ECR.K
    IRCRT PKDCjADPCRK?
    PPCB ID
    KCM03QCWT RCTASRECYEPdR
    VKCTTSKECWl LECGAjSREcfco E
    RAAC1 PCEKAF PCB \/
    7K
    AK
    CSAJSRECUPAJCB CISSQECAIACB GR CY D S RQC AIA C B PDCTVSKECAAPCB SPECLPK GS-CASG ntsqcy
    G CQG
    AKCR1 KK KK
    RE KB RAI REA
    CS
    G 0 KG L LYS
    GKCS
    NRCNI
    KEC2
    AFCN
    CGKI
    AA |AI
    PCX
    AC/
    AI T T
    V IK IK VK
    V
    PL
    V VL
    V GK PK]
    CAIRO. ECQ
    I S ϊ.Υ CRI
    QCQ
    SCR
    SSR SS SS RRJ -KRi sA.DCS ]KN GR GS ADCt SSS SR SG SPOCI PP PKOCS PP C-KQ SR DD SR ;eci:
    jecyc
    ICE J
    YP
    CCSC· CTG
    P S L
    CQL
    DCRGRCB rk|cpRY Q
    DC|AEP|C|? HIE E P K Q P K P
    PG
    DCfLD DCFRK PCGP
    HCI HCEG SCRS SCRS
    GAM1DCQI
    1DCQ<
    1CYI
    CQCLI
    SCRHSGQCI icRg IKCI o
    4cts /kcis ,C'G CRG GRCGT PPCNN
    CQCL
    CQCS iQCL :qca
    CQS )YCI.
    WO 2017/044894
    PCT/US2016/051166
    -------p KC S E S YQC FpVCK S RFG KT NG RCVNG FC DC FGSGVPINVKCRGSRDCLDPCK-KAGMRFGKCINSKCHCTP » < < < . e 'X -Χ' » -λ' » < < <
AU2016321342A 2015-09-09 2016-09-09 Cartilage-homing peptides Abandoned AU2016321342A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562216331P 2015-09-09 2015-09-09
US62/216,331 2015-09-09
US201662278929P 2016-01-14 2016-01-14
US62/278,929 2016-01-14
US201662385734P 2016-09-09 2016-09-09
PCT/US2016/051166 WO2017044894A2 (en) 2015-09-09 2016-09-09 Cartilage-homing peptides
US62/385,734 2016-09-09

Publications (1)

Publication Number Publication Date
AU2016321342A1 true AU2016321342A1 (en) 2018-04-26

Family

ID=58240183

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016321342A Abandoned AU2016321342A1 (en) 2015-09-09 2016-09-09 Cartilage-homing peptides

Country Status (9)

Country Link
US (3) US11090358B2 (en)
EP (1) EP3347035A4 (en)
JP (2) JP6966424B2 (en)
CN (1) CN108135970B (en)
AU (1) AU2016321342A1 (en)
BR (1) BR112018004536A2 (en)
CA (1) CA2994865A1 (en)
IL (1) IL257396B (en)
WO (1) WO2017044894A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010101628A2 (en) 2009-03-02 2010-09-10 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
WO2012125808A1 (en) 2011-03-15 2012-09-20 Massachusetts Institute Of Technology Multiplexed detection with isotope-coded reporters
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US11013814B2 (en) * 2017-03-16 2021-05-25 Blaze Bioscience, Inc. Cartilage-homing peptide conjugates and methods of use thereof
AU2016321342A1 (en) 2015-09-09 2018-04-26 Blaze Bioscience, Inc. Cartilage-homing peptides
CA3020324A1 (en) 2016-04-08 2017-10-12 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
EP3452407B1 (en) 2016-05-05 2024-04-03 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
AU2017322523A1 (en) 2016-09-09 2019-02-21 Blaze Bioscience, Inc. Stable peptides and methods of use thereof
WO2018136614A1 (en) 2017-01-18 2018-07-26 Fred Hutchinson Cancer Research Center Peptide compositions and methods of use thereof for disrupting tead interactions
WO2018187688A1 (en) 2017-04-07 2018-10-11 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
AU2018283161A1 (en) 2017-06-15 2020-01-02 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof
IT201700071296A1 (en) * 2017-06-26 2018-12-26 Alda S R L NEW REAGENTS FOR OPTICAL MICROSCOPY
CA3086040A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
US20210171589A1 (en) * 2018-03-16 2021-06-10 Blaze Bioscience, Inc. Truncated cartilage-homing peptides and peptide complexes and methods of use thereof
JP2021522172A (en) * 2018-04-23 2021-08-30 フレッド ハッチンソン キャンサー リサーチ センター Cartilage homing peptide complex
US11835522B2 (en) 2019-01-17 2023-12-05 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis
CN110357950B (en) * 2019-07-29 2023-04-25 武汉大学 Immunosuppressive polypeptide designed by acidic amino acid scanning method and application thereof
CN111454334B (en) * 2020-03-30 2021-12-14 东北农业大学 Enzymolysis-resistant antibacterial peptide II4II, and preparation method and application thereof
CN111840512B (en) * 2020-07-15 2023-06-09 广州领晟医疗科技有限公司 Composition for treating cartilage repair and/or osteoarthritis
CN113332442A (en) * 2021-06-10 2021-09-03 愈美明德(成都)生物医药科技有限公司 Targeted delivery molecule, particle, preparation method and application thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0932417B1 (en) 1996-10-17 2003-03-05 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
AU2001229494A1 (en) 2000-01-21 2001-07-31 The Burnham Institute Chimeric prostate-homing peptides with pro-apoptotic activity
US20050100555A1 (en) 2001-09-05 2005-05-12 King's College London An Institute Incorporated By Royal Charter Of Stra Homing peptides
CN1655675A (en) 2002-03-26 2005-08-17 综合医院公司 Combination therapy using trefoil peptides
US20060088899A1 (en) 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
FR2877946B1 (en) 2004-11-12 2011-02-11 Commissariat Energie Atomique MAUROCALCIN-DERIVED PEPTIDES FOR USE AS VECTORS FOR INTRACELLULAR ADDRESSING OF MOLECULES OF INTEREST
CN101583370A (en) 2005-09-27 2009-11-18 阿穆尼克斯公司 Proteinaceous pharmaceuticals and uses thereof
US7592009B2 (en) 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
JP5463013B2 (en) 2007-06-19 2014-04-09 国立大学法人 岡山大学 Cartilage marker
JP2011500601A (en) 2007-10-12 2011-01-06 トランスモレキュラー， インコーポレイテッド Systemic administration of chlorotoxin drugs for tumor diagnosis and treatment
EP2531206B1 (en) 2010-02-04 2017-05-31 Morphotek, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
JP2013532126A (en) 2010-05-11 2013-08-15 フレッド ハッチンソン キャンサー リサーチ センター Chlorotoxin variants, conjugates, and methods of using them
US20130280281A1 (en) 2010-07-02 2013-10-24 Jean-Paul Castaigne Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
JP6170435B2 (en) 2010-11-08 2017-07-26 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Fusion proteins containing modified knotton peptides and uses thereof
WO2013078091A1 (en) 2011-11-22 2013-05-30 The Johns Hopkins University Collagen mimetic peptides for targeting collagen strands for in vitro and in vivo imaging and therapeutic use
WO2013078250A2 (en) 2011-11-22 2013-05-30 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides that bind alpha-v-beta-6 integrin
JP5724937B2 (en) 2012-04-23 2015-05-27 ニプロ株式会社 Peptides and preparations that show kidney accumulation
TWI609882B (en) 2012-05-22 2018-01-01 必治妥美雅史谷比公司 Bispecific antibodies and methods of using the same
ES2651113T3 (en) 2012-06-25 2018-01-24 The Brigham And Women's Hospital, Inc. Targeted therapeutic treatments
WO2014063012A1 (en) 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
BR112015013515A2 (en) * 2012-12-10 2017-11-14 Hutchinson Fred Cancer Res methods of generating a mass-defined drug candidate library, and for identifying peptides having a pharmacological property
WO2014165422A1 (en) 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
JP6510494B2 (en) 2013-05-07 2019-05-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Peptide and peptide-active component conjugates for renal drug targeting
EP3024472A4 (en) 2013-07-22 2017-06-28 Kineta One, LLC Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
US11013814B2 (en) 2017-03-16 2021-05-25 Blaze Bioscience, Inc. Cartilage-homing peptide conjugates and methods of use thereof
EP3074388A1 (en) * 2013-11-25 2016-10-05 Sanofi Dotam derivatives for therapeutic use
JP2017501980A (en) 2013-12-23 2017-01-19 キネタ ワン リミテッド ライアビリティ カンパニーＫｉｎｅｔａ Ｏｎｅ，Ｌｌｃ Sustained release depot preparation of therapeutic protein and use thereof
US10533039B2 (en) 2014-05-21 2020-01-14 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
EP3250223A1 (en) 2015-01-08 2017-12-06 University of Iowa Research Foundation Methods for the regeneration of articular cartilage in vivo
US20180264080A1 (en) 2015-01-09 2018-09-20 Kineta One, Llc TOPICAL APPLICATIONS OF Kv1.3 CHANNEL BLOCKING PEPTIDES TO TREAT SKIN INFLAMMATION
WO2016118859A1 (en) 2015-01-22 2016-07-28 Board Of Trustees Of The University Of Arkansas Compositions and methods for selectively depleting senescent cells comprising flip
BR112017027985A2 (en) * 2015-06-26 2018-08-28 Hutchinson Fred Cancer Res therapeutic peptides and methods of use thereof
CN112574316A (en) 2015-07-02 2021-03-30 博际生物医药科技(杭州)有限公司 Interleukin-15 fusion protein for tumor targeted therapy
AU2016321342A1 (en) 2015-09-09 2018-04-26 Blaze Bioscience, Inc. Cartilage-homing peptides
EP3386530A4 (en) 2015-12-11 2019-08-28 Fred Hutchinson Cancer Research Center Peptides for renal therapy
EP3416986A4 (en) 2016-02-19 2019-11-13 Dignity Health Antibody fusion protein and related compositions for targeting cancer
AU2017322523A1 (en) 2016-09-09 2019-02-21 Blaze Bioscience, Inc. Stable peptides and methods of use thereof
WO2018119001A1 (en) 2016-12-19 2018-06-28 Fred Hutchinson Cancer Research Center Peptide-antibody compositions and methods of use thereof
WO2018136614A1 (en) 2017-01-18 2018-07-26 Fred Hutchinson Cancer Research Center Peptide compositions and methods of use thereof for disrupting tead interactions
AU2018283161A1 (en) 2017-06-15 2020-01-02 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof

Also Published As

Publication number Publication date
JP7378449B2 (en) 2023-11-13
BR112018004536A2 (en) 2018-12-11
CN108135970B (en) 2023-09-01
IL257396A (en) 2018-04-30
US20190117728A1 (en) 2019-04-25
EP3347035A4 (en) 2019-05-01
US11090358B2 (en) 2021-08-17
JP2018527348A (en) 2018-09-20
JP6966424B2 (en) 2021-11-17
CA2994865A1 (en) 2017-03-16
US20220016202A1 (en) 2022-01-20
US11648290B2 (en) 2023-05-16
IL257396B (en) 2020-06-30
JP2022009342A (en) 2022-01-14
CN108135970A (en) 2018-06-08
WO2017044894A3 (en) 2017-05-11
EP3347035A2 (en) 2018-07-18
WO2017044894A2 (en) 2017-03-16
US20230364183A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
US20220016202A1 (en) Cartilage-homing peptides
JP7280193B2 (en) Cartilage homing peptide conjugates and methods of use thereof
US11331393B2 (en) Renal-homing peptide conjugates and methods of use thereof
AU2017322523A1 (en) Stable peptides and methods of use thereof
US20230211000A1 (en) Tissue-homing peptide conjugates and methods of use thereof
JP2024015145A (en) Deleted cartilage homing peptides, peptide complexes, and methods of using them
JP2024019603A (en) Cartilage homing peptide complex

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application